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Abbreviation 
ABBREVIATION 
Nomenclature of cytochrome P450: 
CYP106A2   15β-hydroxylase cytochrome P450 or P450-meg 
Abbreaviation: 
A   Ampere 
AdR   Adrenodoxin reductase 
Adx   Adrenodoxin 
ATCC   American Type Culture Collection 
bp   Base pair 
BSA   Bovine serum albumin 
C   Celsius 
CO    Carbon monoxide 
CYP    Cytochrome P450 
Da   Dalton 
DMSO  Dimethylsulfoxide 
DNA    Deoxyribonucleic acid 
dNTPs   Deoxy-NTPs 
DTE   Dithioerythritol 
E. coli   Escherichia coli 
EDTA   Ethylenediaminetetraacetic acid 
FAD    Flavine adenine dinucleotide 
FMN   Flavine mononucleotide 
hr   Hour (s) 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HPLC    High performance liquid chromatography 
K   Potassium 
IPTG    Isopropyl-β-D-thiogalactoside 
min   Minute (s) 
NADPH   Nicotinamide adenine dinucleotide phosphate 
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Abbreviation 
nm   Nanometer 
PAGE   Polyacrylamid gel electrophoresis 
PCR   Polymerase chain reaction 
Pfu    Pyrococcus furiosus 
PMSF    Phenylmethylsulfonyl fluoride 
rpm   Round per minute 
SDS    Sodium dodecylsulfate 
sec   second (s) 
TEMED  N,N,N’,N’-tetramethylethylenediamine 
Tris   Tris(hydroxymethyl)aminomethane 
UV/vis   Ultraviolet and visible wavelength range 
V   Voltage (s) 
WT    Wild type 
Standard abbreviations for amino acids: 
A  Ala  Alanine    L  Leu  Leucine 
R  Arg Arginine    K  Lys  Lysine 
N  Asn  Asparagine    M  Met  Methionine 
D  Asp  Aspartic acid    F  Phe  Phenylalanine 
C  Cys  Cysteine    P  Pro  Proline 
Q  Gln  Glutamine    S  Ser  Serine 
E  Glu  Glutamic acid   T  Thr  Threonine 
G  Gly  Glycine    V  Val  Valine 
H  His  Histidine    W  Trp  Tryptophan 
I  Ile  Isoleucine    Y  Tyr  Tyrosine 
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Abstract 
ABSTRACT 
CYP106A2 is known as 15β-hydroxylase, but also shows 11α-hydroxylase activity for 
progesterone, an important pharmaceutical compound. This work focused on the 
production of a regio-selective hydroxy derivative of progesterone at the C-11 position 
using site directed mutagenesis of CYP106A2. Based on the docked progesterone-
CYP106A2 model, a saturation mutagenesis library (13100 transformants) at positions 
A395 and G397 had been created to verify the effect of these residues on the regio-
selective hydroxylation. Forty of these transformants were randomly selected and 
screened for higher 11α-hydroxyprogesterone production. Mutants A395I and 
A395W/G397K showed the highest 11α-hydroxyprogesterone production (19.5 and 56.4-
fold, respectively) despite a lower catalytic activity as compared with the WT. Therefore, 
these mutants were further mutated to improve their catalytic efficiency. Eight new 
mutants were found to have a higher turnover rate along with an improved 11α-
hydroxyprogesterone production. Mutants A106T/A395I and T89N/A395I showed the 
highest amounts of 11α-hydroxyprogesterone, 2.8- and 4.4-fold increased, respectively, 
compared with the parent mutants, and 54.9- and 85.2-fold, respectively, compared with 
the WT. Interestingly, the in vivo conversion of progesterone with the mutant 
T89N/A395I nearly produced the 11α-hydroxyprogesterone. Since the 11α-
hydroxyprogesterone exhibits an antiandrogeneic activity and plays a role in the 
regulation of the blood pressure, the mutant has a potential scope as biocatalyst. 
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Abstract 
ZUSAMMENFASSUNG 
CYP106A2 ist als 15β-Hydroxylase bekannt, zeigt aber auch 11α-Hydroxylase Aktivität 
für Progesteron. Ziel dieser Arbeit war die Produktion regio-selektiver Hydroxyderivaten 
des Progesterones an Position C-11 mittels zielgerichteter Mutagenese am CYP106A2. 
Eine 13100 Transformanten umfassende Mutantenbank, hergestellt mittels 
Sättigungsmutagenese, ausgehend von einem mit Progesteron gedockten Modell, diente 
als Grundlage. Zur Untersuchung des Einflusses der Aminosäuren auf die Regio-
selektivität wurden 40 Transformanten zufällig ausgewählt und auf eine höhere 11α-
Hydroxyhydroxylierung gescreent. Die Mutanten A395I und A395W/G397K zeigten, 
verglichen mit dem WT, die höchste 11α-Hydroxyprogesterone Produktion (19,5- bzw. 
56,4-fach), trotz geringerer katalytischer Aktivität. Diese Mutanten wurden nochmals 
mutiert, um die katalytische Effizienz zu erhöhen. Acht neue Mutanten mit einer höheren 
Umsatzrate und verbesserter 11α-Hydroxyprogesterone Produktion wurden gefunden. Die 
Mutanten A106T/A395I und T89N/A395I bildeten 2,8- bzw. 4,4-mal mehr 11α-
Hydroxyprogesteron als die jeweilige Ausgangsmutante und sogar 54,9- bzw. 85,2-mal 
mehr als der WT. Interessanterweise hydroxylierte die Mutante T89N/A395I während des 
in vivo Umsatzes Progesteron fast ausschließlich an der 11α-Position. Da 11α-
Hydroxyprogesteron eine antiandrogene Aktivität zeigt und eine Rolle bei der 
Regulierung des Blutdrucks spielt, ist zu sagen, diese Mutanten einem großer Erfolg und 
eine gute Vorraussetzung zur biotechnologischen Anwendung ist. 
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Summary 
SUMMARY 
Nowadays, steroids are widely used as drugs for the treatment of a variety of diseases. 
However, the production of the steroids and their derivatives is difficult by chemical 
methods due to the necessity for regio- and stereo-selective modifications. On the other 
hand, bacterial enzymes are reported to play an important role in performing 
biotransformations at specific positions.  
CYP106A2 from Bacillus megaterium ATCC 13368, one of the few known bacterial 
steroid hydroxylating enzymes, is able to hydroxylate a variety of 3-oxo-∆4-steroids such 
as testosterone, 11-deoxycorticosterone or 11-deoxycortisol at 15β-position. It converts 
progesterone mainly into 15β-hydroxyprogesterone and into minor products such as 11α-, 
9α-, 6β-hydroxyprogesterone. The aim of this work was to create mutants, which could 
alter the stereo- and regio-selectivity of progesterone hydroxylation towards the 11α-
position.  
The starting point was the work described in the Ph.D. Thesis of Lisurek in which 2 
residues, A395 and G397, of CYP106A2 were predicted to have an effect on the regio-
specificity of the progesterone hydroxylation. These residues were mutated to the 
corresponding residues contained in CYP11B1 and produced mutants with an increased 
11α-hydroxyprogesterone production (Lisurek, 2004). Subsequently, a saturation 
mutagenesis at positions A395 and G397 was created by Virus, which contained 13100 
transformants (Virus, 2006). To identify the role of these 2 residues on the regio-
selectivity of progesterone hydroxylation as well as to select the mutant which produced 
high amounts of the 11α-hydroxy product, 40 transformants from the saturation 
mutagenesis library were randomly selected. These mutants were expressed in E.coli 
JM109 cells. As predicted, these selected mutants showed a diverse distribution of 
hydroxylated progesterone products. All mutants increased the minor 11α-, 9α- and 6β-
hydroxyprogesterone production as compared with those of the CYP106A2 wild type. 
Especially, mutants CYP106A2 A395K/G397N and CYP106A2 A395W/G397K showed 
a higher amount of 11α-hydroxyprogesterone relative to 15β-hydroxyprogesterone, up to 
13.5 and 56.4-fold, respectively, compared with that of CYP106A2 wild type. 
Furthermore, these mutants also exhibited a higher 6β-hydroxyprogesterone formation, 
approximately 10-fold in comparison with that of the wild type enzyme. Mutant 
CYP106A2 A395R/G397K converted progesterone mainly in 9α-position, showing a 
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1.26-fold increase relative to 15β-hydroxyprogesterone. Unfortunately, the catalytic 
activity of mutant CYP106A2 A395W/G395K, which showed a drastic shift of the regio-
selectivity of hydroxylation from C-15 to C-11, was lower than 50% compared with that 
of CYP106A2 wild type. Similarly, mutant CYP106A2 A395I, obtained by Virus (Virus, 
2006), lead to 97.2% of 11α-hydroxylated product but showed 50% less turnover rate 
than CYP106A2 wild type. Therefore, these 2 mutants, CYP106A2 A395I and 
CYP106A2 A395W/G397K, were chosen for further mutation by site directed 
mutagenesis to improve the catalytic efficiency. 
The 2 parent mutants CYP106A2 A395I and CYP106A2 A395W/G397W were mutated 
directly at positions which were reported in the literature to increase the catalytic activity. 
Thirty new mutants were obtained and coexpressed with pBAR_Twin, containing the 
cDNAs of AdR and Adx. The fluorescence assay was applied for the screening (Appel et 
al., 2005; Hannemann et al., 2005). Only 13 new mutants showed a higher relative 
fluorescence than the parental mutants. These 13 mutants were expressed and purified. 
The 11α-hydroxylation activity of mutants CYP106A2 A106T/A395W/G397K, 
CYP106A2 A243V/A395I, CYP106A2 T248V/A395I showed improvement of 1.59-, 
2.49- and 3.1-fold compared with the 15β-hydroxylation activity of CYP106A2 wild type. 
These mutants also showed an improvement in the regio-selectivity at 11α-position by a 
factor of 1.5, 1.5 and 1.2, respectively. Especially, mutants CYP106A2 D217V/A395I, 
CYP106A2 A106T/A395I/R409L and CYP106A2 F165L/A395I showed an elevation of 
the 11α-hydroxylation activity (by a factor of 7.1, 7.1 and 9.4, respectively) as compared 
with the 15β-hydroxylation activity of CYP106A2 wild type. They also increased the 
11α-production up to 1.2-, 2.51- and 1.38-fold, respectively, as compared with the single 
mutant CYP106A2 A395I. Interestingly, 2 mutants CYP106A2 A106T/A395I and 
CYP106A2 T89N/A395I produced 11α-hydroxyprogesterone in 2.8- and 4.4-fold higher 
amounts as compared with the parental mutant CYP106A2 A395I, and in 54.9- and 85.2-
fold higher amounts as compared with the wild type enzyme. However, these 2 mutants 
showed only a tiny increase of the catalytic efficiency of 11α-hydroxylation (2.6- and 1.6-
fold) as compared with CYP106A2 wild type catalyzed 15β-hydroxylation. Eight 
mutants, which showed a high catalytic rate along with a prominent 11α-hydroxylation 
activity, were then selected for in vivo progesterone conversion. The distribution of the 
hydroxylated progesterone products was observed to be different when comparing the in 
vitro and in vivo conversion. Except for mutants CYP106A2 A106T/A395I, CYP106A2 
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F165L/A395I and CYP106A2 A395W/G397K which showed slightly less 11α-
hydroxyprogesterone formation, the others showed higher yields of this product during in 
vivo compared with the in vitro conversion. The most interesting result was achieved for 
the progesterone hydroxylation of mutant CYP106A2 T89N/A395I. This mutant 
converted progesterone mainly at 11α-position. If 11α- hydroxyprogesterone was set to 
100%, the ratios of 15β-, 9α- and 6β-hydroxyprogesterone produced by this mutant were 
6.0%, 9.7% and 8.0%, respectively. Furthermore, the in vivo catalytic activity of mutant 
CYP106A2 T89N/A395I was faster than the in vitro conversion. Thus, it can be stated 
that a mutant with a completely changed regio-selectivity of hydroxylation (15β → 11α) 
was obtained being a great success and a prerequisite for a potential biotechnological 
application. 
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Introduction 
1. INTRODUCTION 
1.1. Steroid hormones 
Hormones are defined as organic substances which play a role as chemical messengers 
produced by organs or tissues such as the endocrine glands, the digestive tract, the heart, 
and the kidneys, or even the nerve cells. These substances are secreted by certain cells, 
liberated directly into the bloodstream and transported to a distant part or parts of the 
body where they exert a specific effect in extremely slight amounts. In the human body, 
they are responsible for regulation of metabolism, stimulation or inhibition of growth, 
activation or inhibition of the immune system, induction or suppression of apoptosis, 
preparation of the body for activities. Most hormones are subdivided chemically in 3 main 
classes: peptides, amines and steroids. However, some messenger substances such as the 
eicosanoids act similarly to hormones but act locally and can belong to a fourth group 
(Lehninger et al., 1998). 
The peptide hormones consist of 3 to more than 200 amino acids, involve all hormones of 
the hypothalamus, the hypophyse as well as the pancreas (e.g. insulin and glucagon). The 
amine hormones are the derivatives of amino acids, e.g. tyrosine (adrenaline, 
noradrenaline and thyroxin) which are produced e.g. in the medulla of the adrenal glands. 
The class of the fat soluble steroid hormones is primarily synthesized in the adrenal cortex 
and the gonads. They are generally carried in the blood bound to specific carrier proteins, 
for instance, sex hormone-binding globulin (Lehninger et al., 1998). Steroid hormones are 
composed of three six-membered rings and one five-membered ring, called 
perhydrocyclopentanophenanthren, which defines the “steroid nucleus” (Figure 1.1). 
These fat soluble steroid hormones are derived from cholesterol. They are able to pass 
through the cell membrane and can combine easily with a protein receptor. They are 
subdivided into glucocorticoids, mineralocorticoids, progestins, androgens and estrogens.  
Gluco- and mineralocorticoids are synthesized in the adrenal cortex with the participation 
of cytochromes P450 (Bureik et al., 2002). Glucocorticoids and adrenal androgens are 
synthesized in the Zona fasciculata/reticularis whereas mineralocorticoids are 
synthesized in the Zona glomerulosa of the adrenal gland (Miller and Tyrell, 1995). On 
the other hand, the sexual hormones are made by the testes or the ovaries (Brook, 1995). 
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Figure 1.1: The steroid structure containing the “steroid nucleus”, which is called 
perhydrocyclopentanophenanthren, composes of three six-membered rings and one five-
membered ring. 
The name of the so-called glucocorticoids descends from their role in the regulation of the 
glucose metabolism, their synthesis in the adrenal cortex and their steroidal structure. 
Glucocorticoids bind to the glucocorticoid receptor and cause their broad effects via the 
nuclear receptor affected pathways. The most important glucocorticoids are cortisol and 
corticosterone, whereby cortisol plays this role in human. Cortisol regulates or supports 
functions such as cardiovascular, metabolic, immunologic (suppressing the immune 
answer as well as inflammation routes and allergic reactions) and homeostatic processes. 
Furthermore, in human, corticosterone plays an important role as an intermediate of the 
steroidogenic pathway from pregnenolone to aldosterone. Glucocorticoids influence the 
activity of almost every cell in the body. Glucocorticoids are essential for life but also 
implicated in the pathogenesis of disease. They cause several adverse effects even though 
they still have a major place in the treatment of diseases since past 50 years as 
inflammatory drugs. They also play an important role in the regulation of growth and 
development of human but their levels are normally maintained within very narrow levels 
during development. They are required for the normal maturation of the lung and the 
central nervous system and play a critical role in the control of postnatal growth. 
Disturbances in the glucocorticoid milieu at critical stages of development may thus have 
long-term and potentially harmful effects on physiology, thereby influencing disease 
susceptibility (Buckingham et al., 1997; Buckingham, 2006). 
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Mineralocorticoids are mainly produced in the Zona glomerulosa and play a key role in 
the salt and water metabolisms and in regulating the blood pressure (Fardella and Miller, 
1996). The mineralocorticoid receptor is a nuclear receptor that is critical for controlling 
Na+ and K+ transport in epithelial cells, most notably in the kidney and colon (Pearce et 
al., 2003). It is also present in other non-epithelial tissues such as cardiac myocytes, blood 
vessels, adipose tissue and plays an important role in cardiovascular function, neuronal 
fate and adipocyte differentiation. It can be activated by both, mineralocorticoids and 
glucocorticoids (Yang and Young, 2009). The most important mineralocorticoid is 
aldosterone. Aldosterone is a key regulator of electrolyte and water homeostasis and plays 
a central role in blood pressure regulation (Escher, 2009). In the absence of 
mineralocorticoids, the kidney discards Na+ and retains K+ and H+, leading to 
hyponatremia, hyperkalemia, acidosis, dehydration and death (Miller, 2005). In contrast, 
increased circulating aldosterone is linked with insulin resistance and impaired glucose 
homeostasis which can result in the development of endothelial dysfunction, 
atherosclerosis, and kidney related disease and other disorders. Aldosterone-induced 
oxidative stress and inflammation cause adverse role in impairing insulin signaling. 
Consequently, the mineralocorticoid receptor blockade restores insulin sensitivity, 
counterbalances the deleterious cardiovascular and renal effects of aldosterone, and 
emerges as an alternative to improve blockade of the renin-angiotensin-aldosterone 
system. This effect potentially could contribute to reduce the burden of cardiovascular 
disease (CVD) and chronic kidney disease (CKD) (Lastra-Gonzalez et al., 2008). On the 
other hand, alterations in steroid hormone biosynthesis have been related with a number 
of pathologies, in particular hormone responsive cancers (such as breast and prostate 
cancer) and over production of aldosterone is related to cardiac fibrosis and heart failure 
(Costello-Boerrigter et al., 2007; Funder, 2007; Young et al., 2007; Shapiro et al., 2008). 
Sex hormones are essential for sexual differentiation and reproduction with distinct roles 
in women and men. Reproduction in both sexes is regulated by a hormonal system 
involving the hypothalamus, the pituitary gland, and the gonads (the testes or ovaries). 
Sex hormones also have a protective effect on a number of non-reproductive systems such 
as the immune, cardiovascular and the nervous system and on the bone structure (Evans, 
1988; Hess et al., 1997; Roselli, 2007; Prins and Putz, 2008). There are 3 classes of sex 
steroids: progestins, estrogens and androgens. Progestins play a role in the normal 
menstrual cycle and in the maintenance of pregnancy (Miller, 2005). Androgens regulate 
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male sex characteristics but serve in both sexes for muscle enhancement, and also for 
bone strength in case of estrogen-deficiency (Copland et al., 2009). Estrogens, which are 
responsible for development of female sex characteristics (Ottolenghi et al., 2007), also 
augment bone strength in both sexes (Schoenau, 2006). Sex steroids mostly circulate 
bound by albumin and sex hormone-binding globulin (Hammond and Bocchinfuso, 
1996). 
Several other tissues such as the gastrointestinal tract, the breast, and the immune system, 
which are not traditionally considered as steroid targets, are also affected by sex steroids. 
(Enmark and Gustafsson, 1999; Nagai and Brentani, 2008; Guerriero, 2009). For 
example, estrogen exerts anti-inflammatory effects while progesterone, on the other hand, 
has been shown to exert pro-inflammatory effects on neutrophils (Bouman et al., 2005). 
1.2. Cytochromes P450 
1.2.1. General aspects 
Cytochromes P450 (abbreviated CYP, P450) are hemoproteins which were discovered 
over 55 years ago and are broadly distributed in all domains of life. The name cytochrome 
P450 is derived from the fact that the spectral properties of the b-type heme display a 
typical absorption maximum of the reduced CO-bound complex at 450 nm. Therefore 
cytochrome P450 is a hemoprotein where P stands for pigments and 450 demonstrates the 
absorption peak of the ferrous CO complex at 450 nm. This unusual spectral feature is 
induced by a cystein thiolate group forming the fifth ligand of the heme iron and 
assigning the P450 enzymes as heme thiolate proteins. P450 enzymes are external 
monooxygenases, assuming that they need an external electron donor, which transfers the 
electrons necessary for oxygen activation and the following substrate hydroxylation 
(Bernhardt, 2006). In general, P450 systems catalyze the following reaction: 
RH + O2 + NAD(P)H + H+ → ROH + H2O + NAD(P)+ 
Many members of the P450 superfamily of hemoproteins are currently known, and the 
number grows continuously as more genomes are identified. There are 11614 sequenced 
P450 genes until November 2009, which are annotated by Nelson 
(http://drnelson.utmem.edu/cytochrome.html). The amount of P450 genes varies 
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enormously in different species. For instance, 3282 P450 genes are found in animals, 
1015 in bacteria, 22 in archaea and only 2 are discovered in viruses.  
There are more than 20 different reactions, which can be catalyzed by P450 enzymes such 
as hydrocarbon-, aromatic-, N-hydroxylation, N-, O- and S-dealkylation, alkene-, arene-
epoxidation, N-, S-oxidation, alkyne oxygenation, oxidative deamination, oxidative and 
reductive dehalogenations, alcohol and aldehyde oxidations, dehydrogenation, 
dehydratations, N-oxide reduction, epoxide reduction, reductive β-scission of alkyl 
peroxides, NO reduction, isomerization and oxidative C-C bond cleavage (Sono et al., 
1996; Mansuy, 1998; Guengerich, 2001a, b). To coordinate these functions their 
substrates are also diverse including fatty acid, steroids, prostaglandins as well as a 
multitude of foreign compounds such as drugs, anaesthetics, organic solvents, ethanol, 
alkylaryl hydrocarbon products, pesticides and carcinogens (Bernhardt, 2006). 
A catalytic cycle of the P450 reaction was proposed in 1968 (Gunsalus et al., 1975; 
Griffin, 1979) to prove the roles of iron, protein and oxygen, and was updated in 2005 by 
Denisov et al. shown in the following Figure 1.2. According to this, the catalytic turnover 
of P450 enzyme starts with the binding of substrate to the resting state of the low-spin 
(LS) ferric enzyme (1), results in altering the spin state to the high spin (HS) substrate 
bound complex (2) and perturbs the water coordinated as the sixth ligand of the heme 
iron. The HS Fe3+ is reduced to a ferrous state easily (3). In the next step, oxygen binds 
leading to an oxy-complex (4) which is the final stable intermediate in this cycle. The 
reduction of this complex by insertion of the second electron produces the peroxo-ferric 
intermediate (5a) and its protonated form the hydroperoxo-ferric intermediate (5b). 
Subsequently, ferric hydroperoxy is protonated once at the distal oxygen atom and 
undergoes heterolytic cleavage of the O-O bond to form Compound I (6) and water. This 
species then attacks the substrate to yield the hydroxylated product and dissociates to let 
the cycle start again. Additionally, there are three major abortive reactions: (i) 
autoxidation of the oxy-ferrous enzyme (4) with concomitant production of a superoxide 
anion and return of the enzyme to its resting state (2), (ii) a peroxide shunt, where the 
coordinated peroxide or hydroperoxide anion (5a,b) dissociates from the iron forming 
hydrogen peroxide, thus completing the unproductive (in terms of substrate turnover) two 
electron reduction of oxygen and (iii) an oxidase uncoupling with oxidation of the ferryl-
oxo intermediate to water by a four-electron reduction of the dioxygen molecule (Denisov 
et al., 2005).  
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Figure 1.2: Catalytic cycle of cytochrome P450. 
1.2.2. Electron transport systems for P450 enzymes 
As P450 enzymes are external monooxygenases, they need an external electron donor in 
the electron transfer chain for substrate conversion (Bernhardt, 2006). In general, 
Chapman has divided the P450 enzymes into 4 main classes based on the redox partners 
(http://www.chem.ed.ac.uk/chapman/p450.html). However, in 2007, Hannemann et al. 
updated and classified the electron transport systems for P450 enzymes into 10 classes 
(Hannemann et al., 2007). 
Class I systems involve most bacterial P450 systems as well as the mitochondrial P450 
systems from eukaryotes. They are composed of 3 separate proteins: a FAD-containing 
reductase which transfers reduction equivalents from pyridine nucleotide (NADH or 
NADPH) to the second component of the system, a ferredoxin, which in turn reduces the 
P450 enzyme itself (Hannemann et al., 2007). All 3 proteins are soluble in bacteria 
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(Figure 1.3A). However, only the ferredoxin is a soluble protein of the mitochondrial 
matrix, whereas the reductase and the P450 are membrane associated and membrane 
bound to the inner mitochondrial membrane, respectively (Figure 1.3B) (Bernhardt, 1996 
and 2006; Gunsalus and Sligar, 1978; Lambeth, 1991; Hannemann et al., 2007). 
 
 
A B 
C D 
Figure 1.3: Schematic organization of different P450 systems. A) bacterial system (Class 
Ia); B) mitochondrial system (Class Ib); C) microsomal system (Class II); D) self-
sufficient CYP102A1 (Class VIII) (Bernhardt, 2006; Hannemann et al., 2007). 
Class II P450 proteins are popular in eukaryotes and perform extremely diverse catalytic 
reactions. The monooxygenase system of this class is found in the endoplasmic reticulum 
(ER) of eukaryotes containing two integral membrane proteins: the P450 enzyme and the 
NADPH-dependent P450 reductase (Figure 1.3C). The reductase contains the prosthetic 
groups FAD and FMN, which transfer both required redox equivalents from NADPH to 
one of the many P450 isozymes (Hanukoglu, 1996). 
P450BM-3 (CYP102A1) isolated from Bacillus megaterium is a representative of a class 
VIII P450 (Hannemann et al., 2007). This system consists of P450 proteins, which are 
fused to their eukaryotic-like diflavin reductase partner – P450 reductase – in a single 
polypeptide chain and therefore, are catalytically self-sufficient as monooxygenase from 
NADPH to the component (Figure 1.3D) (Narhi and Fulco, 1986). 
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1.2.3. Cytochrome P450 structure 
The published sequences of P450 proteins reveals that the sequence identity between 
different P450 proteins (from mammalian to fungal or bacteria) is less than 20% 
(Hasemann et al., 1995). However, P450 enzymes share a common overall fold and 
topology. It has been shown that the conserved P450 structural core is formed by a four 
helix bundle composed of 3 parallel helices termed D, L and I and 1 antiparallel helix E as 
well as helices J and K (Presnell and Cohen, 1989). In this conserved form, the heme 
group is confined between the distal I-helix and proximal L-helix and bound to the 
adjacent cysteine heme ligand loop containing the P450 signature amino acid sequence 
FxxFx(H/R)xCxG. The absolutely conserved cysteine is the proximal or “fifth” ligand to 
the heme iron. This sulfur ligand is a thiolate (Dawson et al., 1976) and is the origin of 
the characteristic name given due to the 450nm Soret absorbance observed for the ferrous 
CO complex. Typically, the proximal cysteine forms two hydrogen bonds with 
neighboring backbone amides (Denisov et al., 2005). 
The long I-helix forms a wall of the heme pocket and contains the motif (A/G)-Gx(E/D)T 
which is placed in the middle of the helix. The I-helix also contains a highly conserved 
threonine that is positioned in the active site and is thought to be involved in catalysis 
(Imai et al., 1989; Martinis et al., 1989; Kimata et al., 1995; Vidakovic et al., 1998, Kim 
et al., 2008). The K-helix on the heme proximal side contains the conserved motif Glu-X-
X-Arg, which seems to be responsible for the stabilization of the core structure. The 
substrate binding pocket lies on the A and D pyrrol ring of the heme. There is an enough 
structural diversity to allow for the binding of substrates of significantly different sizes 
and with varying degrees of specificity to different P450 enzymes, although the P450-fold 
is highly conserved (Pylypenko et al., 2003; Zerbe et al., 2002). Gotoh proposed 6 
regions that are involved in substrate recognition site (SRS): the B’-helix region (SRS 1), 
part of the F and G helices (SRS 2 and SRS 3), a part of I-helix (SRS 4), the K-helix β2 
connecting region (SRS 6), and the β4 hairpin (SRS 5) line the P450 active site (Figure 
1.4). The predetermination of SRSs is helpful for the prediction of point mutations within 
the SRSs which significantly influence the substrate specificity (Gotoh, 1992). The SRSs 
are considered to be flexible protein regions, moving upon substrate binding in an 
induced-fit mechanism to favor substrate binding and subsequently the catalytic reaction 
(Pylypenko and Schlichting, 2004; Denisov et al., 2005). 
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SRS 2 
SRS 6 
Figure 1.4: The substrate recognition sequence (SRS) regions of CYP106A2: These 
regions are highlighted in green (SRS 1), in blue (SRS 2), in yellow (SRS 4), in orange 
(SRS 5) and in violet (SRS 6). SRS 5 is not existed in this enzyme. Heme group is 
presented in dark red. The CYP106A2 structure is derived from the computer modeling of 
Lisurek (Lisurek, 2004). 
1.2.4. Substrate binding 
The interaction between substrate and P450 enzymes has been observed according to the 
changes of the UV spectra. These changes indicate certain binding characteristics of 
ligand-P450 complexation reactions. It has been found that there are 3 categories ligand 
binding: type I, type II and type III (or reverse type I). The difference of ligand binding is 
used to classify the variety of P450 active site interactions as well as to calculate the 
modulation of hemoprotein spin state equilibria which can accompany substrate binding 
(Schenkman et al., 1981; Schenkman and Kupfer, 1982). A type I spectral change entails 
a reduction in the Soret absorption at 420 nm and a concomitant increase in the 390 nm 
absorption. In contrast to type I, substrates which exhibit a type II spectral change appear 
a decrease in absorption at around 390 - 405 nm and an increase at 425 - 435 nm, with an 
isobestic point at about 419 nm. The third spectral change that of reverse type I, shows an 
increased absorption of 420 nm and a decrease at 390 nm (Lewis, 1996). In general, it has 
been seen that the substrates for P450 enzymes are hydrophobic and poorly soluble in 
water. Substrate binding to P450 is a complex process since this biomolecular recognition 
event can trigger the change of the spin state from low spin to high spin in the heme iron 
and concomitantly induces a change in the reduction potential from ca. -300 to a ca. 100 
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mV more positive value (Guengerich et al., 1975; Williams-Smith and Cammack, 1977; 
Guengerich, 1983; Daff et al., 1997; Fantuzzi et al., 2004, Denisov et al., 2005). Many 
P450 enzymes have a broad spectrum of possible substrates (for each individual P450). 
When analyzing of the large structural rearrangement by X-ray crystal structure suggests 
that the aforementioned substrate recognition sites are flexible and provide substrate 
access to the heme, which is otherwise buried in the protein globule. In the absence of 
charged and hydrogen-bonding groups on substrate molecules as well as in the active sites 
of the most P450 enzymes, such binding mechanisms provide an alternative means for 
substrate stabilization at the active center (Denisov et al., 2005). 
1.3. CYP106A2  
CYP106A2 from Bacillus megaterium ATCC 13368 was first described by Mc-Aleer et 
al. in 1958 (Mc-Aleer et al., 1958). Until 1970s, however, this enzyme was studied 
continuously in more details by Berg et al. They demonstrated the presence of a 
cytochrome - dependent steroid hydroxylase system in Bacillus megaterium (Berg et al., 
1975, 1976) and subsequently isolated, characterized, and purified the 15β-hydroxylase to 
apparent homogeneity (Berg et al., 1979a, b).  
The CYP106A2 system is composed of 3 soluble protein components: (i) a reductase 
(megaredoxin reductase), (ii) a ferredoxin (megaredoxin), and (iii) the cytochrome P450 
(CYP106A2, P450-meg). The ferredoxin reductase is strictly NADPH-dependent, it 
contains the prosthetic group FMN, and has a molecular weight of 55 - 60 kDa. The 
megaredoxin, which was purified to apparent homogeneity, has a molecular weight of ca. 
14 kDa, (Berg et al., 1982). However, it is still unclear whether megaredoxin possesses a 
[2Fe-2S] cluster or a [4Fe-4S] cluster. The natural function of CYP106A2 is not yet clear. 
The activity of CYP106A2 can also be reconstituted with bovine adrenodoxin reductase 
and bovine adrenodoxin (Berg et al., 1979a; Simgen et al., 2000), with putidareductase 
and putidaredoxin from Pseudomonas putida (Agematu et al., 2006), or with Anabaena 
PCC 7119 ferredoxin reductase (FNR) in combination with either Anabaena PCC 7119 
ferredoxin (Fd) or Anabaena PCC 7119 flavodoxin (Fld) (Lisurek, 2004). Moreover, 
active CYP106A2 was already successfully expressed in Bacillus subtilis 168. Therefore, 
it is assumed that Bacillus subtilis 168 possesses an electron transfer system which can 
support the CYP106A2 activity (Rauschenbach et al., 1993). 
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The CYP106A2 gene was cloned and sequenced in 1993. It is a soluble protein that 
consists of 410 amino acids and has a molecular weight of 47.5 kDa (Rauschenbach et al., 
1993). It can hydroxylate a variety of 3-oxo-∆4-steroids mainly in 15β-position. For 
example, deoxycorticosterone (DOC), testosterone, and androstenedione are converted 
into their 15β-hydroxy homologues. However, ring A-reduced, aromatic, and 3β-hydroxy-
∆5-steroids do not serve as substrates for the 15β-hydroxylase system (Table 1.1) (Berg et 
al., 1976). Because of the capacity to hydroxylate a large variety of substrates, 
CYP106A2 becomes an interesting candidate for industrial production of steroids or their 
intermediates as useful pharmaceutical targets. CYP106A2 converts progesterone not 
only into 15β- and 6β-hydroxyprogesterone (Berg et al., 1979b) but also into di/poly-
hydroxyprogesterone and 2 other products: mono-hydroxyprogesterone at the 11α- and 
9α-positions (Figure 1.5) (Lisurek et al., 2004; Kang et al., 2004). In case of the 11-
deoxycorticosterone conversion, the substrate binding status was not detectable by UV-
Vis spectroscopy. However, an effect of substrate binding has been detected using the CO 
stretch mode infrared spectrum indicating that 11-deoxycoricosterone binds in the heme 
pocket near the iron ligand (Simgen et al., 2000).  
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Figure 1.5: Progesterone was converted by CYP106A2 into 4 mono- (15β-, 11α-, 9α-, 
6β-hydroxyprogesterone) products. 
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Table 1.1: Substrates of CYP106A2 from Bacillus megaterium ATCC 13368 (part 1). 
Substance Conversion Reference 
progesterone + Berg et al., 1976, 1979b; 
Kang et al., 2004 ; Lisurek et al., 2004 
DOC + Berg et al., 1976, 1979b 
6-fluor-16-methyl-DOC + Rauschenbach, 1993 
17α-hydroxyprogesterone + Berg et al., 1976, 1979b 
20α-dihydroprogesterone + Berg et al., 1976, 1979b 
androstendione + Berg et al., 1976, 1979b 
testosterone + Berg et al., 1976, 1979b; 
Agematu et al., 2006 
corticosterone + Berg et al., 1976, 1979b 
aniline + Berg and Rafter, 1981 
estrone - Berg et al., 1976 
estradiol - Berg et al., 1976 
estriol - Berg et al., 1976 
dehydroepiandrosterone - Berg et al., 1976 
pregnenolone - Berg et al., 1976 
5α-androstan-3α,17β-diol - Berg et al., 1976 
5α-dihydrotestosterone - Berg et al., 1976 
5α-androstan-3α,17β-diol - Berg et al., 1976, 1979b 
5α-androstan-3α,17β-diol-
3,17-disulphate 
- Berg et al., 1976 
5β-pregnan-3α,20α-diol - Berg et al., 1976 
cholesterine - Berg and Rafter, 1981 
desoxycholesterine - Berg and Rafter, 1981 
cholic acid - Berg and Rafter, 1981 
desoxycholic acid - Berg and Rafter, 1981 
β-sitosterol - Berg and Rafter, 1981 
lithocholic acid - Berg and Rafter, 1981 
hexadecanoic acid - Berg and Rafter, 1981 
octadecanoic acid - Berg and Rafter, 1981 
prostaglandin F2α - Berg and Rafter, 1981 
biphenyl - Berg and Rafter, 1981 
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Table 1.1: Substrates of CYP106A2 from Bacillus megaterium ATCC 13368 (part 2). 
Substance Conversion Reference 
benzo[a]pyrene - Berg and Rafter, 1981 
lidocaine - Berg and Rafter, 1981 
ethylmorphine - Berg and Rafter, 1981 
aminopyrine - Berg and Rafter, 1981 
7-ethoxyresorufin - Berg and Rafter, 1981 
imipramine + Berg and Rafter, 1981 
betulin acid + Chatterjee et al., 2000 
betulon acid + Chatterjee et al., 2000 
4-pregnen-20β-ol-3-on + Bleif, 2007 
17α-methyltestosterone + Bleif, 2007 
ethisterone + Bleif, 2007 
4-pregnen-17α,20α,21-
triol-3-on 
+ Bleif, 2007 
melengestrol acetate + Bleif, 2007 
dihydrochinopimaric acid + Bleif, 2007 
11-keto-β-boswellic acid + Bleif, 2007 
The amino acid sequence alignment result indicates that CYP106A2 resembles 
CYP106A1 (BM-1) from Bacillus megaterium 14581 with 63% identity and 76.5% 
similarity (Rauschenbach et al., 1993). Unfortunately, all attempts to crystallize 
CYP106A2 have been unsuccessfully yet, probably due to its insufficient stability. 
However, a model of CYP106A2 was constructed in 2004 by Lisurek et al. to gain deeper 
insight into the structure and other properties such as the catalysis, the stability or the 
redox-partner binding of CYP106A2. According to the model, in the heme binding site of 
CYP106A2, the A-ring propionic acid interacts in a bidentate fashion with residue 296, 
the D-ring propionic acid interacts with residues at positions 96, 353 and 100. Amino acid 
247, a strong conserved threonine in the I-helix, is also present in the active site adjacent 
to the heme and is suggested to be involved in the proton shuttle that is important for 
proton delivery and molecular oxygen activation (Lisurek, 2004; Lisurek et al., 2008). 
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1.4. Biocatalysis and evolution of the cytochrome P450 superfamily 
Cytochromes P450 are ubiquitously distributed enzymes, which possess high complexity 
and display a broad field of being catalyzed a variety of interesting reactions (Bernhardt, 
2006). Therefore, cytochromes P450 become promising candidates as biocatalyst for 
biotechnological application in the future. Biocatalysis in this era is regarded as a standard 
technology for the production of chemicals and their derivatives. An analysis of 134 
industrial biotransformations reveals that hydroxylases (44%) and redox biocatalysts 
(30%) are the most prominent categories (Straathof et al., 2002). The use of biological 
catalysis has been dramatically expanded because of the recent developments in the 
artificial evolution of genes that code for enzymes (Powell et al., 2001).  
Steroids comprise a large class of important chemical and biological compounds. Since 
1950, however, steroids have been the traditional field for industrially used microbial 
transformation using P450 enzymes due to their capability of accepting a wide array of 
complex molecules as substrates, and their exclusively selective, reactions with 
unparalleled chiral (enantio-) and positional (regio-) selectivities (Mahato and Garai, 
1997; Powell et al., 2001). These attributes have been implemented in various 
applications, especially in the food and pharmaceutical industries where high reaction 
selectivity on complex substrates is required (Schmid, 2001). In this context, biocatalysis 
has the potential to deliver “greener” chemical syntheses (Woodley, 2008). Nowadays, 
further developmental activities emphasize the application of genetic engineering of 
microorganisms and directed evolution of enzymes for improvement as steroid-
transforming agents (Mahato and Garai, 1997). The engineering of P450 proteins has 
been performed with several purposes. The first and the most fundamental task have been 
to enable successfully the recombinant expression in host systems such as bacteria. This 
in turn led to an effort to solubilize the proteins as a prerequisite for crystallization and 
structural study (Gilliam, 2008). 
1.4.1. Directed evolution 
Directed evolution is a useful tool to improve existing properties of enzymes or to 
develop new features. It does not need any protein structure or any information. An 
approach to improve a single protein or its parts includes cassette library mutagenesis 
(involving random, biased, saturation, and codon-based cassette mutagenesis), and 
random point mutagenesis (including error-prone polymerase chain reaction (PCR), 
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mutator strains, and UV or chemical mutagenesis). This can introduce (partially) random 
mutations either into a small selected region of a gene or through a gene (Powell et al., 
2001). 
The study of directed evolution is always better when wild type enzymes often show an 
undesirable substrate specificity, or a slight stability (during changing in pH, a 
temperature or using a different solvent), or a slight or an insufficient activity (Powell et 
al., 2001). Error prone PCR and gene shuffling methods are frequently applied during 
directed evolution. Generally, these methods become a powerful tool for improving the 
utility of the enzymes for industrial applications to have efficient to broaden the 
enzymatic activity and the substrate specificity. Arnold and coworkers, for example, 
succeeded in increasing the activity of P450 BM-3 towards the saturated hydrocarbon 
octane (Farinas et al., 2001) and even the gaseous alkane propane (Glieder et al., 2002). 
Some mutants were found, which lead either to the (R)- or (S)-enantiomeric products of 
alkane hydroxylation (Peters et al., 2003). Using error-prone PCR, some mutants of 
P450cam (Joo et al., 1999) and P450 BM-3 (Cirino and Arnold, 2003) were created, 
which demonstrated a high activity with hydrogen peroxide, which acts as both an oxidant 
and electron donor, thereby substituting NAD(P)H (Urlacher et al., 2004). However, the 
vast majority of error prone PCR-generated fragments are generally lost during the 
subcloning step, making it the bottleneck in the mutant library construction procedure 
(Bichet et al., 2004). On the other hand, the advantage of DNA family shuffling in 
comparison to other directed evolution techniques is the generation of highly diverse 
variants with a low level of deleterious mutations (Bacher et al., 2002). The DNA 
shuffling was introduced first in a single gene (Stemmer, 1994 a, b) and was subsequently 
extended to family shuffling, involving multi-gene shuffling of a limited number of 
evolutionarily related parental forms with high sequence identity (Crameri et al., 1998). 
The screening of the shuffled library of three highly homologous mammalian genes 
(CYP2C9, CYP2C11 and CYP2C19) for indole oxidation revealed some clones with 
higher levels of indigo pigment production to those of the parental P450 enzymes and two 
clones with elevated P450 expression (Rosic et al., 2007). 
In general, directed mutagenesis involves 2 steps. Firstly, a mutant library is generated 
and secondly, a mutant enzyme, which is changed or improved regarding desired 
characteristics, is selected through a screening process (Slazar and Sun, 2003). The most 
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complicated part of the screening process is to develop and optimize a rapid screening 
system, which characteristics must be adapted to the studied protein.  
1.4.2. Site-directed mutagenesis  
Site directed mutagenesis has been used as a tool for molecular modeling, improving 
substrate range or evolutionary study for cytochromes P450. It was successfully applied 
to identify residue responsible for substrate specificity in many cytochromes P450 In 
contrast to the directed evolution, the rational design of an enzyme through site-directed 
mutagenesis requires a solid structural basis and an understanding of its catalytic 
mechanism (Urlacher et al., 2004). In recent years, in the absence of crystal structures, 
homology modeling has become an important tool to study P450 functions. The models 
can be implemented to identify or confirm key residues, evaluate enzyme-substrate 
interactions and explain changes in protein stability and/or regio- and stereo-specificity of 
substrate oxidation upon residue substitution by site-directed mutagenesis. This 
phenomenon has also been utilized to analyze the binding of inhibitors or activators, as 
well as alterations in inhibition and activation due to residue replacement (Szklarz and 
Halpert, 1997). Several approaches of site-directed mutagenesis have been utilized in past 
several years. Among this, P450 BM-3 (CYP102A1), from Bacillus megaterium, is one of 
the most extensively studied bacterial cytochromes to generate high catalytic activity. The 
analysis of the structure and the comparison of substrate-bound and substrate-free forms 
revealed the importance of the residues R47 and Y51 at the entrance of the substrate 
access channel. The mutation of these residues alters the enzyme’s specificity 
(Carmichael and Wong, 2001; Cowart et al., 2001). However, the substitution of either 
residue R47 or residue Y51 alone did not lead to an observable effect on the substrate 
binding affinity and activity (Li and Poulos, 1999). It was also possible to shift the 
substrate specificity of P450 from C-12 fatty acids to C-10 and C-8 fatty acids using 
mutant CYP102A1 F87V in the fatty acid pseudosubstrates 10- and 8-p-
nitrophenoxycarboxylic acid (Lentz et al., 2001). A triple mutant (CYP102A1 
A74G/F87V/L188Q) was able to hydroxylate indole (Appel et al., 2001) and also a wide 
range of other substrates that have virtually no resemblance to fatty acids, which are 
regarded as the natural substrates of CYP102A1. A key finding in the latter area was the 
oxidation of polycyclic aromatic hydrocarbons (PAHs) (Carmichael and Wong, 2001; Li 
et al., 2001). Three amino acid substitutions in CYP102 (R47L/Y51F/A264G) led to a 
200-fold increase of the activity of this enzyme to PAHs. The available structure of the 
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enzyme shows non-productive binding of the substrates with their ω-end distant from the 
iron in a hydrophobic pocket at one side of the active site. This pocket was filled by larger 
hydrophobic side-chain amino acid replacing residue A82 (Huang et al., 2007) to improve 
substrate binding and catalytic efficiency. Moreover, mutants (CYP102A1 
V78A/F87A/I263G and CYP102A1 S72Y/V78A/F87A) exhibited an alteration in the 
regio-selectivity of the subterminal fatty acid hydroxylation towards γ- and δ-positions, 
which have not been observed in the CYP102A1wild type enzyme (Dietrich et al., 2009). 
Molecular modeling, by doing site directed mutagenesis, is a useful tool that can aid in 
elucidating substrate specificities and to complement site-directed mutagenesis studies in 
order to identify critical structural features of the P450 superfamily and other enzymes 
(Lewis and Lake, 1995). Moreover, using a combination of directed evolution and site-
directed mutagenesis now becomes a choice for molecular evolution researchers because 
it increases the chance to obtain a desired mutant with interesting characteristics. For 
example, CYP102A1 wild type has a low hydroxylation activity for β-ionone (<1 min-1). 
Substitution of phenylalanine by valine at position 87 led to a more than 100-fold increase 
in β-ionone hydroxylation activity (115 min-1). The enzyme activity could be further 
increased by both site-directed and random mutagenesis. The mutant CYP102A1 
R47Y/Y51F/F87V, designed by site-directed mutagenesis, and the mutant CYP102A1 
A74E/F87V/P386S, obtained after two rounds of error-prone polymerase chain reaction 
(PCR), exhibited an increase in activity of up to 300-fold compared to the wild type 
enzyme (Urlacher et al., 2006). 
1.5. Steroid 11-hydroxylation  
The steroid derivatives are difficult to synthesize by chemical pathways due to low regio-
selectivity and reaction rate, whereas the synthesis can be obtained by biotransformation 
with microorganisms with specific regio-selectivity as well as a higher turnover rate. In 
1952, Murray and Peterson from the Upjohn company (Michigan, USA) patented the 
process of 11α-hydroxylation of progesterone by Rhizopus species (Murray and Peterson, 
1952). Since then, a wide range of publications concerning the Rhizopus species (R. 
nigrican, R. arrhizus, R. stolonifer) and their 11α-hydroxylation on different substrates is 
reported (Gabinskaia et al., 1971; Eysymontt et al., 1975; Holland and Chenchaiah, 1985; 
Breskvar et al., 1987; Choudhary et al., 2005). The 11-hydroxylation of steroids is mainly 
found in the fungal kingdom. The 11β-hydroxylase of the filamentous fungus 
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Cochliobolus lunatus hydroxylates 17α,21-dihydroxypregna-1,4-diene-3,20-dione-17-
acetate to yield 11β-deoxyprednisolone-17-acetate, leading to form prednisolone 17-
acetate and subsequently prednisolone. Prednisolone is useful for the treatment of a wide 
range of inflammatory and auto-immune conditions such as asthma (Undisz et al., 1992). 
The P450 from Curvularia lunata (P450lun) produces cortisol from 11-deoxycortisol in 
cell-free extracts (Suzuki et al., 1993), as well as an 11α-product from the compound 17α-
hydroxypregn-4-ene-3,20-dione-21-acetate (cortexolone-21-acetate, RSA) (Wang et al., 
2001) in the presence of NADPH and O2. Likely, an Absidia sp. 28 strain, a cosmopolitan 
and ubiquitous filamentous fungi in nature, is shown to have high activity of 11α-
hydroxylation using 16β-methyl-17α,21-dihydroxy-1,4-pregnadiene-3,20-dione as a 
substrate (Xu et al., 2000). Similarly, another filamentous fungi, Cunninghamella elegans 
was also described to perform the steroid conversion towards 11-hydroxylation. Its 
protoplasts showed 11α-, and 11β-hydroxylating ability of 17α,21-dihydroxypregna-1,4-
diene-3,20-dione (Dtugoński et al., 1992). 
Progesterone hydroxylation at 11α-position by fungi is also reported in Aspergillus 
species. It was found that the different strains of Aspergillus species are involved in the 
oxygenation at C-11 in the steroid skeleton (Fried et al., 1952; Dulaney et al., 1955; 
Charney and Herzog, 1967; Clegg et al., 1973). One of the most investigated strains, A. 
ochraceus TS (Samanta et al., 1978; Ghosh and Samanta, 1981; Samanta and Ghosh, 
1987), can hydroxylate progesterone in high yields (85 - 90% in 30 min) (Jayanthi et al., 
1982). The monooxygenase of A. ochraceus TS was capable of 11α-hydroxylation of 
progesterone. This fungal monooxygenase has many features in common with that of 
mammalian liver microsomes (Samanta and Ghosh, 1987). Some other strains, A. 
fumigatus and A. niger, also exhibit high efficiency of 11α-hydroxyprogesterone 
formation. A. fumigatus hydroxylates exogenous progesterone and forms 11α- and 15β-
hydroxyprogesterone as major products (Smith et al., 1994), whereas A. niger forms 11α- 
and 6β-hydroxyprogesterone in 65.7% and 35.5% relative yield (Walaa et al., 2009). 
Besides in the fungal kingdom, the steroid hydroxylation in 11α-position was also 
discovered in bacteria such as Bacillus cereus (Mc-Aleer et al., 1958) and Streptomyces 
species (Shirasaka and Tsuruta, 1960).  
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In case of human, the 11β-hydroxylase (CYP11B1) participates in the adrenal 
steroidogenesis converting 11-deoxycortisol to cortisol, the main glucocorticoid in 
humans. On the other hand, CYP11B2 firstly catalyzes the conversion of 11-
deoxycorticosterone to corticosterone and then performs 18-hydroxylation and 18-
oxidation to lead aldosterone, the most important human mineralocorticoid. The 11-
hydroxylase activity is found not only in the mitochondrial fraction of adrenals but also in 
the human liver microsomal P450 enzymes. For example, CYP3A4 is found to be 
responsible for testosterone 11β-hydroxylation in the human liver. It has been suggested 
that this reaction may have the potential either for diagnosis or therapeutic treatment of 
adrenal insufficiency diseases (Choi et al., 2005). 
As steroid 11α-hydroxylation plays a pivotal role in biotechnology, several researches 
were carried out and patented. It involves the application of A. ochraceus, A. niger, R. 
stolonifer, R. nigricans, R. arrhizus and strains of Pestelotia which are used for the 
conversion of substrates having a purity of less than 97% and at a concentration greater 
than 10g/L (Wiersma and van der Meijden, 2000 and 2002). 
1.6. Application of steroids as therapeutically agents 
The pharmaceutical application of steroids has long been practised. Many steroids are 
interesting pharmaceutical target substances for the production of anti-inflammatory, 
diuretic, anabolic, contraceptive, ant androgenic, progestational, and antitumor drugs. For 
instance, histone deacetylases (HDAC) are involved in estrogen receptor (ER)-mediated 
gene transactivation. The HDAC inhibitors have been shown to inhibit tumor growth, 
now are used in clinical trials for the treatment of cancer (Secrist et al., 2003; Bicaku et 
al., 2008). As the liver X receptors (LXRα and LXRβ) are involved in cholesterol 
transport, glucose metabolism and inflammation, synthetic LXR ligands have been 
designed to treat disorders such as atherosclerosis and diabetes (Michael et al., 2005). 
Some cholestanes are of great interest since they show an antimicrobial effect (Maltais et 
al., 2004; Hanson, 2006). 
Glucocorticoids are used in the treatment of inflammatory, kidney, lung, skin, eye and 
liver diseases, of allergic reactions, blood illnesses, tumors, and gastrointestinal, 
endocrine and neurological diseases (Buckingham, 2006). Estrogens may be useful for the 
treatment and prevention or delay of the onset of Alzheimer’s disease (Honjo et al., 
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2003). Progesterone is applied in combined oral contraceptives. It is helpful for women 
not only who require contraception but also who expect the advantage of avoiding 
seborrhea or acne (Raudrant and Rabe, 2003; Sitruk-Ware, 2008).  
Progestins and their derivatives are used mainly as contraceptives and in hormone 
replacement therapy for women in the menopause. The 17α-hydroxyprogesterone 
derivative is clinically applied for the treatment of breast cancer (Pasqualini et al., 1998). 
Some other mono-hydroxyprogesterones, e.g. 11α- and 11β-hydroxyprogesterone, have 
been reported to inhibit 11β-hydroxysteroid dehydrogenase, which plays an important 
role of blood pressure regulation (Souness and Morris, 1996; Morita el al., 1996). 11α-
hydroxyprogesterone also exhibits an anti-androgenic activity with minimal estrogenic 
and progestational side effects (Tamm et al., 1982; van der Willingen et al., 1987). 9α-
hydroxyprogesterone is a useful intermediate in the production of fludrocortisone and 
fluoxymesterone, which show both glucocorticoidal and progestational activity (Kang et 
al., 2004; Lisurek et al., 2004). Dienogest and drospirenone have been synthesized in the 
last decade and may be considered as the fourth-generation of progestins. They have 
instead of an androgenic effect a partial anti-androgenic effect which leads to decreased 
salt and water retention and a lowering in blood pressure (Sitruk-Ware, 2008). 
Taken together, it can be stated that steroids are of high pharmaceutical and thus 
biotechnological value. Cytochromes P450 are involved in modifying steroid molecules 
and are therefore target for site-directed mutagenesis and directed evolution to improve 
their properties for a potential industrial application. 
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1.7. Aim of the work 
The overall purpose of this work is to create of mutants CYP106A2 from Bacillus 
megaterium ATCC 13368 by site-directed mutagenesis, which hydroxylate progesterone 
mainly in 11α-position in comparison with the published 15β-position. The shift of 
hydroxylation from the 15β- to 11α-position will help to understand more details for the 
study of structure-function relationship of this enzyme. Moreover, the aim is also focused 
to produce 11α-hydroxyprogesterone due to its higher pharmaceutical value as compared 
with the application of the 15β-hydroxyprogesterone. The main objectives of my 
dissertation are as follows: 
1)  To select mutant clones from the saturation mutagenesis library at position A395 
and G397, which lie on the putative substrate recognition site (SRS) 6 of 
CYP106A2, showing increased production of 11α-hydroxyprogesterone. 
2) To create mutants by site directed mutagenesis which show a high catalytic 
efficiency with retaining their regio-specificity towards 11α-hydroxyprogesterone. 
3) To compare the in vivo and in vitro progesterone conversion for the selected 
mutants. 
Materials and Methods 
2. MATERIALS AND METHODS 
2.1. Materials 
All the chemicals and reagents used in this work have analytical grade. The steroid 
standards (20β-, 15β-, 11α-, 9α-, 6β-hydroxyprogesterone), are gifts from AG Schering 
company (Berlin, Germany). 
2.1.1. Bacteria 
The Escherichia coli bacterial strains used in this work are summarized in the Table 2.1. 
Table 2.1: Genotype of the E. coli strains applied in the experiments. 
Strain Genotype Reference Comment 
TOP10F’ F’{lacIq Tn10 (TetR)} mcrA Δ(mrr-
hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 
recA1 araD139 Δ(ara-leu)7697 galU 
galK rpsL endA1 nupG 
US Patent 
5,487,993 
(Invitrogen, 
2004) 
 
used for 
minipreparation 
JM109 endA1, recA1, gyrA96, thi, hsdR17(rk-, 
mk+), relA1, supE44, Δ(lac-proAB), [F’ 
traD36, proAB, lacIqZΔM15] 
Yanisch-
Perron et al. 
(Promega, 
1985) 
 
expression of 
CYP106A2 
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2.1.2. Plasmids 
In this work, two plasmids pACYC_FHH2 and pBar_Twin were used. Vector 
pACYC_FHH2 carries cDNA of CYP106A2 and pBar_Twin carries cDNAs of 
adrenodoxin reductase (AdR) and of truncated adrenodoxin (Adx 4 - 108) (Hannemann et 
al., 2006). These plasmids were coexpressed in E.coli JM109 to be able to screen for 
active mutants as well as for studying the in vivo progesterone hydroxylation. 
 P_tac 2 
 
 
 
 
 
 
 
Figure 2.1: CYP106A2 is encoded on the 5.4 kb construct pACYC_FHH2 under the 
control of tac promoter and a transcription terminator derived from the rrnB gene. The 
plasmid features the low-copy pMB1 origin of replication and the sequence of the “cat” 
resistance gene. The 6.7 kb vector pBAR_Twin contains two copies of the tac and one 
lacUV5 promoter, the cDNAs from AdR and Adx, the β-lactamase gene, and the high-
copy origin of replication of the pUC series of plasmid (Hannemann et al., 2006). 
ori pMB1 
Cm 
P_trc 
T_rrnb 
CYP106A2 
Nco I 
Sal I 
Xba I 
Hind III 
Nco I 
pACYC_FHH2 
(5.4 kb) 
Nde I 
P_lacUV5 
P_tac 1 
AdR 
ori pUC 
Amp 
lacI 
Kpn I 
Adx pBar_Twin 
EcoR I (6.7 kb) 
T 
Hind III 
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2.1.3. Oligonucleotides 
Oligonucleotides were synthesized by Eurofins MWG Synthesis Company (Ebersberg, 
Germany). The primers for site directed mutagenesis were designed with an online tool to 
introduce a silent site selector into the primer (http://rana.lbl.gov/SSS/bin/SSS2.cgi). The 
sequences of the oligonucleotides were presented in Table 2.2. 
Table 2.2: Sequences of the oligonucleotides (part 1). 
Name  Target Sequence (5’Æ 3’) 
F2for Forward primer for sequencing the whole 
vector pACYC_FHH2_CYP106A2 
GATCTCTAGACTGCACGGT
GCACCAATGC 
F2rev Reverse primer for sequencing the whole 
vector pACYC_FHH2_CYP106A2 
TGCGGTCGACAAAAAGAG
TTTGTAGAAACGC
T89Nfor Forward primer for Quik Change at 
position T89N containing the restriction 
site for Ase I 
CCTGAAAAGATCCAAATT
AATGAATCGGATCCACCT 
T89Nrev Reverse primer for Quik Change at 
position T89N containing the restriction 
site for Ase I 
AGGTGGATCCGATTCATTA
ATTTGGATCTTTTCAGG  
A106Tfor Forward primer for Quik Change at 
position A106T containing the restriction 
site for Acl I 
CTGGCAGCAACGTTCACA
CCT 
A106Trev Reverse primer for Quik Change at 
position A106T containing the restriction 
site for Acl I 
AGGTGTGAACGTTGCTGC
CAG 
D217Vfor Forward primer for Quik Change at 
position D217V containing the restriction 
site for Sca I 
GCGGATGATATCATCTCA
GTACTATTGAAGTCGG 
D217Vrev Reverse primer for Quik Change at 
position D217V containing the restriction 
site for Sca I 
CCGACTTCAATAGTACTGA
GATGATATCATCCGC 
A243Vfor Forward primer for Quik Change at 
position A243V  
ATTTTAGGTGTAGGAGTCG
AG 
A243Vrev Reverse primer for Quik Change at 
position A243V 
CTCGACTCCTACACCTAAA
AT 
R409Lfor Forward primer for Quik Change at 
position R409L containing the restriction 
site for Nhe I 
CCGCTTAAGGCTAGCCTCA
TGTAA 
R409Lrev Reverse primer for Quik Change at 
position R409L containing the restriction 
site for Nhe I 
TTACATGAGGCTAGCCTTA
AGCGG 
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Table 2.2: Sequences of the oligonucleotides (part 2). 
Name  Target Sequence (5’Æ 3’) 
F165Lfor Forward primer for Quik Change at 
position F165L containing the restriction 
site for Bsm BI 
CGAAAGATCGTCTCTTGTT
GAAGAAATGGGTGG 
F165Lrev Reverse primer for Quik Change at 
position F165L containing the restriction 
site for Bsm BI 
CCACCCATTTCTTCAACAA
GAGACGATCTTTCG 
T247Afor Forward primer for Quik Change at 
position T247A containing the restriction 
site for Spe I 
GGAGTCGAGGCAACTAGT
CAT 
T247Arev Reverse primer for Quik Change at 
position T247A containing the restriction 
site for Spe I 
ATGACTAGTTGCCTCGACT
CC 
T247Vfor Forward primer for Quik Change at 
position T247V containing the restriction 
site for Spe I 
GGTGCAGGAGTCGAGGTA
ACTAGTCATTTATTGGCC 
T247Vrev Reverse primer for Quik Change at 
position T247V containing the restriction 
site for Spe I 
GGCCAATAAATGACTAGT
TACCTCGACTCCTGCACC 
T247Ffor Forward primer for Quik Change at 
position T247F containing the restriction 
site for Spe I 
GGTGCAGGAGTCGAGTTT
ACTAGTCATTTATTGGCC 
T247Frev Reverse primer for Quik Change at 
position T247F containing the restriction 
site for Spe I 
GGCCAATAAATGACTAGT
AAACTCGACTCCTGCACC 
T247Sfor Forward primer for Quik Change at 
position T247S containing the restriction 
site for Spe I 
GGAGTCGAGTGGACTAGT
CAT 
T247Srev Reverse primer for Quik Change at 
position T247S containing the restriction 
site for Spe I 
ATGACTAGTCCACTCGACT
CC 
T247Wfor Forward primer for Quik Change at 
position T247W containing the 
restriction site for Spe I 
GGTGCAGGAGTCGAGTGG
ACTAGTCATTTATTGGCC 
T247Wrev Forward primer for Quik Change at 
position T247W containing the 
restriction site for Spe I 
GGCCAATAAATGACTAGT
CCACTCGACTCCTGCACC 
T248Afor Forward primer for Quik Change at 
position T248A containing the restriction 
site for Ahd I 
GCAGGAGTCGAAACAGCC
AGTCATTTATTG 
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Table 2.2: Sequences of the oligonucleotides (part 3). 
Name  Target Sequence (5’Æ 3’) 
T248Arev Reverse primer for Quik Change at 
position T248A containing the restriction 
site for Ahd I 
CAATAAATGACTGGCTGTT
TCGACTCCTGC 
T248Vfor Forward primer for Quik Change at 
position T248V containing the restriction 
site for Ahd I 
GGTGCAGGAGTCGAGACA
GTCAGCCATTTATTGGCC 
T248Vrev Reverse primer for Quik Change at 
position T248V containing the restriction 
site for Ahd I 
GGCCAATAAATGGCTGAC
TGTCTCGACTCCTGCACC 
A395Ifor Forward primer for Quik Change at 
position A395I containing the restriction 
site for Bmr I 
GAATCTTACCGATTCAATT
ACTGGGCAAACTTTG 
A395Irev Forward primer for Quik Change at 
position A395I containing the restriction 
site for Bmr I 
CAAAGTTTGCCCAGTAATT
GAATCGGTAAGATTC 
A395W/ 
G397Kfor 
Forward primer for Quik Change at 
positions A395W and G397K containing 
the restriction site for Pvu II 
CTTACCGACAGCTGGACC
AAGCAAACTTTGACC 
A395W/ 
G397Krev 
Reverse primer for Quik Change at 
positions A395W and G397K containing 
the restriction site for Pvu II 
GGTCAAAGTTTGCTTGGTC
CAGCTGTCGGTAAG 
2.2. Methods 
2.2.1. Preparation of E.coli competent cells 
The preparation of chemically and electro-competent E.coli cells TOP10F’ and JM109 
was carried out as described by Sambrook and Russell (Sambrook and Russell, 2001). 
The transformation efficiency of the competent cells was checked. 
2.2.1.1. Chemically competent cells 
Bacterial cells were streaked from frozen glycerol stock, plated onto LB agar and 
incubated overnight at 37°C. Five ml LB medium (Appendix 6.1.1.) with a selected single 
E.coli colony was inoculated and incubated overnight at 37°C with a shaking speed of 
180 rpm. The culture was 50-fold diluted in 100 ml fresh LB medium, 500 μl of 2M 
MgSO4 was added and shaken continuously at 37°C until an OD600 of 0.4 - 0.6 
(approximately 2.5 - 3 hr) was reached. The cells were harvested in sterile 50 ml Falcon 
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tubes at 3500 rpm for 5 min. The supernatant was discarded and the pellet was gently 
resuspended in approximate 8.5 ml of transfer buffer I (TFPI) (Appendix 6.2.1.1.). The 
cells were stored on ice for 1 hr. After the second centrifugation at 3500 rpm for 5 min, 
the cells were gently resuspended in approximately 1 ml of transfer buffer II (TFPII) 
(Appendix 6.2.1.2.). Aliquots of 50 μl volume of the competent cells were stored at minus 
80°C.  
2.2.1.2. Electro-competent cells 
Preferably, a single colony of E.coli from fresh LB plate was selected for inoculating a 10 
ml LB overnight starter culture in a 37°C shaker. Subsequently, the culture was diluted 
100-fold in 1 L fresh LB medium and placed in a 37°C shaker until the OD600 reached 0.4 
- 0.6. The culture was removed from the shaker and placed on ice. The cells were 
centrifugated at 4000 rpm, and 4°C for 15 min. The supernatant was discarded 
immediately and the pellet was gently washed twice in ice cold destillated H2O and one 
more time in 20 ml ice-cold 10% glycerol. The pellet was centrifuged at 4000 rpm, 4°C 
for 10 min and after removing the supernatant, each pellet was resuspended in 1ml ice-
cold 10% glycerol. 50 μl aliquots of cells were frozen in liquid nitrogen and stored at 
minus 80°C. 
2.2.2. Transformation of the plasmid 
With the aim to introduce the plasmid DNA into E.coli cells, heat shock transformation 
and electroporation were applied. The stressed cells (by physical factors) were recovered 
by nutrient SOC medium (Appendix 6.1.4.) through shaking at 37°C for 1 hr. 
2.2.2.1. Heat shock transformation 
Approximately, 20 ng plasmid DNA was added into a 50 μl freshly thawed aliquot of 
competent cells and placed on ice for 20 min. The heat shock was performed at 42°C for 
90 sec followed by incubation on ice for 5 min. Afterwards, 1 ml SOC medium was added 
to the cell tube and shaken at 37°C, 200 rpm for 1 hr. Suspensions (200 μl) were plated 
out on LB agar containing appropriate antibiotic. 
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2.2.2.2. Eletroporation 
To electroporate DNA into the cells, the electrocompetent cells were mixed with the 
plasmid DNA to be transformed and then pipetted into a 0.1 cm plastic cuvette containing 
electrodes (Peqlab, Erlangen, Germany). A short electric pulse, 1800 V/cm, was applied 
to the cells causing smalls holes in the membrane through which the DNA entered. The 
cells were then incubated with SOC medium before plating out on LB agar containing 
appropriate antibiotic. 
2.2.3. Preparation of plasmid 
2.2.3.1. Minipreparation 
Plasmid rescue and purification were performed following the instruction of a 
commercially available kit from Macherey-Nagel (Nucleobond® Minipreparation, 
http://www.mn-net.com). The DNA yield and purity were determined using the 
absorbance at 260 nm where DNA absorbs light most strongly. DNA concentration can be 
estimated by the following equation: 
Concentration (μg/ml) = A260 × f × xε 
A260: absorbance at 260 nm 
f: dilution factor 
xε: A260 of the pure double strands DNA = 50 μg/ml 
2.2.3.2. “Quick and dirty” preparation 
A transformed E.coli culture was incubated in 5 ml LB plus chloramphenicol (35 μg/ml) 
at 37°C overnight. The culture was centrifuged at 10000 rpm for 5 min. The pellet was 
resuspended in 0.3 ml of L1 buffer (Appendix 6.2.2.). L2 buffer (Appendix 6.2.2.) was 
added with a volume of 0.3 ml, mixed gently and incubated for 5 min at room 
temperature. 0.3 ml L3 buffer (Appendix 6.2.2.) was added and mixed. The suspension 
was centrifuged at 10000 rpm for 1 min for phase separation. Afterwards the supernatant 
was transferred and extracted with 450 μl PCIA (Phenol/Chloroform/Isoamylalcohol, 
25/24/1) and then 450 μl CIA (Chloroform/Isoamylalcohol, 24/1) for a second time. The 
DNA plasmid was precipitated by adding 750 μl isopropanol, mixed and centrifuged at 
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15000 rpm and 4°C for 30 min. The DNA pellet was washed once with 500 μl of 70% 
ethanol and dried by Speed-vac (Univapo 100H, UniEquip, München, Deutschland). The 
plasmid was dissolved in 50 μl distillated water. 
2.2.4. Separation of plasmids pACYC_FHH2 and pBAR_Twin 
For screening, a cotransformation of E.coli with plasmids pACYC_FHH2 (containing the 
cDNA of CYP106A2 wild type or mutants and a chloramphenicol resistance gene) and 
pBAR_Twin (containing the cDNA of adrenodoxin, the cDNA of adrenodoxin reductase 
and an ampicillin resistance gene) (Figure 2.1) was required. After screening, these 
plasmids had to be isolated. The cell-material from glycerol stock (-80°C) was inoculated 
in 5 ml LB plus 35 μg/ml chloramphenicol and incubated at 37°C overnight. 
Subsequently, the plasmid was isolated via the “Quick and Dirty” preparation and 
transformed into chemical competent E.coli cells JM109 by heat shock. The cells were 
spread out on LB agar containing chloramphenicol and incubated overnight at 37°C. 
Approximate 10 single colonies were picked from the LB agar plate and transferred to 
another LB agar containing only chloramphenicol (35 μg/ml) as well as to LB agar 
containing chloramphenicol (35 μg/ml) and ampicillin (100 μg/ml). The plates were 
incubated overnight at 37°C. Only clones containing pACYC_FHH2_CYP106A2 were 
able to grow on chloramphenicol. These clones then were inoculated in LB medium plus 
chloramphenicol for minipreparation. 
2.2.5. Site-directed mutagenesis 
Site-directed mutagenesis was used to make specific point mutations, and delete or insert 
single or multiple amino acids. In this method, Pfu DNA polymerase was used to replicate 
both plasmid strands with a high fidelity. The procedure was performed using a 
recombinant vector with an inserted gene of interest and 2 oligonucleotide primers 
containing the desired mutation. This incorporation of primers generated a mutant 
plasmid containing staggered nicks. The treatment of the product with Dpn I resulted in 
the digestion of the parental DNA template. 
All the mutations in cDNA of CYP106A2 were generated in the vector pACYC_FHH2 
by site-directed mutagenesis using Quik-Change Site-Directed Mutagenesis Kit 
(Stratagene Ltd, Cambridge, UK) according to manufacturer’s instruction and using 
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mutagenic primers list under section 2.1.3. The reaction was carried out as shown in 
Table 2.3. 
Table 2. 3: PCR reaction mix for plasmid DNA. 
Component Volume 
10xPfu reaction buffer 5 μl 
dNTPs (100 mM) 2 μl 
plasmid (10 ng) 1 μl 
primer forward (10 pmol) 1 μl 
primer reverse (10 pmol) 1 μl 
Pfu polymerase 1 μl 
water (dd H2O) up to 50 μl 
Reaction was run in the Thermal cycler PT-100 (MJ Reasearch Inc.) with the following 
program: 
95oC for 5 min 
  95oC for 30 sec 
  60oC for 1 min 18 cycles 
  72oC for 10 min 
  72oC for 10 min 
  4oC for ever 
The PCR product was digested with 1 μl of Dpn I (10 U/μl ) for 3 hr at 37oC to remove 
the parental template. To increase the efficiency of PCR product transformation by 
reducing the salt concentration, 20 μl of PCR product was dialyzed into a petri plate 
containing 10% glycerol through the filter membrane (Millipore, Typ VS 0.025 μm, ∅ 
25mm) for 1 hr at room temperature. After dialyzing, all the 20 μl PCR product was used 
for electroporation into competent E.coli TOP10F’ and spread out on the LB plate 
containing chloramphenicol. On the next day, the single colonies (approximate 6 clones) 
were inoculated in 5 ml of the LB plus chloramphenicol and shaken overnight for plasmid 
minipreparation. Each clone was checked with corresponding restriction digestion and the 
positive clones were sent for sequencing to confirm the mutation. 
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2.2.6. Sequencing and analyzing mutagenesis  
The pACYC_FHH2_ CYP106A2 mutant plasmids were sent to Eurofins MWG Company 
(Ebersberg, Germany) for sequencing. The alignments of sequences between CYP106A2 
wild type and mutants were performed using the program CLUSTALW 1.8. 
(http://www.ebi.ac.uk/Tools/clustalw2/index.html). Translations of amino acids were 
carried out by using the Translate tool (Gasteiger et al., 2003) and the software available 
at http://www.expasy.org/tools/dna.html . 
2.2.7. Heterologous expression of CYP106A2 
CYP106A2 wild type and mutant plasmids were transformed into chemically competent 
E.coli cells JM109 and inoculated in LB medium containing chloramphenicol at 37oC 
overnight for obtaining the preculture (section 2.2.2.1.). Main culture was prepared in 2 L 
Erlenmayer flasks containing 1L TB medium (Appendix 6.1.2.) and antibiotics. The 
preculture was transferred into the main culture (1/100 v/v) and inoculated at 37oC until 
OD600 reached 0.8 - 1.0. Expression procedure was carried out at 30oC with shaking speed 
of 200 rpm for 48 hr, after adding 1 mM IPTG and 0.5 mM 5-aminolevulinic acid. The 
cells were harvested by centrifugation at 6000 rpm for 15 min and stored in –20oC for the 
next study. 
2.2.8. Purification of CYP106A2 
All the purification steps were carried out at 4oC. After thawing of the pellet from minus 
20oC, the cells were suspended in Lysis buffer (Appendix 6.2.3.) and then disrupted by 
sonication (USD 30, WV) for 20 min on ice (Amplitude 30 μm, Puls 30 s, Ratio 1). 
Subsequently, the cells were ultracentrifuged at 35000 rpm for 20 min. The supernatant 
was precipitated in 30 - 70% ammonium sulphate slowly. After ultracentrifugation, the 
pellet was suspended in 100 ml Buffer A (Appendix 6.2.3.). The protein CYP106A2 was 
concentrated by a Centriprep-YM30 device (Millipore, Bedford, MA, USA) and diluted 
with distilled water 1/4 before applying onto a diethylaminoethy anion exchange column 
(DEAE-Sepharose, Tosohass, Stuttgart, Germany). The protein was washed with Buffer 
A to reduce salt and non-specific proteins and then eluted by Buffer B (Appendix 6.2.3.) 
with flow rate 1.5 ml/min and following gradient: 
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0 - 50 ml: 100% Buffer A 
50 - 130 ml: 35% Buffer B 
3.0 ml/fraction  
130 - 250 ml: 50% Buffer B 
250 - 300 ml: 100% Buffer B 
Only CYP106A2 fractions having A417/280 ≥ 0.6, were collected, diluted with distilled 
water (1/1 v/v) and then applied onto a Macro prep ceramic hydroxy apatite (HAP) 
column (BioRad, Hercules, CA, USA). Buffer C (Appendix 6.2.3.) was used for 
equilibration and washing the column. The elution was carried out at a flow rate of 1.5 
ml/min with Buffer D (Appendix 6.2.3.). Following gradient system was used: 
0 - 30 ml: 100% Buffer C 
30 - 120 ml: 40% Buffer D 
4.5 ml/fraction  
120 - 230 ml: 80% Buffer D 
230 - 300 ml: 100% Buffer D 
The collected fractions, which had A417/280 ≥ 0.8 after concentration by Centriprep-YM30, 
were finally applied onto Gel filtration using a Superdex 75 column (Amersham 
Pharmacia Biotech). Buffer E (Appendix 6.2.3.) was used for washing and to elute the 
protein with a flow rate of 0.3 ml/min and 1 ml/fraction. The purified protein fractions 
having A417/280 ≥ 1.0 - 1.2 were concentrated by Centriprep YM30 until a total volume of 
500 μl was reached. 
2.2.9. UV-Vis and CO-difference spectra measurements 
The purified CYP106A2 was measured using an UV-Vis spectrometer of Shimadzu 
Photometer (UV2101PC, Kyoto, Japan) at wavelength from 200 - 700 nm. 
Carbon monoxide (CO) different spectra were used to quantify the cytochrome P450 
concentration according to Omura and Sato (Omura and Sato, 1964). Cytochromes P450 
exhibit a Soret peak at 450 nm in their reduced form iron-CO complex. 
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The concentration was calculated according to the Beer–Lambert equation: 
( )
dε
factordilution  AP450c 490450 ×
×Δ= −  
c(P450) concentration of cytochrome P450 [mM] 
490450A −Δ  absorptional difference at 450 nm and 490 nm 
ε   molar extinction coefficient [91 mM-1×cm-1] 
d  diameter or length of the cuvette [cm] 
2.2.10. Determination of protein concentration (BC Assay) 
Bicinchoninic acid (BC) assay protein quantitation kit (Uptima Interchim, Montluçon, 
France) was used for protein concentration measurement. The BC assay is a colorimetric 
assay, which involves the reduction of Cu2+ to Cu+ by proteins in an alkaline medium and 
chelates Cu+ ions with very high specificity to form a water soluble purple colored 
complex. 
The reaction was measured after 30 min at 37oC by using the high optical absorbance of 
the final Cu+ complex at 562 nm. Absorbance was directly proportional to the protein 
concentration, with a broad linear range between 20 - 2000 μg/ml. Protein concentration 
was calculated with a reference curve obtained for a standard protein which was obtained 
from bovine serum albumin (BSA). Standard protein solutions were prepared freshly 
ranging from 20 μg/ml to 2000 μg/ml and were diluted from the stock solution in the 
same buffer (Appendix 6.3.). 
2.2.11. Sodium dodecylsulphate (SDS) polyacrylamid gelelectrophoresis 
Separation of proteins according to their molecular mass was conducted using the 
Laemmli discontinuous gel electrophoresis (SDS-PAGE) method (Laemmli, 1970). For 
preparing the gel, the separating gel solution (Appendix 6.4.1.) was carefully poured 
between glass plates, overlaid with distilled water and allowed to polymerize at room 
temperature for 30 min. After removing the overlaying water, the stacking gel solution 
(Appendix 6.4.2.) was poured and a comb was inserted. The gel was allowed to 
polymerize for further 30 min. The gel was stored in soaked papers with water at 4oC 
until use. 
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A portion of the protein sample was mixed with 2 x SDS loading buffer (1/1 v/v) and 
heated at 100oC for 5 min. The samples were applied to the slots of the stacking gel for 15 
min at 80 V and then separated on a separating gel at 100 V until the bromophenol blue 
front reached the bottom of the gel. 
After running SDS-PAGE, the gel was stained with coomasie staining solution for 1 hr at 
room temperature and then incubated in destaining solution until the bands for the 
proteins were clearly visible. The gel was finally dried on a gel dryer (Model 583 gel 
dryer, BioRad) for storage. 
2.2.12. Reconstitution of in vitro steroid conversion  
Enzyme activity towards progesterone conversion was performed in 50 mM HEPES 
buffer, pH 7.4. The reconstitution system was established in a total volume of 500 μl 
using a NADPH regeneration system (5 mM glucose-6-phosphate, 1 U glucose-6-
phosphate dehydrogenase, 1 mM MgCl2 and 0.1 mM NADPH). The concentration of Adx 
(4 - 108) was 10 μM, of AdR 0.5 μM and of CYP106A2 from wild type and mutants was 
constant, 0.25μM. Progesterone concentration was varied from 17.5 - 600 μM. The 
reaction was carried out in 30oC for 10 min at 12000 rpm and stopped by addition of 500 
μl chloroform. The steroids were extracted twice with chloroform and evaporated using 
Speed-Vac (Univapo 100H, UniEquip, Munich). The residues were resolved with 
acetonitril for HPLC analysis. 
2.2.13. Screening of mutants 
This method allows to screen the mutants faster which is interesting for steroid 
conversion based on the colorimetric assay protocol from Appel et al. (Appel et al, 2005). 
Electro-competent JM109 cells were cotransformed using the plasmids pACYC_FHH2 
containing sequences of CYP106A2 wild type and mutants, and with pBAR_Twin 
containing the sequences of AdR and Adx (4 - 108). Aliquotes (50 μl) of the 
transformation preparation were spread out on agar plates containing chloramphenicol (35 
μg/ml) and ampicillin (100 μg/ml). The plates were incubated at 37oC overnight. A single 
colonie from each plate was taken and transferred by sterile toothpicks into “half deep 
well plate” (PP-Masterblock, maximal volume 0.5ml, sterile, Boden V-Form, Greiner 
Bio-One, Frickenhausen, Germany) containing 350 μl of LB and both of antibiotics. For 
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each mutant, this procedure was repeated 3 times except for mutants CYP106A2 
A106T/A395I/R409L, CYP106A2 A106T/A395W/G397K/R409L and CYP106A2 
T89N/A106T/A395I/R409L, which were repeated twice. The last three positions in the 
plate were used for inoculation of CYP106A2 wild type. The microtiter plate was sealed 
with a membrane (Breathseal, Greiner, Germany) and shaken at 37oC, 300 rpm overnight 
(Innova Shaker 4230, New Brunswick Scientific, Nürtingen, Germany). On the next day, 
45 μl of preculture was transferred into main culture prepared in “deep well plate” (Mega 
Block 2.2ml, Sarstedt, Nürnbrecht, Germany) containing 1ml of TB media with 0.5 mM 
of 5-aminolevulinic acid, 1 mM of IPTG, 140 μl/L of trace element solution (Appendix 
6.1.3.) as well as 400 μM of progesterone and both antibiotics. The “deep well plate” was 
sealed and inoculated at 30oC, 300 rpm for 48 hr. Afterwards the cultures were harvested 
by centrifugation at 3000 rpm for 20 min. A volume of 600 μl of the supernatants were 
transferred into another clean “deep well plate”. Subsequently, 300 μl of methyl isobutyl 
ketone (Sigma-Aldrich, Seelze, Germany) was added for extraction of the steroids. After 
separation in 2 phases by centrifugation at 3000 rpm for 10 min, 100 μl of the upper phase 
was transferred into a black acid resistant polypropylene microtiter plate with F-trays 
(Greiner, Germany). The organic phase then was mixed with 150 μl of a sulfuric 
acid/acetic acid (90/10 v/v). Fluorescence was measured after incubation in darkness for 
10 min by Plate reader Genios (Tecan, Crailsheim, Germany) and using the Xflour 4 
software. The measurement was set to following conditions: 
Excitation wavelength: 485 nm 
Emission wavelength: 535 nm 
Gain: optimal 
Integration time: 20 μs 
Number of flashes: 5 
The “gain” is the parameter to control sensitivity in the measurement of the process. The 
average of all the measurement was done. 
2.2.14. Whole-cell steroid conversion 
Cotransformed cells JM109 containing two plasmids (pACYC_FHH2_CYP106A2 and 
pBAR_Twin) were prepared as above for preculture (section 2.2.13.). Main culture was 
prepared in 100 ml Erlenmayer flask containing 20 ml of TB media and antibiotics. 
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Preculture was transferred into main culture (1/100 v/v) and inoculated at 37oC until 
OD600 reached 0.8 - 1.0, then 1 mM of IPTG and 0.5 mM of 5-aminolevulinic acid were 
added. The expression procedure was carried out at 30oC, for 24 hr with 200 rpm. An 
aliquot (1 ml) was centrifuged at 14000 rpm for 2 min and washed once with 50 mM of 
potassium phosphate buffer (pH 8.0). The cells were suspended in 1 ml of buffer and 
inoculated at 30oC. Progesterone was dissolved in absolute HPLC grade ethanol or 45% 
hydroxypropyl-β-cyclodextrin. The reaction was initiated by the addition of substrate 
(100 μM and 200 μM) to the test cell-media (6 hr and 12 hr, respectively). The reaction 
was stopped by incubation for 1 min at 100oC to inactivate the biocatalyst. The dead-cells 
were removed by centrifugation at 15000 rpm, 4oC for 5 min. The supernatants were 
carefully transferred into another clean eppendorf tube for the extraction of steroids by 
chloroform. The organic phases were transferred and dried by Speed-Vac (Univapo 100H, 
UniEquip, Munich). The residues were resolved in acetonitril for HPLC analysis. 
2.2.15. High Performance Liquid Chromatogram (HPLC) 
The steroids were analyzed by using a High Performance Liquid Chromatography system 
900er from Jasco Company (Groβ-Umstadt, Germany). The extracted steroids were 
dissolved in 200 μl of acetonitril before analyzing in the HPLC system. The steroids were 
detected by an UV-Vis detector at 240 nm, 25oC controlled by an oven (Techlab, 
Erkerode, Germany) when crossing the column Nova Pak Nucleosil C18 (4 μm, 3.9x150 
mm) or column Macherey-Nagel CC125/4 Nucleodur 100-5 C18ec. The solvent was a 
mixture acetonitril/water (40/60) with a flow rate of 1 ml/min. 20β-hydroxyprogesterone 
was used as internal standard. The data were calculated through hyperbolic equation (f(x) 
= ax/(b+x)) by using Sigma Plot software (Rockware, Golden, CO, USA). 
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3. RESULTS 
CYP106A2 from Bacillus megaterium ATCC 13368 is able to hydroxylate a variety of 3-
oxo-4-ene steroids mainly in the 15β-position. Progesterone is converted predominantly 
into 15β-hydroxyprogesterone and minor amount of 11α-, 9α-, 6β-hydroxyprogesterone 
(Berg et al., 1976; Lisurek et al., 2004). The minor products range from 5 - 10% relative 
value compared with 15β-hydroxyprogesterone. The minor products 11α-, 9α- and 6β-
hydroxyprogesterone have a higher as pharmaceutical value compared with 15β-
hydroxyprogesterone. In 2004, Lisurek constructed and docked progesterone into the 
model of CYP106A2. Amino acids A395 and T396 of CYP106A2, which lie in the 
putative substrate recognition site (SRS) 6, revealed a hydrogen bond with progesterone 
and no other SRS showed an interaction with this substrate. Four residues, S394, A395, 
T396, G397, in this loop were predicted to have an effect on the regio-selectivity of 
CYP106A2. Therefore, they were chosen to be mutated. In order to verify the role of 
these residues, they were altered to corresponding residues of CYP11B1, which resulted 
in 4 site-directed mutants CYP106A2 S394I, CYP106A2 A395L, CYP106A2 T396R and 
CYP106A2 G397P. These mutants were expected to change the regio-selectivity of 
progesterone hydroxylation towards 11α-position. However, the activity of these 4 
mutants in progesterone conversion indicated that only 2 positions of CYP106A2 (A395 
and G397) seem to play a role in altering the regio-selectivity of hydroxylation to the 
originally minor products (Lisurek, 2004; Lisurek et al., 2008). Therefore, a saturation 
mutagenesis library (approximately 13100 transformants) at the positions A395 and G397 
was created by Virus using degenerated primers (Virus, 2006). 
My work started with randomly selecting 40 transformants from the saturation 
mutagenesis library of CYP106A2 having mutations at residues 395 and 397. The aim of 
the work was to screen the mutants for a higher 11α-hydroxyprogesterone production. 
3.1. Screening the saturation mutagenesis library of CYP106A2 SRS6 mutants 
3.1.1. Separation of plasmids pACYC_FHH2 and pBAR_Twin 
Firstly, to know the exact activity of the mutant enzymes in progesterone conversion, 
each vector pACYC_FHH2 containing a single CYP106A2 mutant from the transformant 
had to be separated from pBAR_Twin coexpressed E.coli JM109. The separation was 
performed as described in section 2.2.4. The vector pACYC_FHH2 derived from the 
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original vector pACYC184 was modified by inserting the CYP106A2 expression cassette 
containing 2 restriction sites Nco I and Hind III (Hannemann et al., 2006). 
After minipreparation, the plasmids were checked by restricted digestion with Nco I and 
Hind III at 37°C for 4 - 5 hr. The negative control was done without plasmid. Finally, the 
sizes of the DNA fragments were observed in an 1% agarose gel under UV light. The 
vector and the inserted DNA yielded a 4.1 kb and 1.2 kb fragment, respectively. 
1 2 3
 
Figure 3.1: Agarose gel electrophoresis of pACYC_FHH2 containing cDNA of 
CYP106A2 after cutting by restriction enzymes Nco I and Hind III. 1% agarose gel was 
used. 1: Marker, 2: Negative control, 3: pACYC_FHH2_CYP106A2 from one mutant. 
3.1.2. Heterologous expression of 15β-hydroxylase in E.coli JM109 
All mutants (containing the single vector pACYC_FHH2_CYP106A2) from the 
saturation library were transformed and heterologously expressed in chemically 
competent E.coli JM109 cells as described in section 2.2.7. The pellets, obtained after 48 
hr expression, were suspended in lysis buffer (Appendix 6.2.3.) and then disrupted by 
sonification and centrifuged as described in section 2.2.8. Supernatants as “crude extract” 
enzyme solution were used for CO-difference spectra measurements (Figure 3.2) and the 
calculated from CYP106A2 concentration is shown in Table 3.1.  
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Figure 3.2: CO-difference spectra measurement of the SRS6 CYP106A2 mutants. The 
“crude extract” enzymes were obtained from the supernatant as after sonification. The 
measurements were performed following Omura and Sato’s method to calculate P450 
content (Omura and Sato, 1964). 
The CO-different spectra of the mutants showed the typical maximum absorbance at 
450 nm. However, a low (or higher) amount of cytochrome P420 in “crude extract” 
enzymes, which is an inactive form of cytochrome P450 (showing a Soret peak at 
approximate 420 nm), was also presented. 
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Table 3.1: Concentration of CYP106A2 mutants and wild type after expression in the 
“crude extract” enzyme (part 1). 
Mutant Abbreviation Concentration of P450 
[nmol/L culture] 
Position in micro titer plates 
Mutant 1 486 291005_01_F8 
Mutant 2 511 291005_01_A6 
Mutant 3 471 291005_02_F6 
Mutant 4 558 211005_02_F7 
Mutant 5 536 211005_02_G7 
Mutant 6 172 211005_02_D11 
Mutant 15 542 211005_02_B9 
Mutant 16 691 211005_02_D9 
Mutant 17 632 211005_02_C10 
Mutant 18 689 211005_02_H11 
Mutant 19 201 211005_02_C12 
Mutant 20 239 291005_01_H2 
Mutant 21 197 291005_01_E5 
Mutant 22 490 291005_01_H7 
Mutant 23 583 291005_01_A12 
Mutant 24 544 291005_02_D3 
Mutant 25 537 291005_02_G4 
Mutant 26 582 291005_02_D1 
Mutant 27 579 291005_02_G6 
Mutant 28 681 291005_02_B9 
Mutant 29 204 291005_02_D9 
Mutant 30 433 291005_02_E11 
Mutant 31 423 291005_02_G11 
Mutant 32 673 311005_01_A1 
Mutant 33 668 311005_01_A5 
Mutant 34 671 311005_01_G6 
Mutant 35 662 311005_01_H8 
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Table 3.1: Concentration of CYP106A2 mutants and wild type after expression in the 
“crude extract” enzyme (part 2). 
Mutant Abbreviation Concentration of P450 
[nmol/L culture] 
Position in micro titer plates 
Mutant 36 694 311005_01_E9 
Mutant 37 676 311005_01_F9 
Mutant 38 673 311005_01_D10 
Mutant 39 877 311005_01_F10 
Mutant 40 108 311005_02_C3 
Mutant 41 574 311005_02_F5 
Mutant 42 244 311005_02_C8 
Mutant 43 248 311005_02_F1 
Mutant 44 654 311005_02_D8 
Mutant 45 640 311005_02_E8 
Mutant 46 682 311005_02_D10 
Mutant 47 885 311005_02_B11 
Mutant 48 1194 311005_02_E12 
CYP106A2 WT 1273  
The yields of the P450 protein for the mutants varied from 400 to 700 nmol/L culture, and 
were less than the concentration of CYP106A2 wild type (1273 nmol/L culture). 
However, some CYP106A2 mutants (6, 19, 20, 21, 29 and 40) showed very low 
expression levels (approximately 200 nmol/L culture). Only mutant 48 showed a similar 
expression level as that of the CYP106A2 wild type (1194 nmol/L culture). 
In order to supply for in vitro conversion of progesterone, all “crude extract” enzymes of 
CYP106A2 mutants and wild type were purified by applying on the DEAE Sepharose 
column to reduce the impurities from medium or E.coli cells. All CYP106A2 samples 
were lost approximately 30% - 40% of P450 content after purification (Table 3.2). The 
ratio A417/A280 was used to monitor the purification cytochrome P450 level. 
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Table 3.2: The yield of cytochrome P450 from CYP106A2 mutants after purification 
through the DEAE-Sepharose column (part 1). 
Mutant Crude extract solution 
[nmol/L] 
After DEAE-Sepharose 
column [nmol/L] 
The ratio 
A417/A280 
Mutant 1 486 361 0.5 
Mutant 2 511 342 0.6 
Mutant 3 471 303 0.4 
Mutant 4 558 398 0.5 
Mutant 5 536 411 0.5 
Mutant 6 172 120 0.4 
Mutant 15 542 387 0.5 
Mutant 16 691 442 0.6 
Mutant 17 632 418 0.6 
Mutant 18 689 426 0.6 
Mutant 19 201 171 0.4 
Mutant 20 239 182 0.4 
Mutant 21 197 129 0.4 
Mutant 22 490 372 0.4 
Mutant 23 583 426 0.4 
Mutant 24 544 377 0.5 
Mutant 25 537 361 0.5 
Mutant 26 582 384 0.5 
Mutant 27 579 367 0.5 
Mutant 28 681 434 0.6 
Mutant 29 204 148 0.4 
Mutant 30 433 366 0.4 
Mutant 31 423 370 0.4 
Mutant 32 673 457 0.5 
Mutant 33 668 432 0.5 
Mutant 34 671 469 0.5 
Mutant 35 662 472 0.5 
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Table 3.2: The yield of cytochrome P450 from CYP106A2 mutants and wild type after 
purification through the DEAE-Sepharose column (part 2). 
Mutant Crude extract solution 
[nmol/L] 
After DEAE-Sepharose 
column [nmol/L] 
The ratio 
A417/A280 
Mutant 36 694 484 0.5 
Mutant 37 676 492 0.5 
Mutant 38 673 441 0.6 
Mutant 39 877 579 0.6 
Mutant 40 108 67 0.4 
Mutant 41 574 401 0.4 
Mutant 42 244 172 0.4 
Mutant 43 248 168 0.4 
Mutant 44 654 451 0.5 
Mutant 45 640 469 0.4 
Mutant 46 682 482 0.5 
Mutant 47 885 531 0.6 
Mutant 48 1194 744 0.6 
CYP106A2 WT 1273 827 0.6 
3.1.3. In vitro conversion of progesterone 
To verify the enzyme activity of the mutants, after purifying the related proteins, in vitro 
conversions were done as described in section 2.2.12. During conversion the final 
concentration of the progesterone was 300 μM. The reactions were carried out at 30°C for 
10 min and were stopped by adding chloroform. Each activity measurement for a mutant 
was repeated twice. In the negative control, water was used instead of NADPH. The 
steroids were extracted twice, evaporated before dissolving in acetonitril and finally 
applied on a HPLC system 900er (Jasco Company, Germany) using Nova Pak Nucleosil 
C18 (4 μm, 3.9 x 150 mm) column. Products were detected as described in section 2.2.15. 
The 20β-hydroxyprogesterone was used as an internal standard whereas 15β-, 11α-, 9α- 
and 6β-hydroxyprogesterone were used as external standards. The retention times of 
standards are shown in Table 3.3.  
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Table 3.3: The HPLC retention time of the mono-hydroxylated progesterone product 
analyzed using Nova Pak Nucleosil C18 (4 μm, 3.9 x 150 mm) column with an isocratic 
solvent of 40% acetonitrile and 60% water with the flow rate of 1 ml/min at 25°C are 
shown. The steroids were detected at 240 nm. 
Mono-hydroxylated progesterone Retention time [min] 
20β-hydroxyprogesterone 24.77 ± 0.73 
15β-hydroxyprogesterone 3.76 ± 0.03 
11α-hydroxyprogesterone 4.14 ± 0.06 
9α-hydroxyprogesterone 4.71 ± 0.11 
6β-hydroxyprogesterone 5.42 ± 0.09 
Most CYP106A2 mutants showed a more diverse hydroxylating pattern of progesterone 
compared with that of CYP106A2 wild type. During the experiment, some CYP106A2 
mutants (1, 4, 15 - 19, 25, 27, 31, 32, 34, 35, 40 and 42) did not show any conversion 
(Figure 3.3a and 3.3b), whereas other CYP106A2 mutants converted progesterone into 4 
main mono- (15β-, 11α-, 9α- and 6β-hydroxylated) products of progesterone along with 
some di- or poly-hydroxylated products with different amounts. CYP106A2 mutants 41, 
46 and 47 (Figure 3.3b) showed the highest amounts of absolute 9α-hydroxyprogesterone 
formation (22.3 ± 1.2, 36.1 ± 1.2, 21.3 ± 2.6 nmol product/min nmol CYP106A2, 
respectively) compared with the others. 
Concerning 11α-hydroxyprogesterone formation, it can be seen that most mutants gave a 
higher product yield than CYP106A2 wild type (Figure 3.3a and 3.3b). However, 
CYP106A2 mutants 2, 3, 37 and 39 showed the highest activity of 18.8 ± 3.0, 19.3 ± 1.2, 
20.1 ± 2.8 and 25.7 ± 2.8 nmol product/min nmol CYP106A2, respectively, of 11α-
hydroxyprogesterone production. 
CYP106A2 mutants 5, 6, 33, 37 and 43 could hydroxylate progesterone at the 6β-position 
with higher efficiency than the rest of the CYP106A2 mutants and resulted in 13.7 ± 0.8, 
16.3 ± 1.3, 15.9 ± 1.5, 19 ± 0.8 and 17.4 ± 2.4 nmol product/min nmol CYP106A2, 
respectively (Figure 3.3a and 3.3b). 
The activity of the CYP106A2 mutants observed during the conversion, is shown in Table 
3.4. The progesterone consumption by CYP106A2 wild type for 10 min was set to 100%. 
In general, none of the CYP106A2 mutants showed a significant faster activity than 
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CYP106A2 wild type. With 12 CYP106A2 mutants (2, 3, 5, 6, 20, 33, 37, 41, 43, 46, 47 
and 48) out of 25 presented as “active mutants”, a relative activity similar to that of 
CYP106A2 wild type was observed. Some CYP106A2 mutants (21, 24, 29 and 36) 
showed critically low activities (≤ 25% of CYP106A2 wild type activity) shown in Figure 
3.3a, 3.3b and Table 3.4. 
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Figure 3.3a: The absolute value of hydroxylated progesterone products for the CYP106A2 
mutants 1 to 29. Poly- or di-hydroxyprogesterone product (black), 15β-
hydroxyprogesterone (red), 11α-hydroxyprogesterone (green), 9α-hydroxyprogesterone 
(yellow) and 6β-hydroxyprogesterone (blue) are shown, n.d not detectable. 
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Figure 3.3b: The absolute value of hydroxylated progesterone products from the 
CYP106A2 wild type and from mutants 30 to 48. Poly- or di-hydroxyprogesterone 
product (black), 15β-hydroxyprogesterone (red), 11α-hydroxyprogesterone (green), 9α-
hydroxyprogesterone (yellow) and 6β-hydroxyprogesterone (blue) are shown, n.d not 
detectable. 
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Table 3.4: Comparison of progesterone consumption with CYP106A2 wild type and the 
mutants. 
 Progesterone consumption 
after 10 min [%] 
Comparison with  
CYP106A2 wild type 
CYP106A2 WT 95.4 1.00 
Mutant 2 96.8 1.01 
Mutant 3 93.4 0.98 
Mutant 5 99.6 1.04 
Mutant 6 99.1 1.04 
Mutant 20 80.2 0.84 
Mutant 21 17.3 0.18 
Mutant 22 56.9 0.59 
Mutant 23 62.3 0.65 
Mutant 24 8.6 0.09 
Mutant 26 82.7 0.87 
Mutant 28 45.4 0.48 
Mutant 29 21.3 0.22 
Mutant 30 39.0 0.41 
Mutant 33 98.1 1.03 
Mutant 36 25.1 0.26 
Mutant 37 84.6 0.89 
Mutant 38 49.9 0.52 
Mutant 39 46.3 0.49 
Mutant 41 80.6 0.84 
Mutant 43 81.2 0.85 
Mutant 44 55.6 0.58 
Mutant 45 52.6 0.55 
Mutant 46 98.3 1.03 
Mutant 47 82.8 0.87 
Mutant 48 94.7 0.99 
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Besides the actual activities of the mutants, the most interesting part of this analysis was 
to investigate a possible change of the regio-selectivity of hydroxylation by these mutants. 
CYP106A2 wild type converts progesterone mainly in 15β-position. On setting of 15β-
hydroxyprogesterone to 100%, the minor products of 11α-, 9α- and 6β-
hydroxyprogesterone were found to be 5%, 1.5% and 6.4% respectively. 
The results shown in Table 3.5 illustrate the differences of the distribution of the products 
progesterone hydroxylation. All CYP106A2 mutants increased the formation of the minor 
products by at least 2- or 3-fold. CYP106A2 mutants 21, 36, 39, 41, 46 increased the 
percentage of the 9α-hydroxyprogesterone from 1.5% to 125.8%, 49.7%, 69.6%, 41.5% 
and 84.3%, respectively. CYP106A2 mutants 21, 28, 37, 39, 43 also improved the 11α-
hydroxyprogesterone formation from 5% up to 43.1%, 41.1%, 67.7%, 282.2% and 66.7%, 
respectively. CYP106A2 mutants 21, 37, 39, 43 produced the 6β-hydroxyprogesterone up 
to 36.7%, 63.8%, 107.7% and 64.8%, respectively. 
There were 2 cases, CYP106A2 mutants 21 and 39, where the main product was not 15β-
hydroxyprogesterone. CYP106A2 mutant 21 produced mainly 9α-hydroxyprogesterone 
(125%) compared with 15β-hydroxyprogesterone, but unfortunately, the catalytic activity 
of that mutant enzyme was almost critically 5-fold lower than the wild type protein 
activity (progesterone consumption after 10 min was 18% compared with protein wild 
type). Especially, CYP106A2 mutant 39 showed a drastic changed in the regio-selectivity 
of hydroxylation. The 15β-hydroxyprogesterone became a minor product as compared 
with other products such as 11α-hydroxyprogesterone and 6β-hydroxyprogesterone 
(282.2% and 107.7%, respectively). Even though, the activity of the CYP106A2 mutant 
39 was half as compared with CYP106A2 wild type. The ratio between 15β-
hydroxyprogesterone/11α-hydroxyprogesterone was approximately 1/3. Thus, this mutant 
showed a considerable shift of the regio-selectivity of hydroxylation from the 15- to the 
11-position. This is the greatest shift obtained so far. 
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Table 3.5: Regio-selectivity of the mono-hydroxyprogesterone products derived from 
CYP106A2 wild type and mutants. The relative amounts of hydroxylated products are 
shown. 15β-hydroxyprogesterone was set to 100%. 
 15β-OH-P [%] 11α-OH-P [%] 9α-OH-P [%] 6β-OH-P [%]
CYP106A2 WT 100 5.0 1.5 6.4 
Mutant 2 100 28.5 17.4 13.3 
Mutant 3 100 28.3 9.7 4.2 
Mutant 5 100 23.9 26.7 23.8 
Mutant 6 100 23.5 26.5 27.8 
Mutant 20 100 34.2 32.8 15.8 
Mutant 21 100 43.1 125.8 36.7 
Mutant 22 100 30.2 16.5 15.3 
Mutant 23 100 39.5 13.6 10.8 
Mutant 24 100 15.3 28.5 17.0 
Mutant 26 100 35.4 16.4 16.2 
Mutant 28 100 41.1 12.8 20.0 
Mutant 29 100 14.1 33.5 12.6 
Mutant 30 100 32.2 17.9 9.5 
Mutant 33 100 21.0 6.4 22.9 
Mutant 36 100 39.1 49.7 24.7 
Mutant 37 100 67.7 33.2 63.8 
Mutant 38 100 26.1 13.1 15.1 
Mutant 39 100 282.2 69.6 107.7 
Mutant 41 100 11.7 41.5 13.6 
Mutant 43 100 66.7 36.6 64.8 
Mutant 44 100 16.0 9.6 14.9 
Mutant 45 100 27.0 12.3 15.8 
Mutant 46 100 34.2 84.3 14.2 
Mutant 47 100 12.0 39.3 12.6 
Mutant 48 100 22.1 28.6 14.6 
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3.1.4. Sequencing of the active mutants 
To evaluate the effect of mutation at positions A395 and G397 of the CYP106A2 on the 
progesterone conversion, the “active mutants” were sequenced (Eurofins MWG 
Company, Ebersberg, Germany). The results are described in the Table 3.6. 
The obtained results derived from the saturation mutagenesis of CYP106A2 at positions 
A395 and G397 showed that only in one case, CYP106A2 mutant 39 (CYP106A2 
A395W/G397K), a change into an aromatic amino acid group occured. Obviously, this 
replacement gave a high contribution to the shift in the stereo-selectivity towards 11α-
hydroxylation. From the sequencing results of the active mutants, it can be seen that 
residue A395 has a high frequency of more aliphatic or basic amino acids due to the 
repetitive frequencies of arginine, lysine and glycine (Table 3.6). In addition, the 
substitution of residue A395 to an acid residue (glutamic acid) was also repeatedly 
observed (Table 3.6). Furthermore, the residue G397 was also changed in favor to 
aliphatic and basic amino acids due to the occurrence of lysine, arginine, valine, 
asparagine, leucine. Interestingly, residue G397 of CYP106A2 mutants 5 and 6 was 
substituted by a Stop codon. Therefore, these mutant proteins were shorter than the wild 
type and other mutant CYP106A2 proteins by 14 amino acids. CYP106A2 mutant 44 did 
not change at residue G397, but residue T396 was substituted by proline. Combining the 
replacements at positions A395 and G397, mutant CYP106A2 A395E/G397Stop, 
CYP106A2 A395R/G397P, CYP106A2 A395K and CYP106A2 A395K/G397N occurred 
twice. 
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Table 3.6: Sequencing of the active substrate recognition site (SRS) 6 mutants. The 
changed nucleotide was colored in red. 
Mutant Abbreviation Mutant points Nucleotides changed 
Mutant 2 A395R/G397H gcg → agg; ggt → cac 
Mutant 3 A395H/G397L gcg → cat; ggt → cta 
Mutant 5 A395E/G397Stop gcg → gag; ggt → tga 
Mutant 6 A395E/G397Stop gcg → gag; ggt → tga 
Mutant 20 A395G/G397C gcg → ggg; ggt → tgt 
Mutant 21 A395R/G397K gcg → agg; ggt → aaa 
Mutant 23 A395G/G397V gcg → ggg; ggt → gta 
Mutant 24 A395N/G397R gcg → aat; ggt → cgt 
Mutant 26 A395S/G397K gcg → tca; ggt → aaa 
Mutant 28 A395R/G397V gcg → agg; ggt → gta 
Mutant 29 A395G/G397D gcg → ggg; ggt → gat 
Mutant 30 A395P/G397L gcg → cca; ggt → cta 
Mutant 33 A395R/G397R gcg → agg; ggt → agg 
Mutant 36 A395P/G397K gcg → cca; ggt → aaa 
Mutant 37 A395K/G397N gcg → aaa; ggt → aat 
Mutant 38 A395K gcg → aag 
Mutant 39 A395W/G397K gcg → tgg; ggt → aaa 
Mutant 41 A395R/G397P gcg → cgt; ggt → cca 
Mutant 43 A395K/G397N gcg → aaa; ggt → aat 
Mutant 44 A395V/T396P gcg → gta; acc → ccc 
Mutant 45 A395K gcg → aag 
Mutant 46 A395E/G397V gcg → gag; ggt → gta 
Mutant 47 A395R/G397P gcg → cgg; ggt → cct 
Mutant 48 A395Q/G397R gcg → caa; ggt → cga 
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3.2. Improvement of catalytic efficiency towards 11α-hydroxyprogesterone 
My work focused on the mutants which showed high 11α-hydroxylation activity. Mutant 
CYP106A2 A395W/G397K showed an interesting regio-selectivity to convert 
progesterone mainly in 11α-position. Furthermore, mutant CYP106A2 A395I, one of the 
most interesting mutants from Virus (Virus, 2006), was also able to produce a high 
amount of 11α-hydroxyprogesterone with 97.2% of the relative value compared with 
15β-hydroxylated product. Unfortunately, both mutant enzymes had a 50% lower 
turnover rate than CYP106A2 wild type. Therefore, these 2 mutants were chosen for 
further mutation to improve the catalytic efficiency but still retain high regio-selective 
hydroxylation towards C-11. 
3.2.1. Heterologous expression of mutants CYP106A2 A395I and CYP106A2 
A395W/G397K 
Since for detailed biochemical studies of the mutants, sufficient amounts of the protein 
are necessary, at first the expression and purification procedure for CYP106A2 mutants 
were optimized. Mutants CYP106A2 A395I and CYP106A2 A395W/G397K, the parental 
enzymes for further mutagenesis experiments, were chosen and the expression in E.coli 
JM109 was done as described in section 2.2.7. For this, 5 ml of samples were taken after 
2, 5, 9, 20, 24, 28, 32, 44 and 50 hr to check the pH value, OD600 and cytochrome P450 
content. Because the optical density deviation was linear in the range from 0 - 1.2, 
samples with an optical density of more than 1.2 were diluted 2 - 3 fold. The samples (1 
ml) were centrifuged to remove the supernatants. The pellets were dissolved in potassium 
phosphate buffer pH 7.4 and subsequently broken down by sonification. After 
centrifugation, the supernatants were measured for CO-difference spectra. The results are 
represented in Figure 3.4 and 3.5. 
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Figure 3.4: Heterologous expression of the CYP106A2 A395I mutant in a 2 L Erlenmayer 
flask containing 1 L TB media at 30°C for 50 hr. The data shown here represent 3 
independent experiments. Graphic representation of (A) the progress of cell density (blue 
line) and CYP106A2 content (red bars) and (B) the progress of pH change (aquamarine 
line) and CYP106A2 content (red bars). 
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Figure 3.5: Heterologous expression of the CYP106A2 A395W/G397K mutant in a 2 L 
Erlenmayer flask containing 1 L TB media at 30°C for 50 hr. The data shown here 
represent 3 time independent experiments. Graphic representation of (A) the progress of 
cell density (blue line) and CYP106A2 content (red bars) and (B) the progress of pH 
change (aquamarine line) and CYP106A2 content (red bars). 
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Figures 3.4 and 3.5 showed the relationship between the cell density, pH value and the 
expression of cytochrome P450 during the time interval for 2 of the selected mutants 
(CYP106A2 A395I and CYP106A2 A395W/G397K). The cell density correlated with the 
concentration of CYP106A2, where the higher cell density corresponded to more 
CYP106A2 content. The pH value at the beginning of expression was fixed at 7.4, but 
during the expression the pH dropped down after 2 hr and reached 6.6 ± 0.1 (at 20 - 24 hr) 
and then increased again to 7.0 after 44 hr where CYP106A2 was produced with the 
highest amount. The cell density and pH changes were not different between the 2 
mutants (CYP106A2 A395I and CYP106A2 A395W/G397K). However, their P450 
concentrations gained maxima at 5.09 µM and 2.9 µM after 50hr, respectively. 
3.2.2. Site directed mutagenesis of CYP106A2 A395I and CYP106A2 A395W/G397K 
In order to improve the catalytic efficiency of the 2 parental mutants (CYP106A2 A395I 
and CYP106A2 A395W/G397K), they were further mutated at positions which were 
reported in the literature as leading to increased catalytic activities. According to the work 
of Virus (Virus, 2006) and Rauschenbach (Rauschenbach, 1993), the mutations D217V, 
A243V, A106T, A106T/R409L, T89N/A106T/R409L, T89N/A106T/Q189K/R409L, 
F165L showed higher turnover rates towards progesterone conversion (1.18-, 1.05-, 1.43-, 
1.43-, 1.44-, 1.13- and 2.61-fold, respectively, compared with CYP106A2 wild type).  
Mutants CYP106A2 A106T, CYP106A2 D217V, CYP106A2 A243V and CYP106A2 
A106T/R409L had been identified through the screening from the first generation 
mutagenesis library of CYP106A2 using error prone PCR. The double mutant CYP106A2 
A106T/R409L showed the highest expression yield as well as the fastest catalytic activity. 
Therefore, this mutant was chosen as a template to carry out the second generation 
mutagenesis library. Mutants CYP106A2 T89N/A106T/R409L and CYP106A2 
T89N/A106T/Q189K/R409L were obtained from this second round mutagenesis (Virus, 
2006). Moreover, to evaluate the effect of each mutation not only on enzyme activity but 
also on selectivity of hydroxylation, mutations T89N and R409L were separately studied. 
For mutant CYP106A2 F165L, a 2.5-fold higher progesterone conversion rate was 
reported (Rauschenbach, 1993). 
Finally, a highly conserved threonine (T) within the I-helix of cytochrome P450 family is 
thought to be involved in the proton shuttle and is important for proton delivery and 
molecular oxygen activation. The corresponding residue in CYP106A2 is threonine at 
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position 247 (T247), which is placed in the active site near to heme (Lisurek et al., 2008). 
Interestingly, next to this residue, another threonine, T248, is found. With a desire to 
improve catalytic efficiency of 2 parental mutants (CYP106A2 A395I, CYP106A2 
A395W/G397K) and to explore the role of residues T247 and T248 for the properties of 
CYP106A2, the following mutations were proceduced: T247A, T247V, T247S, T247P, 
T247W, T248A and T248V, respectively.  
Site-specific mutagenesis in this study was performed using the Strategene Quik Change 
Mutagenesis Kit as described in section 2.2.5. The positive clones, after analysis by 
restriction digestion, were sequenced (MWG Company, Ebersberg, Germany) to confirm 
the mutation.  
3.2.3. Quick screening of the “site directed mutagenesis”CYP106A2 mutant library 
in micro titer plates 
To screen each of the 28 CYP106A2 mutants individually as described in section 2.2.7, it 
would take a long time with high costs. Therefore, an efficient screening system which 
was established by Virus (Virus, 2006) was applied to screen the “new mutant” collection 
faster. The principle of this method was derived from a published procedure (Apple et al., 
2005). The authors determined the conversion rate of 11-deoxycortisol to cortisol of a 
CYP11B1 expressing Schizosaccharomyces pombe culture by fluorescence 
measurements. Hannemann et al. (Hannemann et al, 2006) modified this method to 
determine the activity of the steroid hydroxylating CYP106A2 in a micro titer plate 
format. The vectors pACYC_FHH2 containing the CYP106A2 mutants and pBAR_Twin 
containing Adx (4 - 108) and AdR were coexpressed in E.coli cells in micro titer plates as 
described in section 2.2.13. The hydroxylation reaction was followed measuring the 
fluorescence of the mixture with an excitation wavelength of 489 nm and an emission 
wavelength of 535 nm. The measurement results are shown in Table 3.7. 
Mutants with a relative fluorescence unit (R.F.U) of more than 10000 for the 3 replicates 
were chosen for the next kinetic assay. Table 3.7 showed that 13 mutants were similar as 
CYP106A2 wild type. The 2 parental mutants (CYP106A2 A395I and CYP106A2 
A395W/G397K) had R.F.U values of 7244 and 9521, respectively which was a half 
R.F.U value of CYP106A2 wild type. Mutants CYP106A2 A106T/A395I and CYP106A2 
A106T/A395I/R409L revealed the highest R.F.U value (23878 ± 4264 and 24432 ± 2332, 
respectively). 
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Some substitutions such as A106T, A243V, A106T/R409L seemed to affect the activity 
due to increasing the R.F.U value of the new mutants. On the other hand, substitution 
R409L alone was not able to bring the improvement of catalytic activity to the new 
mutants. Similarly, 11 out of 14 mutants at the residues T247 and T248 showed a smaller 
R.F.U value compared with parental mutants. Only 3 mutants (CYP106A2 T247V/A395I, 
CYP106A2 T247W/A395W/G397K and CYP106A2 T248V/A395I) showed an increased 
activity due to a higher R.F.U value compared with the parental mutants. 
Results 
Table 3.7: Representation of mutant positions in the micro titer plate (upper part) and data sheet of fluorescence (R.F.U) measurements 
(lower part). Each mutant was checked 3 times except for CYP106A2 A106T/A395I/R409L, CYP106A2 A106T/A395W/G397K/R409L 
and CYP106A2 T89N/A106T/A395I/R409L (repeated twice). Mutants CYP106A2 A395I, CYP106A2 A395W/G397K and CYP106A2 
wild type were used as controls from position 4H to 12H (filled in black). The selected clones for further studies from this screening are 
filled in grey. 
Position 1 2 3 4 5 6 7 8 9 10 11 12 
A T89N/A395I T89N/A395I T89N/A395I T89N/39 T89N/39 T89N/39 A106T/A395I A106T/A395I A106T/A395I A106T/39 A106T/39 A106T/39 
B F165L/A395I F165L/A395I F165L/A395I F165L/39 F165L/39 F165L/39 D217V/A395I D217V/A395I D217V/A395I D217V/39 D217V/39 D217V/39 
C A243V/A395I A243V/A395I A243V/A395I A243V/39 A243V/39 A243V/39 A395I/R409L A395I/R409L A395I/R409L 39/R409L 39/R409L 39/R409L 
D T247A/A395I T247A/A395I T247A/A395I T247A/39 T247A/39 T247A/39 T247V/A395I T247V/A395I T247V/A395I T247V/39 T247V/39 T247V/39 
E T247F/A395I T247F/A395I T247F/A395I T247F/39 T247F/39 T247F/39 T247S/A395I T247S/A395I T247S/A395I T247S/39 T247S/39 T247S/39 
F T247W/A395I T247W/A395I T247W/A395I T247W/39 T247W/39 T247W/39 T248A/A395I T248A/A395I T248A/A395I T248A/39 T248A/39 T248A/39 
G T248V/A395I T248V/A395I T248V/A395I T248V/39 T248V/39 T248V/39 2 mutants/A395I 2 mutants/A395I 2 mutants/39 2 mutants/39 3 mutants/A395I 3 mutants/A395I 
H 3 mutants/39 3 mutants/39 3 mutants/39 A395I A395I A395I 39 39 39 WT WT WT 
               
R.F.U 1 2 3 4 5 6 7 8 9 10 11 12 
A 10431 13708 12025 5488 5003 4703 21413 20846 29375 17089 18642 10731 
B 10876 11033 7534 3477 3905 1076 15460 12287 10254 3051 3682 4653 
C 12248 10713 10068 19311 16749 17913 8456 8607 8903 4651 6830 7796 
D 6046 7064 4068 6342 3091 3002 9387 11006 10387 6312 8689 7706 
E 3781 2542 1096 8843 10346 8422 3311 2009 5791 4403 6123 7197 
F 1338 1503 714 10653 12763 18897 8245 7467 5078 8321 6012 6392 
G 11375 11937 9011 9407 8450 7377 24033 26964 22300 18564 13120 18256 
H 6701 4319 4888 8012 6732 6989 8901 9903 9760 16897 15409 13487 
59
 
39:  CYP106A2 A395W/G397K     2 mutants/A395I:  CYP106A2 A106T/A395I/R409L 
3 mutants/39 : CYP106A2 T89N/A106T/A395W/G397K/R409L  2 mutants/39:  CYP106A2 A106T/A395W/G397K/R409L 
3 mutants/39 : CYP106A2 T89N/A106T/A395W/G397K/R409L  R.F.U:   relative fluorescence unit 
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3.2.4. Kinetic investigations of the selected mutants 
Plasmids pACYC_FHH2 containing selected CYP106A2 mutants and wild type were 
transformed and heterologously expressed in E.coli JM109 cells as described in section 
2.2.7. The cells from the expressed cultures were harvested by centrifugation at 6000 rpm 
for 10 min and stored at –20 °C until use. 
3.2.4.1 Purification and spectrophotometric characterization of CYP106A2 
To investigate the kinetics of the newly proceduced mutants, the 16 recombinant mutant 
and wild type proteins were purified as described in section 2.2.8. The purification steps 
and purified CYP106A2 are shown in SDS-PAGE (Figure 3.6). Cytochrome P450 
concentration was found to be decreased in every purification step and is shown in Table 
3.8. 
The highest yield of CYP106A2 expression was observed in mutants CYP106A2 
A243V/A395W/G397K (1440 nmol/L culture), CYP106A2 A243V/A395W/G397K 
(1457 nmol/L culture) and CYP106A2 A395I (1550 nmol/L culture). However, the 
CYP106A2 content was reduced by approximately 32%, 18% and 12% after applying on 
the DEAE Sepharose column, the HAP column and the gel filtration column, 
respectively. 
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Figure 3.6: SDS-PAGE of the purification procedure and purified enzymes of the mutants 
and wild type. A) The purification procedure of CYP106A2 wild type (as an example). 
M: marker; 1: supernatant; 2: after DEAE-Sepharose column; 3: after HAP column; 4: 
after Superdex 75 column. B) The purified proteins of mutants. M: marker; 1: CYP106A2 
T89N/A395I; 2: CYP106A2 A106T/A395I; 3: CYP106A2 A106T/A395W/G397K; 4: 
CYP106A2 A243V/A395I; 5: CYP106A2 A243V/A395W/G397K; 6: CYP106A2 
D217V/A395I; 7: CYP106A2 F165L/A395I; 8: CYP106A2 T247V/A395I; 9: CYP106A2 
T247W/A395W/G397K; 10: CYP106A2 T248V/A395I; 11: CYP106A2  
A106T/A395I/R409L; 12: CYP106A2 A106T/A395W/G397K/R409L; 13: CYP106A2 
T89N/A106T/A395I/R409L; 14: CYP106A2 A395I; 15: CYP106A2 A395W/G397K; 16: 
CYP106A2 wild type. 
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Table 3.8: The yield of cytochrome P450 after different purification step. 
Mutant 
Crude 
enzyme 
solution 
[nmol/L] 
After 
DEAE 
column 
[nmol/L] 
After 
HAP 
column 
[nmol/L] 
After 
Superdex 
75 column 
[nmol/L] 
CYP106A2/
total protein
 
[nmol/mg] 
T89N/A395I 845 622 517 483 7.94 
A106T/A395I 1678 1320 1004 846 12.05 
A106T/A395W/ 
G397K 804 576 320 273 5.97 
A243V/A395I 1457 1201 974 878 10.54 
A243V/A395W/ 
G397K 1440 867 532 448 7.21 
D217V/A395I 1245 955 675 467 7.84 
F165L/A395I 1062 631 403 326 6.72 
T247V/A395I 759 532 400 339 6.06 
T247W/A395W/ 
G397K 879 642 437 372 6.93 
T248V/A395I 823 600 401 359 6.80 
A106T/A395I/ 
R409L 702 458 306 242 5.26 
A106T/A395W/ 
G397K/R409L 520 350 201 183 4.65 
T89N/A106T/ 
A395I/R409L 847 513 420 361 6.72 
A395I 1550 1002 780 692 10.76 
A395W/G397K 877 514 382 311 6.67 
Wild type 1273 780 662 567 8.27 
Purified CYP106A2 mutants and wild type were measured using UV-Vis and CO-
difference spectra as described in section 2.2.9 (Figure 3.7). The concentration of 
enzymes was 5 μM in 50 mM potassium phosphate buffer (pH 7.4) for UV-Vis and 10 
μM for CO-different spectra measurements, respectively.  
All protein samples were homogenous and showed the typical oxidized low-spin state of 
the cytochrome P450 with maximum absorption at 568 nm and 534 nm (Q Bands), the 
Soret band at 417 nm, the UV band at 358 nm which was caused by electron transitions of 
the heme chromophore, as well as the protein band at 280 nm, that was evoked by the 
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absorption of the aromatic amino acids. Moreover, the mutants and CYP106A2 wild type 
exhibited the characteristics of reduced P450, which was bound by carbon monoxide, to 
yield the classic CO-difference spectra with a maximum at approximately 450 nm (451.4 
nm except for CYP106A2 A243V/A395W/G397K, CYP106A2 T247V/A395W/G397K 
and CYP106A2 T89N/A106T/A395I/R409L, which showed the Soret peaks at 450.9 nm). 
Purification seemed to decrease the formation of cytochrome P420. Only 5 of the purified 
mutant proteins (CYP106A2 T89N/A106T, CYP106A2 A243V/A395W/G397K, 
CYP106A2 T247V/A395W/G397K, CYP106A2 T89N/A106T/A395I/R409L and 
CYP106A2 A395W/G397K) showed the inactive P450 forms. 
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Figure 3.7: UV-Vis (A) and CO-different (B) spectra of the CYP106A2 wild type and 
mutants. The concentration of the enzymes was 5 μM in 10 mM potassium phosphate 
buffer (pH 7.4) for UV-Vis and 10 μM for CO-different spectra measurements, 
respectively. 1: CYP106A2 T89N/A395I; 2: CYP106A2 A106T/A395I; 3: CYP106A2 
A106T/A395W/G397K; 4: CYP106A2 A243V/A395I; 5: CYP106A2 F165L/A395I; 6: 
CYP106A2 A243V/A395W/G397K; 7: CYP106A2 D217V/A395I; 8: CYP106A2 
T247V/A395I; 9: CYP106A2 T248V/A395I; 10: CYP106A2 T247W/A395W/G397K; 
11: CYP106A2 A106T/A395I/R409L; 12: CYP106A2 A106T/A395W/G397K/R409L; 
13: CYP106A2 T89N/A106T/A395I/R409L; 14: CYP106A2 A395I; 15: CYP106A2 
A395W/G397K; 16: CYP106A2 wild type. 
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3.2.4.2 Kinetic analysis of CYP106A2 mutants concerning progesterone conversion 
The activity of the purified proteins was reconsituted in vitro using truncated bovine 
adrenodoxin (Adx 4 - 108) and adrenodoxin reductase (AdR). The system contained 0.25 
μM of CYP106A2, 0.5 μM of AdR and 5 μM of Adx. Progesterone concentrations ranged 
from 17.5 - 525 μM. The reaction was carried out in a thermal shaker at 30oC for 10 min. 
The 20β-hydroxyprogesterone was used as internal standard (3 μl of a 10 mM solution). 
The steroids subsequently were analyzed using HPLC and the amount of products was 
calculated using the equation (f(x) = ax/(b+x)); standard deviations were derived from 3 
independent experiments. The results are shown in Figure 3.8a, 3.8b, 3.8c and Table 3.9 
and 3.10. 
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Figure 3. 8a: Representation of the progesterone conversion rates depending on substrate 
concentration of the mutants CYP106A2 T89N/A395I, CYP106A2 A106T/A395I, 
CYP106A2 A106T/A395W/G397K, CYP106A2 A243V/A395I. Black lines and circles: 
15β-hydroxyprogesterone; green lines and triangles: 11α-hydroxyprogesterone; red lines 
and stars: 9α-hydroxyprogesterone; blue lines and diamonds: 6β-hydroxyprogesterone. 
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Figure 3. 8b: Representation of the progesterone conversion rates depending on substrate 
concentration of the mutants CYP106A2 A243V/A395W/G397K, CYP106A2 
D217V/A395I, CYP106A2 F165L/A395I, CYP106A2 T247V/A395I, CYP106A2 
T247W/A395W/G397K and CYP106A2 T248V/A395I. Black lines and circles: 15β-
hydroxyprogesterone; green lines and triangles: 11α-hydroxyprogesterone; red lines and 
stars: 9α-hydroxyprogesterone; blue lines and diamonds: 6β-hydroxyprogesterone. 
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Figure 3. 8c: Representation of the progesterone conversion rates depending on substrate 
concentration of the mutants CYP106A2 A106T/A395I/R409L, CYP106A2 
A106T/A395W/G397K/R409L, CYP106A2 T89N/A106T/A395I/R409L, CYP106A2 
A395I, CYP106A2 A395W/G397K and the CYP106A2 wild type. Black lines and 
circles: 15β-hydroxyprogesterone; green lines and triangles: 11α-hydroxyprogesterone; 
red lines and stars: 9α-hydroxyprogesterone; blue lines and diamonds: 6β-
hydroxyprogesterone. 
 
 66
Results 
Table 3.9: Apparent Km and Vmax values of the CYP106A2 mutants resulting from 
calculations. The data presented in Figure 3. 8a, b, c (part 1). 
 Km 
[µM] 
Vmax  
[nmol/min nmol P450] 
kcat/Km 
[M-1 sec-1] x 103
T89N/A395I 
15β-OH-P 
11α-OH-P 
9α-OH-P 
6β-OH-P 
 
40.0 ± 24.9 
83.7 ± 26.7 
93.7 ± 34.9 
33.7 ± 14.8 
 
35.7 ± 6.1 
171.7 ± 20.0 
72.9 ± 9.9 
44.1 ± 5.0 
 
14.9 ± 17.7 
34.2 ± 13.6 
13.0 ± 6.4 
21.8 ± 13.2 
A106T/A395I 
15β-OH-P 
11α-OH-P 
9α-OH-P 
6β-OH-P 
 
31.2 ± 12.7 
91.0 ± 23.6 
39.2 ± 11.4 
29.1 ± 10.5 
 
97.9 ± 10.0 
300.9 ± 28.2 
60.0 ± 4.8 
17.9 ± 1.6 
 
52.3 ± 28.1 
55.1 ± 16.8 
25.5 ± 8.8 
10.3 ± 4.7 
A106T/A395W/G397K 
15β-OH-P 
11α-OH-P 
9α-OH-P 
6β-OH-P 
 
41.6 ± 8.5 
51.6 ± 12.4 
24.4 ± 6.9 
26.7 ± 8.6 
 
63.1 ± 3.6 
96.4 ± 7.0 
10.8 ± 0.7 
12.7 ± 1.0 
 
25.3 ± 5.7 
31.1 ± 8.6 
7.4 ± 2.5 
7.9 ± 3.1 
A243V/A395I 
15β-OH-P 
11α-OH-P 
9α-OH-P 
6β-OH-P 
 
40.4 ± 7.2 
20.2 ± 6.1 
40.1 ± 10.8 
12.5 ± 3.4 
 
47.3 ± 2.3 
64.3 ± 4.0 
9.6 ± 0.6 
8.9 ± 0.4 
 
19.5 ± 3.8 
53.1 ± 23.6 
4.0 ± 1.3 
11.9 ± 3.7 
A243V/A395W/G397K 
15β-OH-P 
11α-OH-P 
9α-OH-P 
6β-OH-P 
 
33.4 ± 11.3 
26.4 ± 7.2 
21.9 ± 9.2 
34.5 ± 9.1 
 
72.3 ± 6.3 
54.6 ± 3.5 
22.1 ± 2.0 
40.2 ± 2.8 
 
36.1 ± 15.0 
34.5 ± 10.8 
16.8 ± 9.4 
19.4 ± 5.9 
D217V/A395I 
15β-OH-P 
11α-OH-P 
9α-OH-P 
6β-OH-P 
 
43.3 ± 7.4 
28.4 ± 12.0 
38.7 ± 14.2 
28.7 ± 14.5 
 
236.8 ± 11.5 
258.1 ± 26.3 
108.3 ± 10.8 
24.8 ± 3.0 
 
91.1 ± 16.9 
151.5 ± 85.9 
46.6 ± 21.8 
14.4 ± 11.0 
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Table 3.9: Apparent Km and Vmax values of the CYP106A2 mutants resulting from 
calculations. The data presented in Figure 3. 8a, b, c (part 2). 
 Km 
[µM] 
Vmax  
[nmol/min nmol P450] 
kcat/Km 
[M-1 sec-1] x 103
F165L/A395I 
15β-OH-P 
11α-OH-P 
9α-OH-P 
6β-OH-P 
 
26.6 ± 10.0 
31.6 ± 7.6 
35.3 ± 14.5 
31.5 ± 10.4 
 
280.7 ± 24.8 
382.7 ± 23.3 
81.1 ± 8.7 
116.7 ± 9.7 
 
175.9 ± 83.8 
201.8 ± 54.7 
38.3 ± 21.0 
61.7 ± 24.8 
T247V/A395I 
15β-OH-P 
11α-OH-P 
9α-OH-P 
6β-OH-P 
 
23.8 ± 5.7 
38.1 ± 11.3 
17.1 ± 6.0 
36.1 ± 10.0 
 
135.6 ± 7.3 
114.1 ± 9.1 
38.7 ± 2.6 
36.1 ± 2.7 
 
95.0 ± 18.8 
49.9 ± 13.9 
37.7 ± 16.1 
16.7 ± 5.4 
T247W/A395W/G397K 
15β-OH-P 
11α-OH-P 
9α-OH-P 
6β-OH-P 
 
52.2 ± 16.7 
38.8 ± 14.2 
31.4 ± 10.4 
40.9 ± 14.8 
 
304.5 ± 29.6 
164.3 ± 16.4 
159.4 ± 13.2 
78.0 ± 7.9 
 
97.2 ± 38.1 
70.6 ± 32.8 
84.6 ± 34.1 
31.8 ± 14.6 
T248V/A395I 
15β-OH-P 
11α-OH-P 
9α-OH-P 
6β-OH-P 
 
55.6 ± 19.3 
51.7 ± 12.5 
17.8 ± 7.1 
58.0 ± 11.9 
 
186.6 ± 20.1 
207.1 ± 15.2 
39.6 ± 3.1 
73.1 ± 4.7 
 
55.9 ± 24.5 
66.8 ± 18.4 
37.1 ± 19.0 
21.0 ± 4.8 
A106T/A395I/R409L 
15β-OH-P 
11α-OH-P 
9α-OH-P 
6β-OH-P 
 
39.1 ± 11.9 
45.7 ± 14.9 
30.4 ± 10.8 
29.7 ± 9.3 
 
166.9 ± 13.8 
415.2 ± 39.2 
129.5 ± 11.1 
36.2 ± 2.8 
 
71.1 ± 25.8 
151.4 ± 60.5 
70.0 ± 31.4 
20.3 ± 7.6 
A106T/A395W/G397K/ 
R409L 
15β-OH-P 
11α-OH-P 
9α-OH-P 
6β-OH-P 
 
 
41.7 ± 18.2 
47.6 ± 13.2 
35.7 ± 12.4 
20.9 ± 10.8 
 
 
305.8 ± 37.8 
266.7 ± 21.8 
93.4 ± 8.6 
29.2 ± 3.2 
 
 
122.2 ± 73.8 
93.4 ± 30.4 
43.6 ± 18.9 
23.3 ± 18.3 
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Table 3.9: Apparent Km and Vmax values of the CYP106A2 mutants resulting from 
calculations. The data presented in Figure 3. 8a, b, c (part 3). 
 Km 
[µM] 
Vmax  
[nmol/min nmol P450] 
kcat/Km 
[M-1 sec-1] x 103
T89N/A106T/A395I/ 
R409L 
15β-OH-P 
11α-OH-P 
9α-OH-P 
6β-OH-P 
 
 
94.1 ± 25.0 
107.8 ± 29.6 
67.7 ± 26.3 
17.7 ± 9.5 
 
 
295.7 ± 28.8 
149.8 ± 15.7 
81.8 ± 10.5 
38.6 ± 4.0 
 
 
52.4 ± 16.5 
23.2 ± 7.6 
20.1 ± 10.4 
36.3 ± 30.3 
A395I 
15β-OH-P 
11α-OH-P 
9α-OH-P 
6β-OH-P 
 
85.5 ± 10.7 
31.6 ± 12.2 
40.1 ± 12.6 
17.8 ± 14.7 
 
87.2 ± 3.9 
79.6 ± 7.8 
25.5 ± 2.2 
11.2 ± 1.8 
 
17.0 ± 2.3 
42.0 ± 20.9 
10.6 ± 4.0 
10.5 ± 3.6 
A395W/G397K 
15β-OH-P 
11α-OH-P 
9α-OH-P 
6β-OH-P 
 
68.6 ± 29.3 
54.7 ± 19.8 
26.8 ± 13.7 
46.2 ± 14.1 
 
26.4 ± 3.7 
71.3 ± 8.0 
17.0 ± 2.0 
26.1 ± 2.3 
 
6.4 ± 3.9 
21.7 ± 10.1 
10.6 ± 8.2 
9.4 ± 3.5 
CYP106A2 WT 
15β-OH-P 
11α-OH-P 
9α-OH-P 
6β-OH-P 
 
292.9 ± 48.7 
203.4 ± 66.9 
209.5 ± 66.4 
117.2 ± 27.3 
 
342.0 ± 29.1 
16.8 ± 2.5 
6.4 ± 0.9 
19.1 ± 1.7 
 
19.5 ± 3.7 
1.4 ± 0.6 
0.5 ± 0.3 
2.7 ± 0.8 
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Table 3.10: Regio-specificity of CYP106A2 mutants towards progesterone conversion. 
 15β-OH-P 
[%] 
11α-OH-P 
[%] 
9α-OH-P 
[%] 
6β-OH-P 
[%] 
T89N/A395I 100 426.2 ± 7.6 176.3 ± 4.8 125.8 ± 6.1 
A106T/A395I 100 274.3 ± 6.9 59.8 ± 2.6 18.4 ± 0.5 
A106T/A395W/ 
G397K 
100 148.5 ± 7.0 18.0 ± 0.3 21.1 ± 0.7 
A243V/A395I 100 144.5 ± 5.4 20.3 ± 0.7 20.5 ± 0.8 
A243V/A395W/ 
G397K 
100 77.1 ± 2.8 31.6 ± 1.8 55.4 ± 3.8 
D217V/A395I 100 114.0 ± 8.2 46.4 ± 2.6 10.9 ± 0.4 
F165L/A395I 100 134.3 ± 9.3 28.1 ± 0.6 41.0 ± 1.8 
T247V/A395I 100 80.6 ± 5.8 29.2 ± 0.2 25.7 ± 0.8 
T247W/A395W/ 
G397K 
100 56.1 ± 4.8 55.6 ± 7.1 26.5 ± 1.7 
T248V/A395I 100 112.2 ± 3.3 23.7 ± 0.9 38.9 ± 1.8 
A106T/A395I/ 
R409L 
100 243.9 ± 9.8 79.6 ± 5.3 22.3 ± 0.3 
A106T/A395W/ 
G397K/R409L 
100 85.7 ± 5.1 31.1 ±1.1 10.2 ± 0.2 
T89N/A106T/ 
A395I/R409L 
100 49.0 ± 4.1 29.6 ± 0.4 16.2 ± 1.9 
A395I 100 97.2 ± 2.1 32.1 ± 0.4 13.5 ± 0.1 
A395W/G397K 100 280.5 ± 4.8 72.6 ± 0.8 105.2 ± 0.9 
CYP106A2-WT 100 5.0 ± 0.8 1.5 ± 0.3 5.1 ± 0.8 
As shown in Table 3.9, new CYP106A2 mutants with significantly improved catalytic 
efficiency along with a high percentage of 11α-hydroxyprogesterone formation were 
obtained. Three mutants (CYP106A2 D217V/A395I, CYP106A2 F165L/A395I and 
CYP106A2 A106T/A395I/R409L) exhibited a significantly increased apparent kcat/Km of 
11α-hydroxyprogesterone formation (7.8-, 10.3- and 7.8-fold, respectively) compared 
with that of 15β-hydroxyprogesterone from CYP106A2 wild type. Moreover, these 
mutants also showed a higher relative amount of 11α-hydroxylated products being 114%, 
134.3% and 243,9%, higher than that of the parental mutant CYP106A2 A395I (97.2%) 
(Table 3.10). Mutants CYP106A2 A106T/A395W/G397K, CYP106A2 A243V/A395I 
 
 70
Results 
and CYP106A2 T248V/A395I only improved the 11α-hydroxylation by 1.6-, 2.7- and 
3.4-fold compared with 15β-hydroxylation of CYP106A2 wild type. However, these 
mutants produced more 11α-hydroxyprogesterone (148.5%, 144.5% and 112.2%, 
respectively) than 15β-hydroxyprogesterone. The new mutations affected not only in the 
velocity but also in the regio-specificity of enzymes. Despite increasing the catalytic 
activity, mutants CYP106A2 A243V/A395W/G397K, CYP106A2 T247V/A395I, 
CYP106A2 T247W/A395W/G397K, CYP106A2 A106T/A395W/G397K and CYP106A2 
T89N/A106T/A395I/R409L showed a decrease of the 11α-hydroxyprogesterone 
formation compared with the parental enzyme (Table 3.10).  
Interestingly, 2 mutants CYP106A2 T89N/A395I and CYP106A2 A106T/A395I clearly 
produced more 11α-hydroxyprogesterone (426.2% and 274.3%) as compared with the 
15β-hydroxyprogesterone. The 11α-hydroxyprogesterone apparent kcat/Km showed little 
increase (1.8- and 2.8-fold) compared with that of 15β-hydroxyprogesterone from 
CYP106A2 wild type. Furthermore, the 11α-hydroxyprogesterone apparent kcat/Km of 
CYP106A2 T89N/A395I (34.2 ± 13.6 [M-1sec-1x103]) was less than that of the parental 
mutant CYP106A2 A395I (42.0 ± 20.9 [M-1sec-1x103]). However, the regio-selectivity 
towards 11α-hydroxyprogesterone was 4.4- and 2.8-fold, respectively, higher than that of 
the parental mutant CYP106A2 A395I. On the other hand, the 9α- and 6β-
hydroxyprogesterone formations of these 2 mutants were also changed. Mutant 
CYP106A2 T89N/A395I showed a formation of 6β- and 9α-hydroxyprogesterone of 
125.8%, 176.3%, respectively, compared to 15β-hydroxylation. In comparison with 
mutant CYP106A2 A395I, mutant CYP106A2 T89N/A395I produced 5.5-fold more 9α-
hydroxyprogesterone and 9.3-fold more 6β-hydroxyprogesterone. Likewise, in the 
CYP106A2 A106T/A395I mutant, the relative values of 9α- and 6β-hydroxyprogesterone 
were 59.8% and 18.4%, demonstrating an 1.9- and 1.4-fold increase compared with 
CYP106A2 A395I mutant. 
3.3. Progesterone conversion in whole-cell system 
Steroid intermediate productions by whole-cell systems nowadays become more popular 
than using isolated enzymes due to time and costs (Straathof et al., 2002). To reveal the 
capacity of the CYP106A2 mutants in in vivo conversions, 7 out of 15 mutants were 
selected and investigated. The selected mutants were chosen according to a high catalytic 
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efficiency as well as 11α-hydroxyprogesterone formation. Coexpression of CYP106A2 
mutants as well as the redox partner (Adx and AdR) was performed in JM109 E.coli cells. 
3.3.1 Retention time of hydroxylated products in the HPLC 
The whole-cell biotransformations of progesterone with CYP106A2 mutants were 
analyzed using a new Macherey Nagel column CC125/4 Nucleodur 100-5-C18ec. The 
standards (15β-, 11α-, 9α- and 6β-hydroxyprogesterone) were checked for the retention 
time in the new system and compared with the old column from Nova Pak. On the new 
column, all the steroids had longer retention times than on the old column. 15β-, 11α-, 
9α-, 6β-hydroxyprogesterone showed peaks at 4.91, 5.33, 6.23 and 6.93 min, 
respectively. 
Retention time [min]
0 10 20 30 40 50
Nova Pak Column
Macherey-Nagel Column
15β-OH-P 
11α-OH-P 
9α-OH-P 
6β-OH-P 
20β-OH-P 
Progesterone 
Figure 3.9: HPLC retention time of the hydroxylated progesterone products in 2 different 
columns, Nova Pak Nucleosil C18 (4 μm, 3.9 x 150 mm) and Macherey-Nagel CC125/4 
Nucleodur 100-5-C18ec. Black: 15β-hydroxyprogesterone, red: 11α- 
hydroxyprogesterone, green: 9α- hydroxyprogesterone, yellow: 6β-hydroxyprogesterone, 
blue: 20β-hydroxyprogesterone and pink: Progesterone. 
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3.3.2. Effect of solvent for progesterone conversion 
The difference between the conversion in vitro and in vivo is working without or with 
living cells. Gram-negative E.coli bacteria cells are sensitive with the agents as a result of 
the effective permeability barrier function of their outer membrane. The outer membrane 
is impermeable to macromolecules and allows only limited diffusion of substances 
through its lipopolysaccharide covered surface (Vaara, 1992). Substances, which 
penetrate through the porin channels easily, have to be hydrophilic compounds or have to 
use some kind of carriers. For example, steroids are usually dissolved in ethanol or 
methanol. Since alcohol can be harmful to the cell, some substances which are 
hydrophobic or are larger hydrophilic compound, which penetrate the outer membrane 
poorly, need another type of a carrier such as cyclodextrin. To compare the effect of the 
solvent carrier on the cells and the resulting in vivo conversions, 10 mM progesterone was 
resolved in absolute ethanol (HPLC grade) and in 45% of hydroxypropyl-β-cyclodextrin 
(HPBCD). Two molecules of hydroxypropyl-β-cyclodextrin are able to carry a single 
molecule progesterone through the cell membrane and are removed afterwards (Vaara, 
1992). CYP106A2 wild type and 3 mutants CYP106A2 T89N/A395I, CYP106A2 
A106T/A395I, CYP106A2 A106T/A395I/R409L were investigated in both solvent carrier 
solutions. Interestingly, the conversions with ethanol were more efficient than those with 
the cyclodextrin carrier in all the tested cases. After 6 hr conversion, all the CYP106A2 
proteins converted 98 - 99% protesterone in absolute ethanol, but only up to 38.5% 
progesterone consumption after 12 hr in cyclodextrin solution were reached (Figure 3.10). 
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Figure 3.10: Consumption of progesterone by CYP106A2 wild type and 3 mutants 
(CYP106A2 T89N/A395I, CYP106A2 A106T/A395I, CYP106A2 A106T/A395I/R409L) 
in absolute ethanol and 45% Hydroxypropyl-β-cyclodextrin-carriers. Grey bars: 
conversion after 6 hr and black bars: conversion after 12 hr. 
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3.3.3. In vivo conversion of progesterone by selected mutants 
CYP106A2 wild type and 7 chosen mutants were reconstituted with Adx and AdR from 
bovine adrenals by coexpression of pACYC_FHH2_CYP106A2 variants and 
pBAR_Twin in 20 ml of E.coli JM109 culture. The negative controls for every sample 
were transformed and expressed with only the plasmid pBAR_Twin. After 24 hr of 
induction, 1 ml of culture was taken out and washed with potassium buffer (pH 7.4) to 
avoid the impurity peaks when analyzing the products by HPLC. The cells were dissolved 
once in potassium buffer (pH 7.4) and 100 µM and/or 200 µM of progesterone was added 
to start the reaction at 30°C for 6 hr and 12 hr, respectively. Steroids were extracted with 
chloroform and applied to an HPLC column for analysis of the products (Figure 3.11, 
3.12 and Table 3.11, 3.12). 
Figure 3.11: Chromatogram of hydroxylated progesterone products after 6 hr from 
CYP106A2 wild type (red line). The negative control (black line) was done the only 
single vector pBAR_Twin. 
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Firgure 3.12: Chromatograms of the hydroxylated progesterone products from 
CYP106A2 wild type and selected mutants in the whole-cell system. The plots after 6 and 
12 hr conversion are in black and green, respectively. 
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Table 3.11: Distribution of hydroxylated progesterone products after 6 hr of in vivo 
conversion. 
 15β-OH-P
[%] 
11α-OH-P 
[%] 
9α-OH-P 
[%] 
6β-OH-P 
[%] 
T89N/A395I 100 1672.2 ± 95.2 161.5 ± 18.6 134.0 ± 16.1 
A106T/A395I 100 227.5 ± 11.7 70.5 ± 4.1 20.3 ± 1.6 
D217V/A395I 100 198.2 ± 17.0 48.5 ± 1.7 19.2 ± 0.6 
F165L/A395I 100 127.3 ± 12.9 22.6 ± 0.8 28.3 ± 1.2 
A106T/A395I/R409L 100 255.6 ± 14.3 74.3 ± 3.2 19.1 ± 0.4 
A395I 100 186.7 ± 5.6 47.1 ± 1.3 28.9 ± 0.5 
A395W/G397K 100 228.5 ± 13.4 68.1 ± 5.5  18.7 ± 0.9 
CYP106A2 WT 100 73.0 ± 1.8 8.3 ± 0.02 35.1 ± 0.7 
Table 3.12: Distribution of hydroxylated progesterone products after 12 hr of in vivo 
conversion. 
 15β-OH-P
[%] 
11α-OH-P 
[%] 
9α-OH-P 
[%] 
6β-OH-P 
[%] 
T89N/A395I 100 1436.3 ± 86.6 158.6 ± 15.1 139.4 ± 14.4 
A106T/A395I 100 220.8 ± 19.5 66.3 ± 7.5 17.2 ± 1.7 
D217V/A395I 100 142.3 ± 11.6 40.9 ± 1.1 16.1 ± 0.3 
F165L/A395I 100 99.9 ± 1.4 18.8 ± 0.3 30.6 ± 1.6 
A106T/A395I/R409L 100 161.2± 13.4 53.5 ± 4.6 14.7 ± 0.4 
A395I 100 184.4 ± 8.4 47.3 ± 0.8 26.3 ± 0.6 
A395W/G397K 100 188.5 ± 9.4 54.1 ± 1.3 24.7 ± 0.3 
CYP106A2 WT 100 50.2 ± 1.8 7.0 ± 0.04 39.2 ± 0.9 
In general, during in vivo conversion all the cases showed a higher amount of 11α-
hydroxyprogesterone compared with the in vitro experiments except for mutants 
CYP106A2 A106T/A395I, CYP106A2 F165L/A395I and CYP106A2 A395W/G397K, 
which showed slightly less (5.2 - 18.5%) 11α-hydroxyprogesterone activity . The 
proportion of 15β/11α/9α/6β from in vivo conversion of CYP106A2 wild type was 
100/73/8.3/35.1, which was different from the in vitro conversion (100/5/1.5/6.4). In 
mutant CYP106A2 F165L/A395I, the 11α-formation was not higher as compared with 
15β-hydroxylated product formation; furthermore, after 12 hr, 11α-hydroxyprogesterone 
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production was lower than the 15β-hydroxyprogesterone production. Moreover, this 
mutant showed quite low activity in the whole-cell system compared with the in vitro 
conversion. The two parental mutants (CYP106A2 A395I and CYP106A2 
A395W/G397K) still showed a rather low activity although the percentage of 11α-
hydroxyprogesterone using CYP106A2 A395I was higher compared with the isolated 
enzyme of this mutant. 
Clearly, the in vivo conversion after 6 hr produced more 11α-hydroxyprogesterone than 
after 12 hr, where the 15β-hydroxylation was increased in every CYP106A2 protein. 
After 12 hr, 15β-hydroxyprogesterone was increased as compared with the others 
products, 11α-, 9α- and 6β-hydroxyprogesterone. 
Taken together, it can be stated that new mutants with changed selectivity and improved 
activity were obtained. The most successful mutant was CYP106A2 T89N/A395I, which 
exhibited mainly 11α-hydroxyprogesterone (1672.2% compared with 15β-hydroxylation) 
in the whole-cell system. Moreover, CYP106A2 T89N/A395I became the most 
interesting mutant for the 11α-hydroxyprogesterone production, as it also showed the 
highest conversion rate in comparison with the others. Moreover, mutant CYP106A2 
A106T/A395I/R409L showed 255.6% of 11α-hydroxylation compared with 15β-
hydroxylation as well as 95% progesterone consumption after 6 hr of in vivo conversion. 
Discussion 
4. DISCUSSION 
4.1. Progesterone bioconversion 
The importance of microorganisms for the synthesis of steroid drugs has been anticipated 
in 1952 when the production of 11α-hydroxyprogesterone by a Rhizopus strain was 
patented (Murray and Peterson, 1952). Moreover, enzymes, which are able to hydroxylate 
progesterone, are derived from filamentous fungi. Similarly, the filamentous fungus 
Nectria haematococca strain 110 contains 4 enzymes that metabolize exogenous steroids. 
Two of these are microsomal cytochromes P450, which act sequentially on progesterone. 
Firstly, a side-chain cleavage enzyme converts progesterone into androstenedione. The C-
19 steroid androstenedione then is converted into an 11α-hydroxylated derivative through 
an 11α-hydroxylase. Two other conversions may occur after side-chain cleavage. The 
enzyme 1-ene dehydrogenase is specific for androstenedione and leads to an unsaturated 
bond within the A ring. The C-17-specific oxidoreductase is also involved in the 
production of androstenedione and testosterone from progesterone (Ahmed et al., 1996). 
Furthermore, algae are also reported as steroid metabolizing organisms. Some species 
such as Cyanidium emersonii, Muriella aurantiaca and Selenastrum capricornutum 
catalyze the hydroxylation of progesterone. The first alga produces 2β-, 6β-, 9α-, 14α-, 
16α- and 21-hydroxyprogesterone, while M. aurantiaca and S. capricornutum show as 
products only 6β-hydroxyprogesterone along with 15α-hydroxyprogesterone. The alga 
Scenedesmus quadricauda biotransforms progesterone into 9α-hydroxyprogesterone and 
3-hydroxy-9,10-seco-pregna-1,3,5(10)-triene-9,20-dione (Pollio et al., 1994). 
Bacterial enzymes hydroxylating progesterone are found in Bacillus, Mycobacterium and 
Streptomyces species. Some enzymes are able to convert progesterone into other 
intermediates. For example, Mycobacterium smegmatis possesses an enzyme which can 
produce progesterone from plant sterols derived from the pulpe of pine trees. It further 
converts progesterone into 17α-hydroxyprogesterone, androstenedione, and other 
androgens (Jenkins et al., 2004). Other enzymes such as Baeyer-Villiger monooxygenases 
(BVMO) also have the capacity of progesterone conversion. A fungal Baeyer-Villiger-
steroid monooxygenase from Cylindrocarpon radicicola, esterifies progesterone to 
produce testosterone acetate and, subsequently, oxidatively lactonises in the next step the 
androstenedions to testololactone (Itagaki, 1986a and b). A bacterial Baeyer-Villiger 
monooxygenase from Rhodococcus rhodochrous also converts progesterone to 
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testosterone acetate (Miyamoto et al., 1995). Likely, cytochrome P450 from the 
Streptomyces roseochromogenes NCIB strain 10984 hydroxylases exogenous 
progesterone, firstly to 16α-hydroxyprogesterone and then to 2β, 16α-
dihydroxyprogesterone (Berrie et al., 1999).  
The bioconversion of progesterone by microorganisms, which is summarized in Table 
4.1, exhibits a significant diversity not only in different species but also concerning the 
products of the progesterone derivatives. In general, microbial steroid conversion has a lot 
of advantages, which can be applied for the biotechnological purpose as the microbial 
enzymes meet the demands of directed evolution. Furthermore, bacterial cytochromes 
P450, being able to perform steroid hydroxylation, can be heterologously expressed in a 
soluble form and are, therefore, the potential candidates for biotechnological application. 
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Table 4.1: Progesterone conversion catalyzed by microbial systems (part 1). 
Organism and Enzyme Product Reference 
Bacillus cereus var. mycoides  
(MB 718) 
unknown 
14α-OH-progesterone 
11α-OH-progesterone 
 
Mc-Aleer et al., 
1958 
Bacillus megaterium  
ATCC 13368 
15β-hydroxylase (CYP106A2) 
15β-OH-progesterone 
11α-OH-progesterone 
9α-OH-progesterone 
6β-OH-progesterone 
Berg et al., 1976 
Lisurek et al., 
2004 
Kang et al., 2004 
Βacillus 
thermoglucosidasius 
strain 12060 
cytochrome P450 
6β-OH-progesterone 
6α-OH-progesterone 
androstenedione 
Sideso et al., 
1998 
Bacillus stearothermophilus 
cytochrome P450 
20α-OH-progesterone 
6β-OH-progesterone 
6α-OH-progesterone 
9,10-seco-20α-OH-progesterone 
6β,20α-diOH-progesterone 
6α,20α-diOH-progesterone 
5α-pregnan-3,6,20-trione 
6-dehydroprogesterone 
Al-Awadi et al., 
2001, 2002 
 
Bacillus subtilus 
cytochrome P450 
6β-OH-progesterone 
6α-OH-progesterone 
20α-OH-progesterone 
Walaa et al., 
2009 
Caldariella acidophila 
unknown 
4-pregnen-3,6,20-trione 
5α-pregnan-3,6,20-trione 
20α-OH-4-pregnen-3-one 
6β-OH-progesterone 
6α-OH-progesterone 
De Rosa et al., 
1981 
Mycobacterium smegmatis 
unknown 
17α-OH-progesterone 
 
Jenkins et al., 
2004 
Streptomyces 
roseochromogenes strain 10984 
progesterone-16α-hydroxylase 
16α-OH-progesterone 
2β,16α-diOH-progesterone 
Berrie et al., 
1999 
Pseudomonas sp. 
unknown 
androsta-1,4-dien-3,17-dion 
17β-hydroxyandrosta-1,4-dien-3-one 
Dhar and 
Samanta, 1993 
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Table 4.1: Progesterone conversion catalyzed by microbial systems (part 2). 
Organism and Enzyme Product Reference 
Rhodococcus rhodochrous 
Baeyer-Villiger 
monooxygenase 
testosteroneacetat 
 
Miyamoto et al., 
1995 
Acremonium strictum 
PTTC 5282 
unknown 
15α-OH-progesterone 
15α-OH-DOC 
7β,15β-diOH-progesterone 
6β,11α-diOH-progesterone 
11α,15β-diOH-progesterone 
6β,11α,17α-triOH-progesterone 
11α,15β,17α-triOH-progesterone 
7β,15β,17α-triOH-progesterone 
Yoshihama, 1993
Faramarzi et al., 
2003 
 
Aspergillus fumigatus 
cytochrome P450 
11α-OH-progesterone 
15β-OH-progesterone 
7β-OH-progesterone 
7β,15β-diOH-progesterone 
11α,15β-diOH-progesterone 
Smith et al., 1994
Aspergillus ochraceus 
cytochrome P450 
11α-OH-progesterone Samanta and 
Ghost, 1987 
Aspergillus niger 
cytochrome P450 
11α-OH-progesterone 
6β,11α-diOH-progesterone 
Walaa et al., 
2009 
Cochliobolus lunatus m 118 
cytochrome P450 
11β-OH-progesterone 
11β,14α-OH-progesterone 
7α,14α-diOH-progesterone 
11-keto-14α-OH-progesterone 
Vita et al., 1994 
Cylindrocarpon radiciola 
Baeyer-Villiger 
monooxygenase 
testosteroneacetate 
 
Itagaki, 1986 
Fusarium culmorium 
unknown 
15α-OH-progesterone 
12β,15α-diOH-progesterone 
Kolek et al., 1998
Mortierella isabellina 
unknown 
14α-OH-progesterone Holland et al., 
1992 
Nectria haematococca 
strain 110 
C17-C20-lyase 
androstenedione 
 
Ahmed et al., 
1996 
Penicillium decumbens 
ATCC 10436 
unknown 
5α-diOH-progesterone 
 
Holland et al., 
1995 
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Table 4.1: Progesterone conversion catalyzed by microbial systems (part 3). 
Organism and Enzyme Product Reference 
Mucor piriformis 
14α-hydroxylase 
14α-OH-progesterone 
5β,14α-diOH-progesterone 
6β,14α-diOH-progesterone 
7α,14α-diOH-progesterone 
7β,14α-diOH-progesterone 
Madyastha and 
Joseph, 1993 
Madyastha, 1994 
and 1996 
Phycomyces blakesleeanus 
progesterone hydroxylase 
7α-OH-progesterone 
15β-OH-progesterone 
6β-OH-progesterone 
14α-OH-progesterone 
15α-OH-progesterone 
Smith et al., 1991
Ahmed et al., 
1995 
Rhizopus nigricans 
cytochrome P450 
11α-OH-progesterone 
6β,11α-diOH-progesterone 
11α-OH-5α-pregnan-3,20-dione 
Kim and Kim, 
1991 
Trichophyton mentagrophyton 
unknown 
15α-OH-progesterone 
11α-OH-progesterone 
1-dehydroprogesterone 
Clemons et al., 
1989 
Curvularia clavata Jain 
unknown 
7α,14α-dihydroxypregn-4-ene-3,20- 
dione 
11β,14α-dihydroxypregn-4-ene-
3,20-dione 
Vujcić and 
Jankov, 1990 
Chlorella emersonii 
strain C211-8b 
unknown 
2β-OH-progesterone 
6β-OH-progesterone 
9α-OH-progesterone 
14α-OH-progesterone 
16α-OH-progesterone 
21-OH-progesterone 
Pollio et al., 1994
Muriella aurantiaca  
strain C249-1 
unknown 
6β-OH-progesterone 
15α-OH-progesterone 
 
Pollio et al., 1994
Selenastrum capricornutum 
strain T1648 
unknown 
6β-OH-progesterone 
15α-OH-progesterone 
 
Pollio et al., 1994
Scenedesmus quadricauda 
strain T76 
unknown 
9α-OH-progesterone 
3-hydroxy-9, 10-seco-pregna-1, 3, 5 
(10)-triene-9, 20-dione 
Pollio et al., 1994
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4.2. Expression and purification of CYP106A2 
Bacillus megaterium ATCC 13368 was shown to be able to hydroxylate progesterone 
(Berg et al., 1976). Later, a cytochrome P450 from this strain has been purified, which 
was able to perform 15β-hydroxylation of 3-oxo-Δ4-steroids. However, the expression 
yield of the cytochrome P450, subsequently identified as CYP106A2, was only 8 
pmol/mg of protein (Berg et al., 1979a). 
Rauschenbach (1993) firstly cloned and completely sequenced the gene of this steroid 
15β-monooxygenase (CYP106A2) and heterologously expressed it in E.coli and 
B.subtilis cells. The P450 concentration in crude protein extracts rose up to 77 - 260 pmol 
and 250 pmol per mg of total soluble protein in E.coli and B.subtilis, respectively 
(Rauschenbach et al., 1993). Subsequently, the cDNA of CYP106A2 was expressed in 
E.coli BL21DE3 using the expression vector pKKHC. This led to a significant increase of 
the expression yield up to 4400 pmol/mg of protein, corresponding to 4330 nmol/L 
culture (Simgen, 2000). The optimization of the expression conditions gave a yield of 
8000 pmol/mg of total protein (corresponding to 13699 nmol/L culture) (Lisurek, 2004). 
However, the expression level CYP106A2 using pACYC_FHH2 which is necessary to 
use when performing a coexpression of the redox partner with pBAR_Twin, was lowered 
significantly. The yield was only 1273 nmol/L culture, which was 10-fold lower in 
comparison with that using the pKKHC vector. Nevertheless, the expression system is 
sufficient enough to be used for the screening of the mutants and their subsequent 
purification. The highest content (1678 nmol/L culture) of cytochrome P450 was obtained 
with mutant CYP106A2 A106T/A395I. The other mutants varied in their expressed level 
from 400 - 800 nmol/L culture. It was found that only 8 CYP106A2 mutants (6, 19, 20, 
21, 29, 40, 42, 43) showed lower expression levels (< 300 nmol/L culture). Although the 
yield of the expressed protein in pACYC_FHH2 system was lower than in other 
expression systems (e.g. using pKKHC as an expression vector), the pACYC_FHH2 
plasmid has other advantages. E.g. it can be coexpressed with another plasmid 
(pBAR_Twin), which is providing the electron transfer partners AdR and Adx. This 
coexpression system is useful for the application of molecular evolution approaches in 
order to select mutants of CYP106A2 with higher stability, activity, and changed regio- 
and stereo-selectivity. 
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To get a reasonable amount of mutant proteins, the expression and purification of 
CYP106A2 had to be optimized. The heterologous expression of CYP106A2 was 
optimized using the single mutant CYP106A2 A395I and the double mutant CYP106A2 
A395W/G397K. During the expression of the CYP106A2 mutants three factors (OD600, 
pH and P450 content) were measured in parallel. Although the P450 content showed a 
difference between the two mutants (5.1 μM for CYP106A2 A395I and 3μM for 
CYP106A2 A395W/G397K), the OD600 reached approximately 3.0 after 32 - 44 hr of 
expression. During the investigated time, the pH value decreased from 7.4 to 6.6 in the 
first 20 hr and rose up to 7.0 again. However, in the mutant CYP106A2 A395I, the P450 
content dramatically increased while the pH was at a minimum (6.6). In contrast, the 
amount of CYP106A2 increased steadily despite a reduced pH value in the double mutant 
(CYP106A2 A395W/G397K). In both cases, the maximum P450 content was gained at 44 
hr of expression. This observation suggests that the heterologous expression of 
cytochrome P450 can be measured after 20 hr for the evaluation of a successful 
expression or to control other parameters such as pH or cell density during expression. 
Several methods of cytochrome P450 purification procedures had been used in the past. 
Berg et al. purified CYP106A2 through 5 chromatographic columns including DEAE-
cellulose, Ultrogel ACA-54, DEAE-Sepharose, octyl-Sepharose and HAP. During this 
complete purification procedure, approximately 97% of the cytochrome P450 was lost. In 
that case, 77.3% of P450 was lost during octyl-Sepharose and HAP columns (Berg et al., 
1979a). Similarly, Simgen et al. purified CYP106A2 by (NH4)2SO4 precipitation and then 
3 chromatographic columns including DEAE-Sepharose, HAP and gel filtration. During 
this procedure, only 35 - 50% of the protein was lost (Simgen, 2000).  
In this work, the purification procedure of Simgen was followed. The loss of the 
CYP106A2 content was about 50%. After applying on the DEAE Sepharose column, the 
loss of CYP106A2 was approximately 30 - 35% of cytochrome P450. The P450 content 
was reduced by 15 - 24% after application on the HAP column. Finally up to 10 - 15% 
was lost after gel filtration (Superdex 75). The absorptions of the protein at the 
wavelengths 417 nm and 280 nm showed the typical absorbance of a cytochrome P450 in 
its low-spin state. The ratio of A417/A280 was used to monitor the purification level of the 
cytochrome P450. A higher ratio represented the more homogenous from of the 
CYP106A2. The ratio A417/A280 of the CYP106A2 mutants was only around 1.0 - 1.2, 
being less than the value published before for the wild type enzyme (1.7 – 1.8) (Simgen, 
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2000; Lisurek, 2004). This finding could be due to more protein impurities or higher apo-
protein levels probably caused by a decreased stability of the mutants. 
4.3. Hydroxylation of progesterone by CYP106A2 mutants  
4.3.1. Rational behind this study 
CYP106A2 from Bacillus megaterium ATCC 13368 converts progesterone and produces 
not only 15β-hydroxyprogesterone but also 11α-, 9α- and 6β-hydroxylated products 
which rates ranged from 5 - 10% (Lisurek et al., 2004; Kang et al., 2004). Lisurek et al. 
constructed a homology model of CYP106A2 and identified 6 substrate recognition sites 
(Table 4.2) being important for the activity of this enzyme. The amino acid residues lying 
within each substrate recognition site are therefore promising candidates for site-directed 
mutagenesis. So, in this work, they were chosen to alter the regio-selectivity and the 
activity of CYP106A2. 
Table 4.2: The substrate recognition sites of CYP106A2 derived from a computer model 
(Lisurek, 2004) 
Substrate recognition site (SRS) Residues 
1. B/B’- and B’/C-loop R66, E78, S81, E84, N87, I88, T89 
2. F-Helix L171, F175, F178 
3. G-Helix not available 
4. I-Helix R235, M238, L239, A243, T247, T248 
5. β1-4 F289, N290, L291, K293, L294, R296 
6. β4-1/β4-2-loop A395, T396 
The regio-specificity of the progesterone hydroxylation was evaluated by Lisurek 
(Lisurek, 2004; Lisurek et al., 2008). During the docking of progesterone into 
CYP106A2, at least one hydrogen bond between the C-3 keto group of progesterone and 
the loop between residue A395 and residue T396 within the putative substrate recognition 
site (SRS) 6 was found and no other SRS was observed to be involved. Therefore, these 
residues were chosen for site-directed mutagenesis and mutants were created to change 
the hydroxylation pattern. On the other hand, to change the regio-selectivity from the 15- 
to 11-position, CYP106A2 was aligned with human CYP11B1 to identify the analogue 
residues between the 2 proteins in the SRS 6 region. The alignment between these 2 
enzymes in the SRS 6 showed a high degree of diversity between amino acids 394 and 
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398 of CYP106A2 giving rise to the production of 5 mutants (CYP106A2 S394I, 
CYP106A2 A395L, CYP106A2 T396R, CYP106A2 G397P and CYP106A2 Q398S). 
Distinct changes in the progesterone hydroxylation pattern were observed for the 2 central 
mutants in SRS 6 (CYP106A2 A395L and CYP106A2 G397L), whereas mutations in 
position 394 and 398 had no effect for the regio-selectivity, and mutant CYP106A2 
T396R was an inactive enzyme (Lisurek, 2004; Lisurek et al., 2008). It was assumed that, 
only 2 residues, A395 and G397 of CYP106A2, could affect the regio-selectivity of 
progesterone hydroxylation. Therefore, saturation mutagenesis was used in following 
studies to produce a library of mutants with changes in positions 395 and 397 (Virus, 
2006). However, only a few mutants had been analyzed in that work so that further 
investigations using this library were necessary to screen for mutants with changed regio-
selectivity of the hydroxylation. 
 
Figure 4.1: The binding pocket of CYP106A2 was docked with the substrate 
progesterone. The substrate, the heme-cofactor and the loop A395-G397 are shown in 
stick representation. The hydrogen bonds between the substrate and amino acid T396 are 
exhibited in green. 
4.3.2. Progesterone hydroxylation of CYP106A2 mutants within the SRS 6 region 
To screen for a changed regio-selectivity of hydroxylation, 40 transformants of the 
saturation mutagenesis library have been selected and studied for their product pattern. 
The CYP106A2 mutants were cloned into plasmid pACYC_FHH2 as described in section 
2.2.4. Afterwards the mutants were expressed in E.coli JM109 and the corresponding 
proteins were purified. This work started with the aim to select a mutant which showed a 
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higher 11α-hydroxyprogesterone production rate. Therefore, after purification, the 
CYP106A2 mutant proteins were reconstituted with AdR and truncated Adx (4-108) for 
the in vitro studies (to convert progesterone). The hydroxylated products were analyzed 
using HPLC and it was found that the amount of the former side products (11α-, 9α-, 6β-
hydroxyprogesterone) were higher in almost the active mutants compared with the 
CYP106A2 wild type where 15β-hydroxyprogesterone was the most prominent product. 
The active mutants showed at least 2-fold higher formation of the 11α-hydroxylated 
product than the wild type enzyme. Furthermore, 2 mutants (CYP106A2 A395K/G397N 
and CYP106A2 A395W/G397K) showed the highest proportion of 11α-
hydroxyprogesterone being 13.5- and 56-fold, respectively, higher compared with the 
relative value of CYP106A2 wild type. Mutant CYP106A2 A395W/G397K produced 
more 11α-hydroxyprogesterone than 15β-hydroxyprogesterone (Table 4.2). Similarly, all 
the active mutants with high 11α-hydroxyprogesterone formation also showed at least 4-
fold higher 9α-hydroxyprogesterone formation than that of CYP106A2 wild type. Mutant 
CYP106A2 A395R/G397K gave 125% of the 9α-hydroxylated product in comparison 
with 15β-hydroxyprogesterone (100%). However, this tendency was not observed for the 
hydroxylation at the C-6 position. In general, most of the mutants produced 2 - 4 folds 
more 6β-hydroxyprogesterone in comparison with CYP106A2 wild type, whereas mutant 
CYP106A2 A395H/G395L reduced the formation of the 6β-hydroxylated product. Taken 
together, the 2 SRS 6 mutants CYP106A2 A395W/G395K and CYP106A2 
A395K/G397N were the most interesting ones showing a significant changes of the regio-
selectivity towards the 11α-, 9α-, 6β-position (Table 4.2). Unfortunately, none of these 
most interesting mutants showed a similarly high turnover rate as CYP106A2 wild type. 
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Table 4.2: Relative regio-specificity towards 11α-hydroxyprogesterone formation of the 
CYP106A2 wild type and mutants. For each cytochrome, the 15β-hydroxyprogesterone 
amount was set to 100%. The obtained results are compared with the results of 1: Lisurek 
(Lisurek, 2004), 2: Virus (Virus, 2006) and 3: Tin (Tin, 2006). 
 15β-OH-P 
[%] 
11α-OH-P 
[%] 
9α-OH-P 
[%] 
6β-OH-P 
[%] 
CYP106A2-WT 100 5.0 1.5 6.4 
A395K/G397N 100 67.7 33.2 63.8 
A395W/G397K 100 282.2 69.6 107.7 
CYP106A2-WT 1 100 9.0 3.9 9.1 
A395L 1 100 38.9 20.0 7.0 
G397P 1 100 40.7 9.0 20.9 
A395I 2 100 97.2 32.1 13.5 
A395L/G397S 2 100 101.6 20.9 20.3 
A395L/G397P 2 100 61.3 25.3 13.5 
A395I/G397D 3 100 105.0 51.0 21.0 
A395I/G397H 3 100 73.0 39.0 0.0 
A395F 3 100 64.0 31.0 41.0 
As shown in Table 4.2, the mutants with the so far highest formation of 11α-, 9α- or 6β-
hydroxyprogesterone have been obtained in this work. The amount of 11α-
hydroxyprogesterone was nearly 3-fold higher than the best value published so far, the 
amount of 9α-hydroxyprogesterone was 1.4-fold, and that of 6β-hydroxyprogesterone 
5.2-fold higher. It can also be seen that, the ratio of 15β-hydroxyprogesterone to the other 
products (11α-, 9α- and 6β-hydroxyprogesterone; 100/5/1.5/6.4) was different from that 
described previously by Lisurek et al., where the ratio was (100/9/3.9/9.1). This is due to 
a difference in the reaction time during the in vitro assay. The reaction time was set to 3 
min in Lisurek’s work (Lisurek, 2004), whereas in this study, 10 min were used. This 
shows that, the prolongation of the reaction time could cause changes in the hydroxylation 
pattern, leading to an increase of 15β-hydroxyprogesterone and a decrease of the other 
products (Table 4.2). 
When analyzing the progesterone hydroxylation towards the 11α-position, a trend in 
altering residues at the positions 395 and 397 has been observed. In the CYP106A2 wild 
type, the residue in position 395 is an alanine, which is a non-polar amino acid and 
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occupies a small place in the structure of the enzyme. In the mutants which exhibited a 
higher ratio of 11α-hydroxyprogesterone, amino acid A395 was observed to change into a 
larger amino acid such as isoleucine, leucine, lysine, phenylalanine or tryptophan. Except 
for lysine, which is a polar amino acid, the others are uncharged and possess larger side 
chains than alanine. On the other hand, glycine in position 397 is also a small and non-
polar amino acid. This residue was substituted mainly by polar amino acids such as 
asparagine, lysine, serine or aspartic acid, which are also larger than glycine. 
Interestingly, the combination between a non-polar amino acid in position 395 
(isoleucine, leucine or tryptophan) and a polar amino acid (lysine, aspartic acid or serine) 
in position 397 resulted in the highest 11α-hydroxyprogesterone formation. In contrast, 
mutants CYP106A2 A395K/G397N or CYP106A2 A395L/G397P, where one of these 
positions was not occupied by an optimal amino acid, showed only 67.7% and 61.3% of 
11α-hydroxyprogesterone, respectively. On the other hand, single mutants such as 
CYP106A2 A395F or CYP106A2 A395I were also affected showing an 11α-
hydroxyprogesterone formation rose up to 64 and 97.2%, respectively. Furthermore, 
mutant CYP106A2 A395E/G397Stop hydroxylated progesterone as the CYP106A2 wild 
type enzyme showing 4 mono-hydroxylated products. Interestingly, despite having only 
396 instead of 410 amino acids, this mutant worked properly. This raised the question 
about the role of the residues from position 397 to 410. These residues resided on the C-
terminal part of the CYP106A2 sequence and probably might not play an important role 
for the progesterone hydroxylation. It was assumed that, the position 395 could be more 
important than position 397 to alter the regio-specificity. 
In contrast, when investigating the progesterone hydroxylation at the 9α-position, no 
concerning distinct amino acids tendency could be observed. Mutant CYP106A2 
A395R/G397K, showing 125.8% of relative 9α-hydroxyprogesterone formation, was 
altered at both positions to polar and positively-charged amino acids. On the other hand, 
mutant CYP106A2 A395E/G397V, showing 84.3% 9α-hydroxyprogesterone, was 
substituted by both a polar and non-polar amino acid. In mutant CYP106A2 
A395W/G397K, producing 69.6% of 9α-hydroxy product, amino acid A395 was replaced 
by a non-polar amino acid, whereas amino acid G397 was changed to a polar, positively-
charged one. When considering the formation of 6β-hydroxyprogesterone, it can be 
observed that, the mutants CYP106A2 A395R/G397K, CYP106A2 A395K/G397N, and 
CYP106A2 A395W/G397K showed an increased production of this product. This 
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suggests that, a combination of two polar, positively-charged amino acids or of a polar, 
positively-charged amino acid with a non-polar, neutral amino acid, could lead to an 
increase of the 6β-hydroxylation. 
These results support the hypothesis that the free CYP106A2 enzyme may exist in a 
dynamic equilibrium with multiple conformations and that the equilibrium is apparently 
determined by a few critical residues including those at positions 395 and 397. As 
discussed by Joyce, due to the changing position of this equilibrium in the absence of a 
substrate, the mutations can decrease the proportion of the binding energy, which is used 
up in shifting the equilibrium on the substrate binding, and so leading to a net increase in 
affinity (Joyce et al., 2004).  
It was shown that the pocket structure of P450 is geometrically flexible and can be altered 
by mutation of a single amino acid at a key position. For example, the substitution of 
phenylalanine by valine at position 209 of CYP2A5 altered the product specificity from 
the 2-position to the 7-position as the major hydroxylation site (Negishi et al., 1996b). 
Furthermore, mutations of amino acid residues in the substrate access and binding region 
may be evolutionarily fixed. They may provide the cytochrome P450 with new activities 
which are advantageous for the survival of an individual. The non-synonymous mutations 
were accumulated more within the substrate recognition sites than outside of these sites 
(Gotoh, 1992). Residue 478, which is located in the putative substrate recognition site 
(SRS) 6 of CYP2B2, has shown to play a role in controlling the stereo-selectivity of the 
androstenedione hydroxylation. It may be mediated by alterations in the secondary or 
tertiary structure of the cytochrome, leading to changes in the orientation of the substrate 
in the active site (Kedzie et al., 1991; He et al., 1992 and 1994). In CYP106A2, the both 
residues A395 and G397 lay on the putative SRS 6 and are small side-chain amino acids. 
The size of the side-chain may play a major role in determining the P450 activities 
(Iwasaki et al., 1991). Although the size is not the only factor, it remains to be 
understood, how a change of the size of the side-chain results in a dramatic alteration of 
the P450 activities (Negishi et al., 1996a). As mentioned before, CYP106A2 hydroxylates 
progesterone at 4 different positions. This suggests that the substrate can be fitted to 4 
completely different orientations in the pocket. The substitutions of residues A395 and 
G397 by a range of larger amino acid residues may prevent the binding of the 
progesterone in the mode as seen in CYP106A2 wild type and directly result in the 
repacking and displacement of the structural unit. 
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However, the both mutants, CYP106A2 A395I and CYP106A2 A395W/G397K, which 
showed the highest 11α-hydroxyprogesterone production, had a 50% lower activity 
compared with CYP106A2 wild type. Therefore, these mutants were further mutated to 
improve their catalytic efficiency. 
4.3.3. Progesterone hydroxylation of CYP106A2 mutants within the I-helix 
In order to increase the turnover rate of the two selected mutants showing the highest 
11α-hydroxyprogesterone formation, CYP106A2 A395I and CYP106A2 A395W/G397K, 
residues close to the central region of the heme, were chosen for replacement. The highly 
conserved threonine residue within the I-helix of the cytochrome P450 was previously 
found to play an important role for the electron transfer and the molecular oxygen 
activation. This residue facilitated the coordination of a water ligand to the ferric heme, 
the binding of oxygen to the ferrous prosthetic group, and the cleavage of the bound 
dioxygen molecule to provide the final activated oxidizing species. Therefore, mutation at 
this residue was reported to affect directly in catalytic efficiency of cytochromes P450 
(Imai et al., 1989; Raag et al., 1991; Truan and Peterson, 1998; Kim et al., 2008). 
According to the docked progesterone-CYP106A2 model, the residue T247 in the middle 
of the I-helix of CYP106A2 corresponded with the strongly conserved amino acid in most 
cytochromes P450. Residue T247 is placed in the active site adjacent to the heme and is 
followed by residue T248 (Figure 4.2). In order to verify their important role on the 
catalytic activity, the 2 mutants CYP106A2 A395I and CYP106A2 A395W/G397K were 
used as parental enzymes and the following mutations were introduced by site-directed 
mutagenesis: T247A, T247V, T247S, T247P, T247W, T247A and T248V. 
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Figure 4.2: The residues forming the active site of the docked complex of CYP106A2 and 
progesterone. The heme is shown in red and the docked progesterone in green.  
The results in this work revealed that the mutations at the positions T247 and T248 of 
CYP106A2 did not show a significant effect on the optical absorption of the enzyme. 
Even though, this could lead to subtle and local structural changes in the heme 
environment of the residues T247 and T248 as described for the analogous mutant 
CYP102A1 T252A (Raag et al., 1991). According to the docking experiment, residue 
T247 showed hydrogen bonds towards residues A243, V245, and T248, whereas residue 
T248 interacts with residues P147 and L252. The substitutions at positions T247 and 
T248 lead to an alteration of the hydrogen bond network in the active site. Besides the H-
bond with residue V245, the mutation at residue T247 shifted the H-bond from residue 
A243 to residue S249 and to residue N290. In another case, the replacement of tryptophan 
for threonine in position 247 showed an additional H-bond with residue G242. Changing 
of residue T247 also showed to have an effect on the residue T248 surrounding area, 
where the connection with residue P147 was replaced by residues L251 and G364. 
Mutation at residue T248 created a new H-bond with residue H250 besides the connection 
with residues L251 and L252. Furthermore, the substitutions of residue T248 by alanine 
or valine also influenced the rearrangement of the H-bond network of residue T247 and 
its surroundings with residue N290. Moreover, the residue A243 showed a direct 
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interaction with progesterone. This resulted in a loss of the connection with residue T247. 
Consequently, residue N290 showed one H-bond directly to the progesterone, therefore, 
the substitutions of residues T247 and T248 may serve to alter the opening of a proton 
channel to the substrate binding pocket around the heme iron. It was shown that the 
replacement of the corresponding residue T243 from P450nor with asparagine, alanine 
and valine dramatically reduced the enzymatic activity (Obayashi et al., 2000), whereas 
the catalytic activity was considerably retained on substitutions by serine and glycine 
(Okamoto et al., 1998). Similarly, the mutations T214A, T214V, and T213A/T214A of 
CYP119 lead to a 2 – 3 fold increase of the styrene epoxidation activity compared to the 
CYP119 wild type (Koo et al., 2000 and 2002). In this study it was found that only 3 
mutants (CYP106A2 T247V/A395I, CYP106A2 T247W/A395W/G397K and CYP106A2 
T248V/A395I) showed a higher hydroxylation activity compared with the parental 
mutants (CYP106A2 A395I and CYP106A2 A395W/G397K) but still a lower activity 
than CYP106A2 wild type (Table 3.7). The estimations of enzyme kinetic parameters 
showed an improvement of the catalytic activity of these 3 mutants in comparison with 
that of CYP106A2 wild type. For the 15β-hydroxyprogesterone formation, the kcat/Km 
values of mutants CYP106A2 T247V/A395I, CYP106A2 T247W/A395W/G397K and 
CYP106A2 T248V/A395I were 4.87-, 4.98- and 2.87-fold, respectively, higher as that of 
CYP106A2 wild type. Interestingly, the 11α-hydroxyprogesterone formation also 
presented a higher turnover rate being 2.56-, 3.62- and 3.43-fold, respectively, higher as 
the 15β-progesterone formation rate of CYP106A2 wild type. Thus, the mutations at this 
conserved threonine residue may have an impact on the substrate recognition as well as 
on maintaining an efficiently functioning enzyme (Clark et al., 2006). The substrate 
recognition change was obviously followed by a change of the regio-selectivity of the 
hydroxylation. Unfortunately, only mutant CYP106A2 T248V/A395I retained a high 
proportion of 11α- hydroxyprogesterone (112.2%), as compared with 15β-hydroxylated 
product, while the others (CYP106A2 T247V/A395I, CYP106A2 
T247W/A395W/G397K) lost their ability to hydroxylate predominantly at the C-11 
position. The decrease in the progesterone regio-specificity may be related to the 
enzymatic turnover rate. In this case, the catalytic activity of CYP106A2 T247V/A395I, 
CYP106A2 T247W/A395W/G397K was faster than that of the parental mutants 
(CYP106A2 A395I and CYP106A2 A395W/G397K) which led to an equilibrium-
disruption of the mutants in the substrate binding region placing an oxygen atom at the C-
15 position. Nevertheless, in order to understand the role of this conserved threonine for 
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the correct positioning of the substrate and productive hydroxylation during the catalytic 
cycle of CYP106A2, the crystal structures of mutants and the wild type enzyme are 
necessary. 
4.3.4. Progesterone hydroxylation of CYP106A2 mutants in other positions 
Besides the conserved threonine in the I-helix, it was suggested that, another threonine at 
position 89 has an effect on the regio-specificity of the hydroxylation (Virus, 2006). The 
role of the corresponding residue was studied in CYP2C1, where residue V113 was 
replaced by an alanine. The mutant CYP2C1 V113A showed a 21-hydroxylase activity of 
progesterone, which was not observed in CYP2C1 wild type (Kronbach et al., 1991). 
Furthermore, it was shown that, the mutations V117A and F209L of the coumarin-7-
hydroxylase (CYP2A5) were able to perform a 15α-testosterone hydroxylation (Lindberg 
and Negishi, 1989). Residue T89 of CYP106A2 corresponds to residue V113 of CYP2C1 
as well as residue V117 of CYP2A5, whereas the residue F209 of CYP2A5 is related to 
residue F165 of CYP106A2. The amino acid T89 of CYP106A2 was first selected and 
mutated by Rauschenbach. However, the replacement of T89 by alanine, phenylalanine, 
and serine (mutants CYP106A2 T89A, CYP106A2 T89F and CYP106A2 T89S) did not 
show an increase in the catalytic activity of CYP106A2 towards 15β-
hydroxyprogesterone formation (Rauschenbach, 1993). The evaluation of the regio-
selectivity of progesterone hydroxylation by these mutants has not been done yet. On the 
other hand, if the residue T89 was substituted by an asparagine, which possesses a side-
chain one methylene group longer than threonine and contains a more polar (amine) 
group, a dramatic increase of 11α-hydroxyprogesterone formation by 85- and 344-fold 
during the in vitro and in vivo conversion, respectively, compared with this formation in 
the wild type was observed (Tables 3.10, 3.11 and 3.12). Inspection of the computer 
model of CYP106A2 shows that a change of the H-bond network can be observed in 
mutant CYP106A2 T89N. Besides the H-bonds to the heme and residue R296, mutant 
CYP106A2 T89N also showed additional bonds to residues S64 and G87. The effect of 
this change is not fully understood so far, as it needs the crystal structure to verify 
changes of the substrate binding to this mutant. Besides this, substitution F209L of the 
coumarin-7-hydroxylase (CYP2A5) altered the regio-selectivity towards the testosterone 
15α-hydroxylation (Lindberg and Negishi, 1989). The residue F165 of CYP106A2 
corresponds with residue F209 of CYP2A5. However, this residue does not belong to the 
active center of CYP106A2. Therefore, a mutation at this position will probably not lead 
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to a change in the substrate regio-specificity. According to Virus’s work, the mutant 
CYP106A2 F165I had no impact on the regio-selectivity of the progesterone 
hydroxylation. But this mutant as well as mutant CYP106A2 F165L showed increased 
catalytic efficiencies (1.25- and 2.5-fold) compared with CYP106A2 wild type 
(Rauschenbach, 1993; Virus, 2006). Interestingly, the apparent kcat/Km of 15β- and 11α-
hydroxyprogesterone formations by mutant CYP106A2 F165L/A395I increased up to 9.0- 
and 10.3-fold, respectively, compared with the value of 15β-hydroxy product from 
CYP106A2 wild type, and up to 10.3- and 4.8-fold compared with the corresponding 
values for mutant CYP106A2 A395I. 
The directed evolution of CYP106A2 to reach higher 11-deoxycortisol and progesterone 
hydroxylations by CYP106A2 resulted after one round of error prone PCR in 2 mutants, 
CYP106A2 A106T and CYP106A2 A106T/R409L, with an increment of 1.43- and 3-fold 
in case of progesterone and 11-deoxycortisol as a substrate, respectively. However, the 
single mutant CYP106A2 A106T seemed to be less stable than the double mutant 
CYP106A2 A106T/R409L. Therefore, the double mutant was chosen as a template for the 
second round of error prone PCR. The mutants CYP106A2 T89N/A106T/R409L and 
CYP106A2 A106T/Q189K/T399S/R409L presented an apparent kcat/Km of 15β-OH-RSS 
which were 3.3- and 4.3-fold higher than CYP106A2 wild type (Virus, 2006; Virus and 
Bernhardt, 2008). The combination of the substitutions A106T with the 2 selected SRS 6 
mutants created a double (CYP106A2 A106T/A395I) and a triple mutant (CYP106A2 
A106T/A395W/G397K). The new mutant CYP106A2 A106T/A395I exhibited a higher 
hydroxylation activity, whereas the triple mutant CYP106A2 A106T/A395W/G397K 
showed a similar activity as CYP106A2 wild type (Table 3.7). Investigation of the 
enzyme kinetics showed a 1.1-fold increase in the apparent kcat/Km of the 11α-
hydroxyprogesterone formation with mutant CYP106A2 A106T/A395I and a 1.4-fold 
increase with mutant CYP106A2 A106T/A395W/G397K compared with the parental 
mutants (CYP106A2 A395I and CYP106A2 A395W/G397K). Moreover, the 
combination of mutations A395I and A395W/G397K with mutant CYP106A2 
A106T/R409L led to an increase in the catalytic rate towards C-11 hydroxylation by a 
factor of 3 and 4.3, respectively. In contrast, mutant CYP106A2 
T89N/A106T/A395I/R409L showed a decrease of the apparent kcat/Km compared with 
mutant CYP106A2 A395I. This decrease also influenced the distribution of the 
hydroxylated products. Interestingly, except for mutant CYP106A2 
 96
Discussion 
T89N/A106T/A395I/R409L, the other combinations still retained or even improved the 
regio-selectivity of progesterone toward the 11α-position. In comparison with the 
CYP101 structure of Pseudomonas putida, it was further suggested that residue A106 of 
CYP106A2 could have a critical function in the interaction with the redox partner 
adrenodoxin. Experimental evidence indicated that negatively-charged amino acids on the 
electron donor (Geren et al., 1984 and 1986; Bernhardt et al., 1984 and 1987) interact 
with positively-charged amino acids of the P450. A common region of positive charges is 
centered over the cystein pocket of all bacterial cytochromes P450 type I that interact with 
a ferredoxin (Stayton and Sligar, 1990; Wada and Waterman, 1992). The 3 arginine 
residues on the surface of CYP101 (R72 in the B-helix, R109 and R112 in the C-helix) 
are essential for the successful electron transfer from putidaredoxin (Pochapsky et al., 
1996; Koga et al., 1993; Nakamura et al., 1994; Unno et al., 1996). The corresponding 
positively-charged residues in the CYP106A2 are K53, R97 and R100. Residue A106 is 
found in close proximity to the residues R97 and R100, in or next to the C-helix. The 
substitution of A106T from a non-polar amino acid to a polar amino acid could affect the 
binding of adrenodoxin to mutant CYP106A2 A106T. In contrast, mutation R409L did 
not seem to be involved in the interaction with adrenodoxin due to the far distance from 
the charged residues on the proximal site. According to the docking experiment, residue 
R409 did not belong to the active center of the enzyme and showed an H-bond with 
residues K377 and H378 in the β3-3 sheet, and with residue D131 in the β3-1 sheet. The 
replacement of R409 by a leucine leads to a change of the H-bond network. Residue L409 
is connected to residues H378 and F376, which both are located in the β3-3 sheet. This 
mutation may create a minimal conformational change of the C-terminal part of 
CYP106A2 (Virus and Bernhardt, 2008). 
In several P450 structures, the helices F and G form a flexible loop, which is part of the 
substrate access channel. This F/G loop will move towards the I-helix after substrate 
binding in order to close the access channel. This movement was observed in CYP101 
(Dunn et al., 2001) and in CYP119 (Park et al., 2002). According to the docked 
progesterone-CYP106A2 model, residue D217 is located in the H-helix of the 
CYP106A2. This residue may be involved in the conformational changes process upon 
substrate binding (Virus and Bernhardt, 2008). A role of residue A243 in the steroid 
hydroxylation of CYP106A2 was also suggested by Virus (Virus, 2006). Although 
residue A243 directly contacted to progesterone in the docked progesterone-CYP106A2 
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model, its mutation (A243V) affected only the catalytic activity of the enzyme by 
increasing the 11-deoxycortisol hydroxylation 1.8-fold (Virus, 2006). This correlates with 
the effect observed with the mutant CYP106A2 A243V/A395I. It improved the apparent 
kcat/Km of 11α-hydroxylation 2.72-fold compared with the 15β-hydroxyprogesterone 
formation of CYP106A2 wild type due to a decrease of the Km value. 
4.4. In vivo conversion of progesterone  
Biotransformation whole-cell systems are more popular than the isolated enzymes due to 
their economic advantages. Those systems can adapt to the pharmaceutical requirements 
for producing steroid intermediates, which are difficult to synthesize by chemical means. 
However, the most complicated point in the field of biocatalysts is cofactor-dependent 
redox reactions (Zhao and van der Donk, 2003; Urlacher et al., 2004). Although the 
natural function of CYP106A2 is unclear, it requires an electron transfer system for its 
activity. In order to supply the reducing equivalents necessary for steroid hydroxylation 
activity, CYP106A2 was reconstituted in vitro with truncated Adx (4 – 8) and AdR from 
bovine adrenals. When using CYP106A2 in vivo, thus, also a corresponding redox chain 
must be available. 
Directed evolution requires a fast screening system with a high accuracy. Hannemann et 
al. designed an E.coli system for whole-cell mediated steroid synthesis. The two-
component electron transfer chain was implemented into E.coli cells by coexpression of 
the corresponding coding sequences from pBAR_Twin, containing the cDNAs of AdR 
and Adx together with plasmid pACYC_FHH2 containing the cDNA of CYP106A2 
(Hannemann et al., 2006). This system and the detection of the steroid hydroxylation by 
fluorescence measurement can be applied for screening (Appel et al., 2005; Virus et al., 
2006). This combination meets the molecular evolution demands due to the reduction of 
time and costs as well as the reliability at measurements.  
This method was validated in this work when the CYP106A2 wild type and the 32 mutant 
enzymes were coexpressed with pBAR_Twin and pACYC_FHH2, containing the cDNA 
of CYP106A2 or its mutants, in micro titer plates. From those experiments, 13 mutants 
were selected according to their higher relative fluorescence units compared with 
CYP106A2 wild type (Table 3.7). Eight mutants showed also a higher in vitro activity of 
progesterone hydroxylation (Table 3.9). 
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Besides using the whole-cell system for screening purposes, it can also be applied for 
steroid production. Interestingly, an alteration of the regio-selectivity of the in vivo 
progesterone hydroxylation was observed. The amount of 11α-hydroxyprogesterone in 
the whole-cell bioconversion increased compared to that of the isolated enzyme. Using 
the wild type protein, 11α-hydroxyprogesterone amounted to 5.0% and 73.0% in the in 
vitro and in vivo conversion, respectively, compared to the 15β-hydroxylation (set to 
100%). The single mutant CYP106A2 A395I lead in vivo to 186.7% of 11α-
hydroxyprogesterone, whereas in vitro conversion was only to 97.2%. The most dramatic 
change in the regio-specificity was achieved with mutant CYP106A2 T89N/A395I. This 
mutant showed a 4-fold higher 11α-hydroxyprogesterone production compared to 15β-
hydroxyprogesterone formation. This ratio was raised up to 16-fold with the whole-cell 
biocatalyst system. An increase of the 11α-hydroxyprogesterone formation was also 
observed in mutant CYP106A2 D217V/A395I (from 114% to 198.2%). In contrast, the 
mutants CYP106A2 F165L/A395I and CYP106A2 A106T/A395I/R409L produced in 
both cases almost the same amount of 11α-hydroxyprogesterone, whereas the mutants 
CYP106A2 A106T/A395I and CYP106A2 A395W/G397K showed in vivo less 11α-
hydroxyprogesterone production compared with the isolated enzyme. Furthermore, when 
the in vivo biotransformation was longer than 12 hr, the formation of 11α-
hydroxyprogesterone decreased compared with the 15β-hydroxyprogesterone formation. 
The mutant CYP106A2 D217V/A395I reduced the 11α-hydroxyprogesterone formation 
from 198.2% to 142.3% and CYP106A2 A106T/A395I/R409L dropped the activity from 
255.6% to 161.2%. In vitro, CYP106A2 hydroxylates progesterone mainly in the 15β-
position. However, when a reconstitution system using CYP106A2 wild type not only 
with AdR and Adx but also with the alcohol dehydrogenase (ADH) from Lactobacillus 
brevis was performed, the main product of the progesterone conversion was 11α-
hydroxyprogesterone, which was about 2-fold higher than the 15β-hydroxy product 
(Zehentgruber et al., 2010). This observation could be due to the effect of the cofactors in 
the electron transfer system or to the interaction between the proteins in the E.coli cells. 
The details of this mechanism still need to be investigated. 
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4.5. Outlook 
Steroid derivatives obtained by microorganisms are often advantageously for the 
industrial synthesis of steroid drugs. So far, the 11α-, 11β-, 15α- and 16α-hydroxylations 
are accomplished in the steroid industry, mainly by microbial transformations (Jekkel et 
al., 1998). CYP106A2 exhibits a high potential for application in the biotechnological 
industry due to its ability to perform stereo- and regio-selective hydroxylations. This 
protein can be expressed with high yield in E.coli. By using directed mutagenesis, 
CYP106A2 mutants, which show an increased catalytic efficiency as well as a changed 
substrate regio-selectivity, were obtained. With regard to a possible biotechnological 
application, CYP106A2 should be studied with further substrates in order to determine its 
total substrate spectrum. On the other hand, the substrate spectrum and the hydroxylated 
products could also be expanded by using different, newly created CYP106A2 mutants. 
In this work, the mutants CYP106A2 A106T/A395I and CYP106A2 A106T/A395I 
presented using the in vitro conversion a 2-fold higher portion of 11α-
hydroxyprogesterone compared with 15β-hydroxyprogesterone. Interestingly, mutant 
CYP106A2 T89N/A395I produced in vivo mainly 11α-hydroxyprogesterone, which was 
16-fold higher compared with the 15β-hydroxy product. 11α- and 11β-
hydroxyprogesterone are reported to be inhibitors of the 11β-hydroxysteroid-
dehydrogenase type I and II (Souness et al., 1995). The 11α-hydroxylation also plays a 
role in the production of key intermediates to synthesize Gestoden and Desogestrel, 2 
widely used contraceptive drugs. The successful creation of numerousness mutants, which 
hydroxylate progesterone at the C-11 position, suggests that the same strategy can also be 
used to alter the regio-selectivity towards other positions, such as 6β, 7β, 9α, 11β, 14α or 
15α. It should be noted in this context that 6β,14α-dihydroxyandrost-4-ene-3,17-dione 
and 14α-hydroxyandrost-4-ene-3,6,17-trione possess androgen activity and are useful 
inhibitors for breast cancer cells. The 7β-hydroxylation of finasteride can be useful a 
medicine for the prostate cancer therapy (Pamidi and Jia, 1998). 
However, in order to apply the right strategy in altering the substrate specificity of 
CYP106A2, the crystallization of this enzyme and the determination of the crystal 
structure are necessary. The crystal structure will give a deeper insight into the structure-
function relationship of this enzyme. 
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6. APPENDIX 
6.1. Media 
6.1.1. Luria-Bertani (LB) Broth 
Bacto-Tryptone  10 g 
Yeast extract   5 g 
NaCl    10 g 
Add H2O   1000 ml 
6.1.2. Terrific Broth (TB) 
Tryptone   12 g 
Yeast extract   24 g 
Glycerin   4 ml 
Add H2O   900 ml 
After autoclaving, add 100 ml of sterilized potassium phosphate buffer 
K2HPO4   0.72 M 
KH2PO4   0.17 M 
6.1.3. Trace element solution (140 µl/L Medium) 
FeCl2 x 6 H2O   2.7 g 
CaCl2 x 2 H2O  0.2 g 
Na2MoO4 x 2 H2O  0.2 g 
CoCl2 x 6 H2O  0.2 g 
ZnCl2 x 4 H2O  0.1 g 
CuSO4 x 5 H2O  0.186 g 
H3BO3    0.05 g 
Add H2O   90 ml 
Salt mixture was respended in 10 ml of concentrated HCl and sterilized by filtration 
6.1.4. SOC medium 
Tryptone   20 g 
Yeast extract   5 g 
NaCl    0.5 g 
Add H2O   980 ml 
After autoclaving, add 20 ml of sterilized 1M glucose 
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6.2. Buffer 
6.2.1. Preparation of chemically competent cells 
6.2.1.1. Transfer buffer I (TFPI) 
1M CH3COOK:  3 ml 
1M KCl:   10 ml 
1M CaCl2:   1 ml 
Glycerol:    12 ml 
Filled up to 80 ml with distillated water, adjusted pH to 6.1 
 Add 1M MnCl2  5 ml 
Filled up to 100 ml with distillated water, pH should be 5.8. 
6.2.1.2. Transfer buffer II (TFPII) 
0.2M MOPS:   1 ml 
 1M KCl:   0.2 ml 
 1M CaCl2:   1.5 ml 
 Glycerol   2.4 ml 
Filled up to 20 ml with distillated water, pH should be 6.5-7.0. 
Both of TFPI and TFPII was sterilized by filtration and stored in the refrigerator at 4°C 
before used. 
6.2.2. “Quick and Dirty” preparation 
L1 buffer (pH 8.0):  100 μg/ml RNase A 
   50 mM Tris/Cl 
10 mM EDTA 
L2 buffer:   200 mM NaOH 
1% SDS 
L3 buffer (pH 5.1)  2.8 M CH3COOK 
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6.2.3. Purification of CYP106A2 
Lysis buffer:   50 mM Tris/Cl, pH 8.5 
1 mM EDTA 
100 mM NaCl 
0.1 mM DTE  
1 mM PMSF 
Buffer A:   20 mM potassium phosphate buffer pH 7.4 
0.1 mM DTE 
Buffer B:    Buffer A plus 0.5 M NaCl 
Buffer C:   10 mM potassium phosphate buffer pH 7.4 
0.1 mM DTE 
Buffer D:   100 mM potassium phosphate buffer pH 7.4 
0.1 mM DTE 
Buffer E:    50 mM potassium phosphate buffer pH 7.4 
6.3. Standard protein solutions vary from 20 - 2000 μg/ml  
 x μl BSA standard 
(2000 μg/ml) 
x μl Water/Buffer Protein content 
(μg/ml) 
Σ (μl) 
A 100 0 2000 100 
B 50 50 1000 100 
C 37.5 62.5 750 100 
D 25 75 500 100 
E 20 140 250 160 
F 40 of (E) 60 100 100 
G 20 of (E) 80 20 100 
H 0 100 0 100 
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6.4. Sodium dodecylsulphate (SDS) polyacrylamid gelelectrophoresis 
6.4.1. Preparation of the polyacrylamide separating gel 
Final acrylamide concentration Stock solutions 
10% 12% 15% 
4xLT 3.75 ml 3.75 ml 3.75 ml 
10% APS 75 μl 75 μl 75 μl 
dest. H2O add 15 ml add 15 ml add 15 ml 
30% AA/Bis 5 ml 6 ml 7.5 ml 
TEMED 7.5 μl 7.5 μl 10 μl 
6.4.2. Preparation of the polyacrylamide stacking gel 
Stock solutions 5% acrylamide concentration 
4xUT 2.5 ml 
10% APS 50 μl 
dest. H2O add 10 ml 
30% Arcylamide/Biss 1.6 ml 
TEMED 5 μl 
6.4.3. Buffer 
4x Buffer for separating gel (4xLT): 1.5M Tris/Cl, pH 8.8 
0.4% SDS 
4x Buffer for stacking gel (4xUT):  0.5M Tris/Cl, pH 6.8 
0.4% SDS 
2x SDS loading buffer:   125 mM Tris/Cl, pH 6.8 
20% glycerol 
4% SDS 
10% β-mercaptoethanol 
0.004% bromphenol blue 
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6.4.4. Staining solution:   0.1% Coomassie Brilliant Blue G-250 
      40% Methanol 
10% Acetic acid 
6.4.5. Destaining solution:   25% Methanol 
10% Acetic acid 
6.5. The DNA sequence of CYP106A2 (Rauschenbach et al., 1993) 
ATGAAAGAAG TTATTGCAGT AAAAGAAATT ACTAGGTTTA AAACAAGGAC GGAGGAATTT        60 
AGCCCGTACG CTTGGTGTAA AAGGATGTTA GAAAATGACC CTGTGAGTTA TCACGAAGGA       120 
ACGGATACGT GGAATGTCTT TAAATATGAA GATGTGAAGC GGGTTCTCAG TGATTATAAA       180 
CATTTTTCAA GTGTTCGGAA ACGGACGACG ATTTCAGTTG GAACGGATAG TGAGGAAGGT       240 
TCTGTGCCTG AAAAGATCCA AATCACTGAA TCGGATCCAC CTGATCATAG AAAACGCCGT       300 
TCACTGCTGG CAGCAGCATT CACACCTAGA AGTCTTCAAA ACTGGGAACC TCGCATTCAG       360 
GAAATTGCAG ATGAATTGAT TGGACAAATG GATGGTGGAA CGGAAATCGA TATTGTGGCA       420 
TCATTGGCGA GTCCGCTTCC GATCATTGTC ATGGCCGATT TGATGGGGGT TCCCTCGAAA       480 
GATCGTTTAT TGTTTAAGAA ATGGGTGGAT ACCTTATTTC TTCCTTTTGA TAGAGAAAAG       540 
CAAGAAGAAG TAGATAAATT GAAGCAAGTT GCAGCAAAAG AATACTATCA GTATTTGTAT       600 
CCGATTGTTG TGCAAAAACG ATTGAACCCG GCGGATGATA TCATCTCAGA TCTATTGAAG       660 
TCGGAAGTGG ATGGGGAAAT GTTTACGGAT GATGAGGTTG TCCGGACGAC CATGCTGATT       720 
TTAGGTGCAG GAGTCGAGAC AACCAGTCAT TTATTGGCCA ATAGCTTTTA TTCGCTGCTA       780 
TATGATGACA AAGAAGTTTA TCAAGAGTTA CATGAAAACC TGGATTTAGT TCCGCAGGCG       840 
GTCGAAGAAA TGCTCCGTTT CCGATTCAAT CTTATTAAAT TGGATCGCAC TGTAAAGGAA       900 
GATAACGATC TATTGGGAGT GGAATTGAAA GAAGGGGATA GCGTGGTTGT TTGGATGAGT       960 
GCAGCTAATA TGGACGAAGA GATGTTTGAA GACCCCTTCA CACTTAATAT CCACCGCCCT      1020 
AATAATAAGA AACATCTCAC ATTCGGTAAT GGCCCTCATT TCTGCCTCGG AGCACCGCTA      1080 
GCCAGGCTGG AAGCGAAGAT TGCGCTTACT GCATTCCTGA AGAAATTCAA GCATATTGAA      1140 
GCGGTGCCAT CGTTCCAGTT AGAAGAGAAT CTTACCGATT CAGCGACCGG TCAAACTTTG      1200 
ACCTCACTAC CGCTTAAGGC AAGCCGCATG TAA                                   1233 
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6.6. The protein sequence of CYP106A2 
XMKEVIAVKEITRFK TRTEEFSPYAWCKRM LENDPVSYHEGTDTW NVFKYEDVKR 55 
VLSDYKHFSSVRKRT TISVGTDSEEGSVPE KIQITESDPPDHRKR RSLLAAAFTP 110 
RSLQNWEPRIQEIAD ELIGQMDGGTEIDIV ASLASPLPIIVMADL MGVPSKDRLL 165 
FKKWVDTLFLPFDRE KQEEVDKLKQVAAKE YYQYLYPIVVQKRLN PADDIISDLL 220 
KSEVDGEMFTDDEVV RTTMLILGAGVETTS HLLANSFYSLLYDDK EVYQELHENL 275 
DLVPQAVEEMLRFRF NLIKLDRTVKEDNDL LGVELKEGDSVVVWM SAANMDEEMF 330 
EDPFTLNIHRPNNKK HLTFGNGPHFCLGAP LARLEAKIALTAFLK KFKHIEAVPS 385 
 
6.7 Publication resulting from this work 
Kim Thoa Nguyen, Cornelia Virus, Michael Lisurek, Frank Hannemann, Rita Bernhardt 
(2007). Molecular Evolution of CYP106A2 from Bacillus megaterium ATCC 13368. 
Poster presentation. Bio-Hanoi 2007 - Conference "From Biosciences to Biotechnology 
and Bioindustry", Hanoi (Vietnam). 
Kim Thoa Nguyen, Cornelia Virus, Frank Hannemann, Rita Bernhardt (in preparation). 
Changing the regio-selectivity of CYP106A2 from C-15 to C-11 of progesterone. 
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